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SUMMARY 
This work focuses on the study of neuropharmacological mechanisms underlying 
opioid tolerance, in particular, the involvement of NO signalling pathways. Opioids are 
potent drugs used for pain relief. However, their therapeutic potential is limited as their 
long-term use leads to the development of tolerance to their analgesic effects. Opioid 
tolerance is a complex phenomenon and the underlying mechanisms have not been fully 
elucidated. Understanding the ways in which tolerance can be attenuated would be a 
significant advantage in the therapeutic use of these agents. The noradrenergic nucleus 
locus coeruleus (LC) contains a high-density of MORs and it has been extensively used as 
a model to explore the cellular and molecular mechanisms underlying opioid tolerance. In 
this regard, there is substantial evidence showing the involvement of mu-opioid receptor 
(MOR) desensitization in the development of tolerance. 
The signaling messenger nitric oxide (NO) has been widely recognized to play 
pivotal roles in the regulation of multiple physiologic and pathophysiological processes. It 
is produced from L-arginine by the enzymatic action of NO synthase (NOS). The main 
target of NO is the enzyme soluble guanylyl cyclase (sGC), which catalyzes the formation 
of 3'5'-cyclic guanosine monophosphate (cGMP). This second messenger activates a 
number of effectors, such as the cGMP-dependent protein kinase (PKG). NO also reacts 
with oxygen derivatives to produce reactive oxygen and nitrogen species (ROS), such as 
the powerful oxidant molecule peroxynitrite. NO modulates opioid actions, as it was 
found to be involved in Met5-enkephalin (ME)-induced MOR desensitization in vitro and 
in the neuronal adaptations occurring in vivo during morphine tolerance. We carried out 
four studies to explore the role of NO and its downstream signaling pathways 
(sGC/cGMP and ROS) in the adaptations triggered by different opioid agonists both in 
vitro and in vivo.  
 
STUDY 1  
 
In the first study, we investigated by single-unit extracellular recordings in vitro the 
involvement of NO-activated pathways in MOR desensitization induced by ME (3 or 10 
μM) in the rat LC. For this purpose, we tested the effect of different modulators of the 
sGC/PKG pathway and antioxidants on ME-induced desensitization in LC neurons from 
Summary  
  
 
 
 
rat brain slices. Perfusion with ME (3 and 10 μM) reduced ME (0.8 μM) effect in a 
concentration-related manner, indicative of MOR desensitization. ME (3 μM)-induced 
desensitization was enhanced by the NO donor DEA/NO (100 µM) and the soluble 
guanylate cyclase (sGC) activators A 350619 (30 μM) or BAY 418543 (1 μM). DEA/NO-
induced enhancement was blocked by the sGC inhibitor NS 2028 (10 μM). Paradoxically, 
ME (10 μM)-induced desensitization was not modified by the sGC inhibitor NS 2028 (10 
and 30 μM), the PKG inhibitor Rp-8-Br-PET-cGMP (1 μM) or the antioxidants Trolox 
(200 µM), U-74389G (10 µM) or melatonin (100 µM). However, it was attenuated by a 
combination of a sGC inhibitor (NS 2028 10 μM) and an antioxidant (Trolox 200 µM). 
Our results suggest that MOR desensitization in the LC may be mediated or regulated by 
NO through sGC and reactive oxygen species signaling pathways. 
 
STUDY 2 
The ability of morphine to induce rapid MOR desensitization in native LC neurons 
has been questioned. In the second study, we characterized by single-unit extracellular 
recordings in vitro the desensitization of MOR induced by morphine in KCl-excited LC 
neurons from rat brain slices. ME-induced desensitization was tested as a reference for 
morphine. This KCl-protocol allowed us to monitor continuously the effect of 
supramaximal concentrations of opioid agonists. Since the contribution of NO to MOR 
desensitization induced by non-peptide opioid agonists is unknown, we further explored 
the involvement of the neuronal NOS isoform in acute MOR desensitization. As 
expected, ME (10 μM) induced substantial desensitization of MOR, since the inhibitory 
effect of ME (0.8 or 25.6 μM) was diminished after or during application of ME (10 µΜ). 
Our results show that morphine (30 μM) also causes significant desensitization of MOR 
in the LC, so that the inhibitory effect of a supramaximal test concentration of ME (25.6 
μM), applied before-after or during the desensitization period, was markedly reduced. In 
contrast, the inhibitory effect of gamma-aminobutyric acid (GABA; 1 mM) was unaltered 
after application of ME (10 µM) or morphine (30 µM). Perfusion with a combination of 
the nNOS inhibitors 7-nitroindazole (7-NI, 100 μM) and S-methyl-L-thiocitrulline 
(SMTC, 10 μM) attenuated the induction of MOR desensitization induced by ME, but it 
failed to alter the desensitization induced by morphine. These results demonstrate the 
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ability of morphine to induce acute MOR desensitization in vitro and highlight the 
agonist-selective regulation of MOR desensitization by neuronal NOS. 
 
STUDY 3 
In this study, we examined by electrophysiological techniques in LC neurons the 
effect of chronic treatments with 7-nitroindazole (7-NI; 30 mg/kg/12 h, i.p.), a selective 
neuronal nitric oxide synthase (nNOS) inhibitor, and the antioxidants Trolox + ascorbic 
acid (TX+AA; 40 and 100 mg/kg/day, respectively, i.p.) and U-74389G (10 mg/kg/day, 
i.p.), on the development of cellular tolerance induced by three different opioid agonists 
(morphine, methadone and fentanyl). For induction of morphine tolerance, rats were 
treated subcutaneously (s.c.) with a slow release emulsion containing free base morphine 
(200 mg/kg) for 72 h. For methadone (60 mg/kg/day, 6 days) and fentanyl (0.2 
mg/kg/day, 7 days), tolerance was induced by s.c. implantation of osmotic pumps. 
Concentration-effect curves for the inhibitory effect of the opioid agonist ME on the cell 
firing rate was evaluated by single-unit extracellular recordings of LC neurons from brain 
slices. Morphine, methadone and fentanyl treatments caused different degrees of 
rightward shifts of concentration-effect curves for ME and they increased the EC50 by 4, 2 
and 3 folds, respectively, as compared to those in sham-treated animals. This suggests 
that opioids induce agonist-dependent cellular tolerance in LC neurons. Co-administration 
of TX+AA or U-74389G attenuated tolerance to ME effect in morphine-treated animals 
when compared to the control (morphine/vehicle group). In contrast, co-treatment with 
either U-74389G or 7-NI failed to alter the tolerance to the inhibitory effect of ME in 
methadone- or fentanyl-treated animals. Administration of TX+AA, U-74389G or 7-NI in 
sham-treated rats failed to change the effects induced by ME as compared to vehicle 
groups. Taken together, our results suggest that NO/ROS pathways modulate the 
development of cellular tolerance induced by morphine treatments, but not by treatments 
with other opioid agonists that have different pharmacodynamic profiles. 
 
STUDY 4 
In the fourth study, we used the tail-flick technique in rats to examine the effect of 7-
nitroindazole (7-NI; 30 mg/kg/12 h, i.p.), a selective nNOS inhibitor, and the antioxidant 
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agent U-74389G (10 mg/kg/day, i.p.) on the development of opioid antinociceptive 
tolerance induced by prolonged treatments with morphine, methadone and fentanyl. For 
induction of morphine tolerance, rats were treated subcutaneously with a slow release 
emulsion containing free base morphine (200 mg/kg) for 72 h. For methadone (60 
mg/kg/day, 6 days) and fentanyl (0.2 mg/kg/day, 7 days), tolerance was induced by s.c. 
implantation of osmotic pumps. Thus, morphine treatments induced a strong degree of 
tolerance to the antinociceptive effect of a challenge dose of morphine. Methadone 
treatments induced weaker a degree of antinociceptive tolerance. On the contrary, no 
tolerance to morphine challenge effects was observed in fentanyl-treated animals. Co-
treatment with the antioxidant U-74389G partially blocked morphine-induced analgesic 
tolerance. On the contrary, 7-NI or U-74389G administration failed to affect the 
development of antinociceptive tolerance induced by methadone. Our results suggest that 
NO/ROS pathways are involved in the development of opioid antinociceptive tolerance 
induced by morphine treatments, but not by treatments with other opioids that have 
different pharmacodynamic profiles. 
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1.1 OPIOID RECEPTORS  
 
The existence of opioid-binding sites was first proposed by Beckett and Casy in 1954 
and in 1973 they were found in mammalian brain tissue (Pert and Snyder, 1973; Simon et 
al., 1973; Terenius, 1973). The confirmed presence of opioid receptors led to a search for 
endogenous ligands, resulting in the discovery of the enkephalins (Hughes et al., 1975), 
β-endorphin (Cox et al., 1976) and dynorphins (Goldstein et al., 1979). However, it was 
not until 1976 when Martin and colleagues presented the first evidence of the existence of 
different types of opioid receptors. 
 To date, four opioid receptors have been cloned, μ receptor (MOR), δ receptor 
(DOR), κ receptor (KOR) and the nociceptin receptor (NOP), also known as the opioid 
receptor like-1 (ORL-1), or nociceptin/orphanin FQ (N/OFQ) receptor. Despite high 
sequence similarity of the NOP receptor to opioid receptor subtypes (63–65%), 
endogenous opioid peptides have very low affinity for the NOP receptor (for review, see 
Donica et al., 2013). Moreover, NOP receptor-mediated actions oppose many 
antinociceptive actions of classic opioid agonists. Although both hyperalgesic and 
analgesic actions of supraspinally administered N/OFQ have been reported, spinally 
administered N/OFQ predominantly produces analgesia (Mogil and Pasternak, 2001). On 
the other hand, other receptors such as σ or ζ were initially proposed as opioid receptors. 
However, the σ receptor was cloned and classified as a single transmembrane-spanning 
protein and it is no longer considered a member of the opioid receptor family (Monassier 
and Bousquet, 2002). The ζ receptor is an opioid growth factor receptor with no 
homology with classical opioid receptors (Zagon et al., 2000). In addition, a λ receptor 
and a β-endorphin-sensitive ε receptor were described (Wüster et al., 1979). However, 
these receptors are poorly characterized, and verification for their existence through 
identification of their respective genes is still lacking.  
The nomenclature for the opioid receptors remains controversial. In molecular 
biology, δ, κ and μ opioid receptors are DOR, KOR and MOR, respectively (Dhawan et 
al., 1996). However, the International Union of Pharmacology Committee on Receptor 
Nomenclature and Drug Classification (NC-IUPHAR) considers that the well-established 
greek letter names (μ, δ and κ) are most appropriate, but when Greek symbols are not 
permitted or impractical, the use of mu, delta or kappa, or MOP, DOP or KOP is 
permissible (Cox et al., 2015) (Table 1.1). The terms “μ opioid receptor” or “MOR” have 
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been used throughout this thesis because this terminology is the most commonly used in 
our field. 
 
Table 1.1. Classification of opioid receptors. The International Union of Pharmacology Committee on 
Receptor Nomenclature and Drug Classification (NC-IUPHAR)-approved nomenclature for opioid 
receptors (IUPHAR Review 9) (Cox et al., 2015). 
 
 
1.1.1 Molecular and structural aspects of MOR 
 
Among all the opioid receptors, MORs have been the most extensively studied due to 
their role in mediating the actions of morphine and other clinically relevant analgesic 
agents, as well as drugs of abuse. Thus, opioid agonists such as morphine, fentanyl or 
methadone show a considerably higher affinity for MOR than for DOR and KOR (Raynor 
et al., 1994). 
Opioid receptors belong to the large superfamily of seven transmembrane-spanning 
G protein-coupled receptors (GPCRs), which produce their cellular effects via coupling 
with Gi/Go transduction cascades. Genetic knock-out studies have established that MORs 
are encoded by a single structural gene (OPRM1), which was isolated and its sequence 
was defined in the 90s (Chen et al., 1993; Liang et al., 1995; Wendel and Hoehe, 1998). 
Pharmacological studies have long suggested that this gene generates a wide diversity of 
MOR spliced variants (Wolozin and Pasternak, 1981; Pasternak, 2014). There are three 
major classes of MOR splice variants in mice, rats and humans. The first class comprises 
full length 7 transmembrane domain variants. The second set lacks exon 1, which 
generates truncated 6 transmembrane domain variants. The third set involves a single 
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transmembrane protein encoded by exon 1. All three classes are functionally relevant 
(Pasternak, 2014) (Fig. 1.1). Disruption of exons 1, 2 or 3 eliminates morphine actions, 
indicating that morphine responses depend upon the full-length, 7 transmembrane 
variants. However, knock-out animals targeting exon 1 retain morphine-6β-glucuronide 
(M6G) analgesia, suggesting that its analgesic mechanisms are distinct from those of 
morphine (Schuller et al., 1999). On the other hand, when targeting the exon 11, 
morphine and methadone analgesia is mantained, but the analgesic actions of heroin, 
M6G and fentanyl are markedly diminished (Pan et al., 2009). 
 
Figure 1.1. The mouse Oprm1 gene and the MOR splice variants (Pasternak, 2014). 
 
X-ray crystallography has revealed the atomic structures of the mouse MOR 
(Manglik et al., 2012) (Fig. 1.2) and DOR (Granier et al., 2012). Recently, the crystal 
structures of the human KOR (Wu et al., 2012), DOR (Fenalti et al., 2014) and NOP 
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(Thompson et al., 2012) have been also unveiled. As in other GPCRs, the structure of the 
MOR consists of seven transmembrane alpha-helices that are connected by three 
extracellular loops and three intracellular loops. In most available GPCR structures, the 
ligand is partially buried within the helical bundle. In contrast, the binding pocket of the 
MOR has been found to be large and accessible (Manglik et al., 2012). The openness of 
the binding site may explain why opioids display their actions so quickly and why their 
effects can be also rapidly reversed. Endomorphin 1 and 2 are small peptides with the 
highest affinity and selectivity profile for MOR (Zadina et al., 1997). However, it is not 
clear whether they function as endogenous opioids in the mammalian CNS, since no 
precursor protein has been identified yet (Corbett et al., 2006). 
 
Figure 1.2. Overall view of MOR receptor structure. Views from within the membrane plane (left), 
extracellular side (top, center panel) and intracellular side (bottom, center panel) show the typical seven-
pass transmembrane GPCR architecture of MOR. The ligand is shown in green spheres (Manglik et al., 
2012). 
 
Over the last decade, an increasing number of studies have explored the ability of 
GPCRs, including opioid receptors, to heteromerize. It has been suggested that MOR 
exists primarily as a dimer that may oligomerize with DOR into tetramers (Golebiewska 
et al., 2011). In agreement, Manglik et al. (2012) observed that MOR crystallizes in 
tightly linked pairs, through a four-helix bundle pattern that is formed by transmembrane 
segments 5 and 6 (Fig. 1.3). 
 
   Introduction 
   
7 
 
 
Figure 1.3. MORs crystallized with a ligand (yellow), forming an intimate pair (Buchen, 2012) 
 
Interestingly, opioid receptor heteromers are becoming novel therapeutic targets (for 
review, see Fujita et al., 2014). The MOR/DOR heteromer has been the most extensively 
studied. Both receptors exist in close proximity to form interacting complexes in living 
cells (Gomes et al., 2004). While MOR or DOR homomers are coupled to a Gi/o-protein, 
MOR/DOR heteromer could signal via Gz proteins (Hasbi et al., 2007) and/or through β-
arrestin 2 (Rozenfeld et al., 2007). An anti-analgesic role for the DOR/MOR heteromer 
has been reported (Milan-Lobo et al., 2013) and it might be a novel therapeutic target in 
the treatment of pain. Furthermore, MOR/KOR heteromers may also be viable targets for 
pain management. Thus, administration of a MOR/KOR heteromer selective ligand 
exhibits 50-times greater antinociceptive potency than morphine, it does not lead to 
physical dependence and it promotes low antinociceptive tolerance upon chronic 
intracerebroventricular administration (Yekkirala et al., 2011).  
1.1.2 Anatomical location and functions of MOR  
 
MORs are widely distributed throughout the CNS. High densities of MOR are found 
in regions such as the cortex, caudate-putamen, habenula and interpeduncular nuclei, 
hippocampus, hypothalamic nuclei, raphe medianus, inferior colliculus, parabrachial 
nuclei, locus coeruleus, ambiguus nucleus, sensory trigeminal complex, nucleus of the 
solitary tract and the dorsal horn of the spinal cord. MORs are also present on dorsal root 
ganglion cells and on peripheral nerves (Mansour et al., 1994; Arvidsson et al., 1995; 
Truong et al., 2003). 
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MOR activation by endogenous and exogenous ligands results in a multitude of 
effects, which include analgesia, sedation, respiratory depression, euphoria, dependence 
and reward, hormone release, inhibition of gastrointestinal transit or cell proliferation 
(Waldhoer et al., 2004; Feng et al., 2012) (Fig. 1.4). In general, agonists selective for 
MOR or DOR are analgesic and rewarding, whereas KOR-mediated actions have been 
reported to be psychotomimetic and dysphoric (Pfeiffer et al., 1986). Pain modulation by 
MOR takes place at the periphery (Stein, 1991) and the spinal and supraspinal levels of 
the CNS (Yaksh, 1987; Dickenson, 1991). Dissociating pain control from side effects 
such as respiratory depression has long been a goal in opioid drug development. 
Unfortunately, to date, opiate drugs showing good analgesic profile with lack of 
respiratory depression have not been identified. On the other hand, it has been proposed 
that an endogenous antiopioid system exists to regulate and compensate the opioid system 
and maintain the homeostasis (Harrison et al, 1998). The most studied endogenous 
antiopioid peptides are the Tyr-Pro-Leu-Gly-NH2 (Tyr-MIF-1) family of peptides and 
nociceptin/orphanin FQ (Ciccocioppo et al., 2000; Pan and Kastin, 2007). 
 
Figure 1.4. Most relevant functions mediated by MOR. Effects in red are desirable effects, whereas those in 
blue are adverse effects. Some, such as sedation or euphoria, can be therapeutic or adverse depending upon 
the context (Kelly, 2013). 
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1.1.3 Molecular aspects of acute activation of MOR  
 
As previously mentioned, MORs are coupled to pertussis toxin-sensitive Gi/Go 
proteins. In the resting state, G proteins are heterotrimers consisting of a GDP-bound α 
subunit and a βγ dimer. Upon activation of the receptor, there is a conformational change 
that permits G protein binding to the receptor and the release of GDP from the Gα 
subunit. Next, the Gα subunit binds a new molecule of GTP. This exchange destabilizes 
the complex and triggers the dissociation of the Gα subunit from the Gβγ dimer and the 
receptor. Then, both Gα-GTP and Gβγ can activate different signaling cascades.  
Both Gα and Gβγ interact with multiple cellular effector systems, which lead to 
inhibition of adenylyl cyclases and voltage-gated Ca2+ channels and stimulation of G 
protein-activated inwardly rectifying K+ channels (GIRKs) (for review, see Law et al., 
2000; Nagi and Pineyro, 2014). These actions hyperpolarize the neuron, reducing its 
electrical activity and therefore, decreasing the ability to release neurotransmitters. 
Furthermore, MOR-coupled G proteins can activate other effectors, including G protein-
coupled receptor kinases (GRKs) or β-arrestins. Additionally, MORs have been reported 
to interact with phospholipase Cβ (PLCβ), which mobilizes intracellular Ca2+, and also 
with mitogen-activated protein kinase (MAPK) cascades, such as extracellular-signal-
regulated kinases (ERKs) and the Jun N-terminal kinases (JNKs) (Law et al., 2000). 
Although opioid receptors are predominantly coupled to Gi/Go proteins, coupling to 
pertussis toxin-insensitive Gs or Gz proteins has been also reported (Crain et al., 1996; 
Garzón et al., 1998). In fact, it has been suggested that chronic morphine treatment 
induces a change in the coupling of MOR from Gi/o to Gs and this switch in the Gα 
subunit coupling is associated with a stimulation of adenylyl cyclases (Wang et al., 2005; 
Wang and Burns, 2006). In addition, it has been hypothesized that GPCRs exist in 
different states regarding the association with G proteins. Thus, GPCRs that are 
preassociated with G proteins (pre-coupled receptors) are thought to signal more rapidly 
than receptors that are dependent on collision coupling (Lohse et al., 2008). 
On the other hand, over the past decades, numerous studies have shown that not all 
agonists activate the same intracellular signaling pathways, even though they act at the 
same receptor (Kenakin, 1995; Raehal et al., 2011; Kelly, 2013). Indeed, the term 
“functional selectivity” or “biased agonism” has emerged to describe these different 
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efficacies of ligands to activate diverse signaling pathways. Functional selectivity has 
been demonstrated at the MOR (Fig. 1.5). Thus, there are agonist-dependent differences 
in MOR responses with respect to key signaling events, including phosphorylation, 
endocytosis and trafficking (Raehal et al., 2011; Kelly, 2013). These differences between 
agonists may be related to the differential development of analgesic tolerance after 
prolonged use of various opioids in vivo. However, the precise nature of this diversity 
remains to be elucidated. 
 
Figure 1.5. Scheme representing functional selectivity at the MOR. The specific Gαi subunits to which 
MORs couple are dictated by the agonist and the cellular system. Moreover, MORs can be phosphorylated 
in response to agonist occupation by multiple kinases. Phosphorylation by a particular kinase influences 
secondary cascade interactions. Receptor interaction with β-arrestins can be dependent or independent of 
receptor phosphorylation. In addition, the MOR can be internalized in response to an agonist. Endocytosis 
may involve clathrin- or caveolin-dependent processes and may result in the activation of subsequent 
signaling pathways, receptor recycling or degradation. Image modified from Raehal et al. (2011). 
 
1.1.4 MOR regulation: desensitization and tolerance 
 
One major limitation of opioids used in clinical practice is the development of 
tolerance after long-term administration. Therefore, it is relevant to study the cellular and 
molecular mechanisms underlying this process. Tolerance is a complex physiological 
adaptation that involves, at the very least, receptor, cellular, synaptic and behavioral 
changes. There is good evidence that desensitization is a key process that contributes to 
the development of tolerance. In fact, both terms tolerance and desensitization are 
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referred to a loss of responsiveness to an opioid agonist. However, desensitization is 
linked to molecular changes at the level of receptor signaling that occurs within seconds 
or minutes during agonist application, whereas opioid tolerance applies to the loss of 
responsiveness after long-term exposure (days to weeks) (Dang and Christie, 2012; 
Williams et al., 2013). Both desensitization and tolerance may be associated with a 
reduction of functional receptors. Desensitization can be homologous if the reduced 
effects are restricted to the activated receptor, or it can be heterologous if desensitization 
generalizes to other receptors (Lefkowitz et al., 1983). 
As it happens with other GPCRs, MORs can undergo rapid desensitization. The 
classic model of GPCR desensitization has been described to begin with phosphorylation 
of activated receptors by kinases followed by β-arrestin binding. After phosphorylation 
and β-arrestin binding, receptors are presumably uncoupled from their effectors and at 
this point, the receptor is in a desensitized state. Then, β-arrestin-bound receptors can be 
internalized via a clathrin-dependent pathway. Finally, after endocytosis, receptors can be 
recycled back to the membrane or they can suffer lysosomal degradation (for review, 
Connor et al., 2004; Williams et al., 2013) (Fig. 1.6). To add more complexity to the 
process, opioid agonists differ in their ability to promote MOR regulation (Borgland et 
al., 2003; von Zastrow, 2010). These differences among opioid agonists to cause MOR 
regulation may lead to differential abilities to induce tolerance (Dang and Christie, 2012). 
 
Figure 1.6. The generally accepted pathway for acute MOR regulation. Modified from Connor et al. 
(2004). 
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Opioid agonists elicit distinctive agonist-selective patterns of phosphorylation, which 
account for the agonist-selective ability to promote MOR internalization (Doll et al., 
2011; Illing et al., 2014). Different types of kinases have been reported to phosphorylate 
MOR, depending on the agonist used to activate the receptor. For example, the full 
agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) induces desensitization by a 
G protein-coupled receptor kinase (GRK)-dependent mechanism (Johnson et al., 2006). 
GRKs selectively recognize ligand-activated receptors (Freedman and Lefkowitz, 1996). 
For that reason, phosphorylation by GRKs is associated with homologous desensitization 
(Gainetdinov et al., 2004). Both GRK2 and GRK3 have been implicated in MOR 
desensitization in vitro (Kovoor et al., 1998; Zhang et al., 1998). In addition, cyclic AMP 
dependent protein kinase A (PKA), protein kinase C (PKC), calcium/calmodulin-
dependent protein kinase (CaMKII) (Mestek et al., 1995), tyrosine kinases (Pak et al., 
1999) or MAPK (Polakiewicz et al., 1998) have all been described to phosphorylate 
MOR and promote desensitization. In contrast to DAMGO, morphine-induced 
desensitization has been described to be PKC-dependent (Bailey et al., 2004; Johnson et 
al., 2006; Bailey et al., 2009b; Levitt and Williams, 2012). Unlike GRK-dependent 
phosphorylation, PKA- or PKC-mediated phosphorylation is not necessarily followed by 
rapid endocytosis. Moreover, second messenger-dependent protein kinases not only 
phosphorylate agonist-activated receptors, but they can phosphorylate indiscriminately 
other receptors that have not been activated by the agonist, which can lead to 
heterologous desensitization (Gainetdinov et al., 2004).  
Phosphorylation of a GPCR appears to increase the affinity of the receptor for β-
arrestin binding (Lohse et al., 1993). In the CNS, β-arrestin 1 and β-arrestin 2 are 
concentrated especially at postsynaptic sites (Attramadal et al., 1992). Arrestin-dependent 
internalization promotes sequester of MORs in receptor-containing endosomes. 
Internalization of MOR is also an agonist-dependent phenomenon. Thus, enkephalins, 
DAMGO, fentanyl and methadone induce significant internalization of MOR, whereas 
morphine fails to promote internalization in different systems (Arden et al., 1995; Keith et 
al., 1996; Sternini et al 1996; Trapaidze et al., 2000; Alvarez et al., 2002; Bailey et al., 
2003; Minnis et al., 2003). It has been suggested that agonists that induce substantial 
MOR internalization have less potential to cause tolerance (Finn and Whistler, 2001), 
because they would allow for receptor reinsertion in the membrane. On the contrary, 
some studies have established that internalization is not necessary for recovery of MOR-
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mediated effects (Arttamangkul et al., 2006; Dang et al., 2011). In addition, there is no 
clear evidence that strongly internalizing agonists produce differential tolerance 
compared with weakly internalizing opioids in humans. Thus, continuous administration 
of transdermal fentanyl in pain patients (high efficacy, moderate endocytosis) was found 
to produce greater tolerance in comparison with buprenorphine (low efficacy, non-
internalizing) (Sittl et al., 2006).  
Regarding the time-course of these pathways involved in MOR regulation, 
phosphorylation of MOR at putative GRK sites is rapid, apparently saturating within 1–2 
minutes when receptors are stimulated by highly efficacious peptide agonists. 
Internalization seems to be slower with time constants generally in the order of ≥5 
minutes and reaching steady state in less than 30 minutes. Recovery from rapid 
desensitization is thought to occur in approximately 1 hour (Williams et al., 2013) (Fig. 
1.7). On the other hand, down-regulation refers to a reduced number of receptors present 
in cells, as a result of enhanced degradation and/or reduced biosynthesis of receptors 
(Tsao and von Zastrow, 2000). It can be distinguished from the process of internalization, 
which is characterized by a physical redistribution of receptors between the membrane 
and intracellular compartments without a detectable change in total receptor number. 
Down-regulation is also a much slower process, typically induced over a period of hours 
to days after prolonged or repeated exposure to an agonist (Law et al., 1982). 
Figure 1.7. Time-course of the mechanisms that lead to MOR desensitization (Williams et al., 2013). 
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On the other hand, other mechanisms have also been suggested to participate in MOR 
desensitization. These mechanisms include regulators of Gβγ dimers such as the 
phosducin-like proteins (Garzón et al., 2002) or the regulators of G protein signaling 
(RGS) (Potenza et al., 1999; Garzón et al., 2001, 2005). RGS proteins accelerate the 
hydrolysis of GTP by the Gα subunit, thereby limiting the duration of GPCR signaling 
(for review, see Jean-Baptiste et al., 2006). Moreover, RGSs have been reported to favor 
MOR desensitization by binding and sequestering agonist-activated Gα subunits (Garzón 
et al., 2001, 2005). On the other hand, Raveh et al. (2010) have suggested that GRKs 
enable rapid GIRK desensitization through a mechanism that, surprisingly, does not 
involve their kinase activity, but rather depends on their ability to bind the Gβγ subunits 
required for downstream signaling. 
As previously mentioned, desensitization of MOR is thought to contribute to opioid 
tolerance. However, other multiple mechanisms participate in the development of 
tolerance at both spinal and supraspinal levels in vivo. Thus, opioid tolerance is associated 
with impaired receptor resensitization and with receptor down-regulation (Dang and 
Christie, 2012; Williams et al., 2013). Studies that have explored fast components of 
desensitization and recovery in neurons from chronically treated animals are of particular 
interest. Thus, MOR desensitization is facilitated in rats treated with morphine, whereas 
recovery from desensitization is inhibited when compared to untreated animals (Dang and 
Williams, 2004). Hence, a desensitizing stimulus applied to neurons following chronic 
morphine treatment causes subsequent MOR uncoupling to a much greater extent than 
those from untreated animals. 
On the other hand, a large list of molecules acting on different pathways have been 
reported to block opioid tolerance, including N-methyl-D aspartate receptor (NMDAR) 
antagonists (Elliott et al., 1994), nNOS inhibitors (Santamarta et al., 2005), PKC 
inhibitors (Hull et al., 2010), substance P antagonists (Foran et al., 2000), serotonin 
reuptake inhibitors (Nayebi et al., 2009), calcium channel blockers (Dogrul et al., 2005) 
or calcitonin gene-related peptide receptor antagonists (Powell et al., 2000). Spinal glia 
activation and neuronal apoptosis also appear to contribute to opioid tolerance (Song and 
Zhao, 2001; Mao et al., 2002; Watkins et al., 2005; Zhou et al., 2010). Unfortunately, 
despite decades of study, the mechanisms underlying opioid tolerance remain far from 
clear.  
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1.1.5 Morphine, methadone and fentanyl: three different opioids 
 
The six most common clinically used opioids are morphine, oxycodone, 
hydromorphone, fentanyl, buprenorphine and methadone (Pergolizzi et al., 2008). 
Although these drugs differ in their chemical structure, the primary target for their actions 
is the MOR (Eddy and May, 1973; Raynor et al., 1994). Methadone is a synthetic opioid 
with potent analgesic effects that has been widely used for the treatment of opioid 
dependence (Dole et al., 1966), but its use has extended to pain management as well. 
Thus, it has been studied as a therapy for cancer pain and other chronic pain states (De 
Conno et al., 1996; Gardner-Nix, 1996; Ripamonti et al., 1997). However, the clinical use 
of methadone as an analgesic is complex because of its prolonged and variable half-life 
(typically ≈ 24 hours). Methadone has no active metabolites or prodrug forms and it is 
administered clinically as a racemic mixture. The R-isomer possesses analgesic activity 
whereas the S-isomer is inactive or weak as an opioid (Scott et al., 1948; Ingoglia and 
Dole, 1970). It has been reported that R-methadone has a 10-fold higher affinity for MOR 
than S-methadone and both isomers have a low affinity for DOR and KOR (Kristensen et 
al., 1995). In addition, methadone has non-opioid pharmacologic actions including 
inhibition of the reuptake of monoamines (Codd et al., 1995), blockade of NMDARs 
(Gorman et al., 1997; Ebert et al., 1998; Matsui and Williams, 2010) and blockade of 
GIRK channels (Rodríguez-Martín et al., 2008; Matsui and Williams, 2010). The 
blockade of NMDARs by methadone might be considered as one of its potentially 
relevant therapeutic actions because the NMDAR antagonist, MK801, reduces 
hyperalgesia (Mao et al., 1992), enhances opioid analgesia (Ebert et al., 1998) and 
attenuates morphine tolerance and dependence (Trujillo and Akil, 1991; Bilsky et al., 
1996). Moreover, it has been shown that opioid analgesics that inhibit monoamine 
reuptake, such as methadone, induce antidepressant-like effects that may account for their 
analgesic effects by regulating the affective dimension of pain (Rojas-Corrales et al., 
2002). However, this observation seems to disagree with the clinical reports about 
methadone-treated patients showing more risk to suffer depression (Brienza et al., 2000; 
Peles et al., 2007). 
Fentanyl is a synthetic opioid which was ﬁrst synthesized by Janssen in the 1960s, in 
an effort to produce opioid analgesics with stronger analgesic activity and better safety 
profile than morphine. Fentanyl and analogues are among the most potent opioid 
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analgesics known, estimated to be up to 100 times more potent than morphine 
(Vardanyan and Hruby, 2014). It has short-acting analgesic activity after intravenous or 
subcutaneous administration. However, the low molecular weight, high potency and lipid 
solubility of fentanyl make it suitable for transdermal delivery. Transdermal fentanyl is 
effective and well tolerated for the treatment of chronic pain caused by malignancy and 
non-malignant conditions (Kornick et al., 2003). Concerning future prospects, there are 
still many possibilities for development of novel fentanyl-related multivalent ligands. Of 
particular interest would be ligands with mixed and/or balanced µ and δ opioid receptor 
activities (Vardanyan and Hruby, 2014). 
 
 
Figure 1.8. Molecular structures of methadone (A), fentanyl (B) and morphine (C). 
 
The pharmacological actions of methadone and fentanyl differ in many ways from 
morphine. Morphine is the prototypical opioid drug used clinically for severe pain control 
and its potent antinociceptive effects have been shown to be mediated by the MOR 
(Matthes et al., 1996). It has been reported that fentanyl and morphine are full agonists for 
inhibiting cAMP accumulation and partial agonists for stimulating GTPγS binding (Zaki 
et al., 2000). Methadone has been described to be a full agonist in GTPγS binding studies 
(Rodríguez-Martín et al., 2008). Other studies measuring GIRK currents have reported 
that morphine and methadone are partial agonist at the MOR (Bailey et al., 2003; Johnson 
et al., 2006), but this may be because methadone blocks GIRK channel-mediated 
potassium conductance (Rodríguez-Martín et al., 2008; Matsui and Williams, 2010).  
 At the molecular level, morphine, methadone and fentanyl display different 
regulatory events at the MOR. Studies examining morphine-induced desensitization have 
yielded inconsistent and often contradictory results. While some authors have reported 
that morphine is a very poor desensitizing agent (Blake et al., 1997; Alvarez et al., 2002; 
Bailey et al., 2003), others have observed a more significant MOR desensitization by 
morphine (Dang and Williams, 2005; Arttamangkul et al., 2008). Accordingly, there is 
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considerable evidence that ongoing PKC activity is required for morphine-induced 
desensitization and tolerance (Bailey et al., 2004, 2009a; 2009b; Hull et al., 2010; Levitt 
and Williams, 2012; Sánchez-Blázquez et al., 2013). On the other hand, methadone- and 
fentanyl-induced analgesic tolerances have been reported to be GRK3-dependent 
(Terman et al., 2004; Melief et al., 2010). Moreover, as explained in section 1.1.4, 
morphine differs from most opiates in its poor ability to internalize MORs (Arden et al., 
1995; Keith et al., 1996; Sternini et al 1996; Trapaidze et al., 2000; Alvarez et al., 2002; 
Bailey et al., 2003; Minnis et al., 2003). On the contrary, methadone and fentanyl have 
been found to induce rapid desensitization and efficacious internalization in different 
systems (Whistler et al., 1999; Zaki et al., 2000; Alvarez et al., 2002; Minnis et al., 2003; 
Koch et al., 2005; Arttamangkul et al., 2008; Virk and Williams, 2008; Anselmi et al., 
2013). On the other hand, systemic administration of fentanyl has been reported to have 
the greatest relative efficacy, followed by methadone and morphine (Sirohi et al., 2008; 
Madia et al., 2009).  
 
1.2 NITRIC OXIDE  
 
In 1980, Furchgott and Zawadzki reported that the relaxation of the smooth muscle 
of in vitro preparations of rabbit aorta in response to acetylcholine was dependent on the 
presence of endothelial cells in the preparation. They established that acetylcholine-
treated endothelium was releasing a diffusible factor that would relax blood vessels by 
activating guanylate cyclase (Furchgott and Zawadzki, 1980). The diffusible factor was 
then termed the endothelium-derived relaxing factor (EDRF), although it was later 
identified as nitric oxide (NO) (Ignarro et al., 1987; Palmer et al., 1987). Soon after, its 
presence in the CNS was detected (Garthwaite et al., 1988). 
1.2.1 Synthesis of NO  
 
NO is produced when L-arginine is transformed to L-citrulline through catalysis by 
the NO synthase (NOS) (Tayfun-Uzbay and Oglesby, 2001). Three isoforms of NOS have 
been identified, products of different genes, with different localization, regulation and 
catalytic properties (for review see Marletta, 1994; Alderton et al., 2001). Neuronal NOS 
(nNOS) (also known as NOS-1) was the first synthase to be cloned and it is found in the 
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brain, peripheral nerves and some non-neuronal tissues. The second NOS to be cloned 
was isolated from macrophages and it is known as inducible NOS (iNOS or NOS-2) 
because it is readily induced in many tissues by proinflammatory cytokines. Finally, 
endothelial NOS (eNOS or NOS-3) was the last to be cloned. eNOS can be bound to 
plasma membranes and is typically expressed in vascular endothelium, airway epithelium 
and endocardial cells. Both nNOS and eNOS, are grouped together as constitutive NOS 
(cNOS), because they are usually constitutively expressed in the cell. Unlike iNOS, Ca2+-
calmodulin (CaM) is required for the activation of nNOS and eNOS (Toda et al., 2009). 
Furthermore, a mitochondrial NOS (mtNOS) has been described (Bates et al., 1995, 
1996). Its existence is questioned (Lacza et al., 2006), but the presence and the relevance 
of heart mitochondrial NOS has been recently reviewed (Zaobornyj and Ghafourifar, 
2012). 
1.2.2 nNOS: structure, localization and regulation  
 
The nNOS consists of 1434 amino acids with a predicted molecular weight of 160.8 
kDa (Boissel et al., 1998). The active form of the nNOS is the dimer. Each monomer 
contains an oxygenase domain (N-terminal) and a reductase domain (C-terminal), which 
can be separated by a regulatory CaM binding motif (for review, see Zhou and Zhu, 
2009). The oxygenase domain binds the substrate L-arginine and contains a 
tetrahydrobiopterin (BH4) binding site and a heme active site. The reductase domain 
binds the substrate nicotinamide adenine dinucleotide phosphate (NADPH) and it 
contains a binding site for flavin mononucleotide (FMN) and flavin adenine dinucleotide 
(FAD). Electrons (e-) donated by NADPH flow from the reductase domain to the 
oxygenase domain via FMN and FAD, a process that is regulated by CaM binding 
(Roman et al., 2006) (Fig. 1.9).  
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Figure 1.9. Schematic representation of the nNOS structure. nNOS catalyzes the oxidation of L-arginine to 
form L-citrulline and NO. The enzyme contains an oxygenase domain and a reductase domain, separated by 
a calmodulin binding motif. Electrons are donated by NADPH and transfer from the reductase domain to 
the oxygenase domain via FMN and FAD (Zhou and Zhu 2009). 
 
In the CNS, nNOS-containing neurons are present in many areas, with the highest 
densities occurring in the accessory olfactory bulb and granule cells of the cerebellum. 
nNOS can be located either pre- or post-synaptically. Although neurons that express 
nNOS represent only roughly 1% of cell bodies in the cerebral cortex, virtually every 
neuron in the cortex is exposed to nNOS nerve terminals (for review, see Esplugues, 
2002). 
As NO is a highly diffusible molecule that cannot be stored in the cells, new 
synthesis is required to exert its actions. Fractionation studies have demonstrated that 
brain nNOS exists in particulate and soluble forms (Hecker et al., 1994). Rothe et al 
(1998) showed that nNOS immunoreactivity of brain neurons was mainly distributed in 
cytosol far from membranes. A nuclear localization of nNOS in cultured astrocytes of rats 
has also been reported (Yuan et al., 2004). Differential subcellular localization of nNOS 
in the cell may contribute to its diverse functions. 
It has been shown that phosphorylation of nNOS regulates its activity. Several 
kinases have been reported to phosphorylate the nNOS, such as PKA, calmodulin- 
dependent kinases or PKC. Phosphorylation by CaMKII results in a decrease in enzyme 
activity, whereas a moderate increase in enzyme activity is observed after 
phosphorylation by protein kinase C (Nakane et al., 1991; Rameau et al., 2004). 
Introduction  
    
20 
However, the most important regulator of nNOS activity seems to be free Ca2+, which 
stimulates nNOS through interaction with CaM. It has been reported that electron flow 
from FAD to FMN slows down when CaM and Ca2+ are absent (Matsuda and Iyanagi, 
1999). When Ca2+ levels increase, CaM binds to nNOS, activating nNOS. On the 
contrary, when Ca2+ concentration decreases to basal levels, CaM dissociates from nNOS, 
and it becomes inactive again (For review, Zhou and Zhu, 2009). Availability of calcium 
ions to stimulate NOS may originate from the extracellular space through voltage-
dependent Ca2+ channels (Alagarsamy et al., 1994) or glutamate ionotropic NMDARs 
(Bredt and Snyder, 1989; East and Garthwaite, 1991). NO has been also reported to 
mediate the release of Ca2+ from neuronal intracellular Ca2+ stores via ryanodine 
receptors (Kakizawa et al., 2012). 
1.2.3 Targets for NO 
 
The potential reactions of NO are numerous and dependent on many different factors. 
NO can readily diffuse through cell membranes and reacts with cellular components, 
exerting both direct and indirect effects (Davis et al., 2001). The direct effects are 
mediated by the reaction of NO with metal complexes, whereas indirect effects are 
mediated by the formation of reactive nitrogen species (RNS) and reactive oxygen species 
(ROS) (shortening, from now on, we will name them indistinctly ROS). The source, the 
site and the concentration of NO are the major factors determining whether NO will elicit 
direct or indirect effects (Wink and Mitchell, 1998). Thus, direct effects occur at low NO 
concentrations (< 1 µM), far from the site of NO production, whereas indirect effects of 
NO become significant at higher local concentrations of NO (> 1 µM). 
 
1.2.3.1 The NO/cGMP signal transduction pathway 
 
The first characterized and probably the most physiologically relevant direct effect of 
NO involves the interaction of NO with the soluble hemeprotein guanylate cyclase (sGC) 
(Arnold et al., 1977; Ignarro, 1999). However, NO has been described to react also with a 
variety of other FeII-systems including the heme centres of haemoglobin, myoglobin, 
NOS and cytochrome P450 (Heinrich et al., 2013). 
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The enzyme sGC catalyzes the formation of 3’-5’-cyclic-guanosine-monophosphate 
(cGMP) from guanosine 5’-triphosphate (GTP), which acts as an intracellular messenger. 
This enzyme is typically found as a heterodimer, consisting of a larger α-subunit and a 
smaller heme-binding β-subunit, although homodimers of these subunits can also form 
(Zabel et al., 1999). Mammals express four sGC subunits (α1, α2, β1 and β2) and two 
existing isoforms of the heterodimeric guanylyl cyclase are known: α1β1 and α2β1, which 
are functionally indistinguishable (Russwurm and Koesling, 2002). The β2 subunit does 
not yield a catalytically active GC upon coexpression with the other subunits (Russwurm 
et al., 2013). Studies on the expression revealed a ubiquitous distribution of the α1β1 
isoform and a more limited occurrence of α2β1 (Mergia et al., 2003). The highest 
expression of α2β1 is found in brain where both isoforms are present in similar amounts. 
On the other hand, there are seven transmembrane forms of GCs, known as particulate 
GCs (pGCs). In contrast to sGC, pGCs are activated by natriuretic peptides (Leitman et 
al., 1994). 
Although sGC possesses basal activity, it is activated many fold by NO. The 
activation of sGC by NO in vitro and in vivo occurs in milliseconds. The generally 
accepted mechanism for sGC activation is the nitrosylation of the regulatory ferrous 
heme, producing a pentacoordinate ferrous-nitrosyl (Fe2+-NO) complex (Stone and 
Marletta, 1996; Derbyshire and Marletta, 2012; Heinrich et al., 2013). One major 
prerequisite for the NO-induced activation of sGC is the presence of the reduced Fe2+ 
heme moiety; its removal abolishes any NO-induced enzyme activation (Ignarro et al., 
1986). It should be noted that the sGC response decreases upon repeated exposure to NO 
and a single pretreatment of cells with NO can significantly reduce cGMP stimulation 
upon the second exposure (Schroder et al., 1988; Bellamy et al., 2000). 
cGMP acts on different targets, such as specific protein kinases, cyclic nucleotide-
degrading phosphodiesterases (PDEs) and cyclic nucleotide-gated ion channels (Lucas et 
al., 2000) (Fig. 1.10). The cGMP-dependent protein kinases (PKGs) are attractive 
candidates as mediators of cGMP signaling. The PKGs belong to the serine/threonine 
kinase family. Molecular cloning has identiﬁed two genes that encode PKGI and PKGII. 
The N terminus of PKGI is encoded by two alternatively spliced exons that produce the 
isoforms PKGIα and PKGIβ. PKGs exist as homodimers and share common structural 
features. They are composed of three functional domains: an N-terminal domain, a 
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regulatory domain and a catalytic domain (Feil et al., 2003). PKGI family is more 
commonly involved when cGMP signaling is mediated by NO (Potter et al., 2011). 
PKGI is majorly expressed in all types of smooth muscle, platelets and specific 
neuronal areas such as cerebellar Purkinje cells, hippocampal neurons and the lateral 
amygdala. PKGII is prominent in most brain regions, intestinal mucosa and kidney 
(Lohmann et al., 1997; Hofmann and Wegener, 2013). The Iα and Iβ PKGs are soluble 
enzymes and interact with different proteins through their distinct N termini. On the 
contrary, the PKGII is anchored at the plasma membrane. PKGs have been reported to 
phosphorylate a large amount of target proteins including the PKA type I regulatory 
subunit (Geahlen and Krebs, 1980), PDE5 (Thomas et al., 1990) or the ryanodine receptor 
(Takasago et al., 1991).  
PDEs are enzymes that regulate the cellular levels of the second messengers cAMP 
and cGMP, by controlling their rates of degradation. In mammals, PDEs are encoded by 
21 genes, producing 11 distinct PDE families and splice variants. They are classified as 
cAMP specific (PDEs 4, 7, 8), cGMP specific (PDEs 5, 6, 9) and dual specificity PDEs 
(PDE 1, 2, 3, 10, 11) (Bender and Beavo, 2006). On the other hand, cyclic nucleotide-
regulated cation channels are ion channels which are also activated by the binding of 
cGMP or cAMP. These channels pass Na+, K+ and Ca2+. They have been originally 
identified in photoreceptors and olfactory receptor neurons, where they play a 
fundamental role in sensory transduction, buy they have been also reported to exist in 
several other cell types and tissues including brain, kidney or endocrine tissues (Kaupp 
and Seifert, 2002; Biel, 2009).  
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Figure 1.10. cGMP signaling pathways: cGMP generators (green) and effectors (red), as well as some 
downstream pathways and cellular functions (grey boxes) that are involved in the effects of endogenous 
cGMP and/or cGMP-elevating drugs (blue) (modified from Feil and Kemp-Harper, 2006). 
 
1.2.3.2 ROS generation  
 
NO can react with either O2 or O2
·- to produce ROS, through reactions of nitrosation, 
oxidation or nitration (Huie and Padmaja, 1993; Wink and Mitchell, 1998). NO can also 
react with NO2 to produce N2O3. More importantly, reaction of NO with O2
·- involves the 
generation of the powerful oxidant peroxynitrite (ONOO-), a key mediator of NO toxicity 
(for review see Radi, 2013). 
Mitochondria is a central intracellular source of O2
·-, and peroxynitrite formation is 
favored by the easy diffusion of NO from the cytosol (Poderoso et al., 1996). O2
·- is 
continuously forming during normal cellular metabolism as a product of cellular oxidases 
such as NADPH oxidase (NOX) and xanthine oxidase. Its production is tightly controlled 
by manganese superoxide dismutase (MnSOD) as well as other antioxidant enzymes such 
as catalase or glutathione peroxidase (GPx). However, superoxide production rates 
increase several fold during the disruption of cellular redox homeostasis and with 
inflammatory stimuli. Under these conditions of nitroxidative stress, increased O2
·- 
production overwhelms the cellular antioxidant defenses and allows the generation of 
peroxynitrite (Salvemini and Neumann, 2010) (Fig. 1.11). Peroxynitrite is a potent 
oxidant and pro-inflammatory molecule. It mediates the oxidation of both non-protein and 
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protein sulfhydryls (Radi et al., 1991a), lipid peroxidation (Radi et al., 1991b) and protein 
tyrosine nitration (Beckman, 1996).  
Another remarkable target for ROS is DNA. Chemical alteration of DNA may 
provide important consequences in a variety of pathological mechanisms. There are three 
potential chemical mechanisms by which NO can damage DNA. The first is direct 
reaction of ROS with the DNA structure. The second is through inhibition of repair 
processes and the third is increasing genotoxic species production, such as alkylating 
agents (Wink and Mitchell, 1998). NO/ROS are involved in many pathological processes, 
as discussed below. 
 
Figure 1.11. ROS are generated under tightly 
controlled antioxidant conditions during normal 
physiology (A). However, under nitroxidative 
stress conditions antioxidant defenses are not 
sufficient and peroxynitrite production is 
significantly increased (B) (Salvemini and 
Neumann, 2010). 
 
 
 
 
1.2.4 Physiological and pathophysiological role of NO signaling pathways 
 
NO has an array of functions (for review, see Pacher et al., 2007) (Fig. 1.12). In the 
CNS, it is involved in neuronal plasticity, facilitating long-term potentiation, which is a 
long-lasting enhancement in signal transmission between two neurons (Malen and 
Champman, 1997). NO has complex influences on memory formation through regulation 
of synaptic plasticity. Thus, NO regulates fear memory consolidation (Ota et al., 2008). 
Inhibition of NO synthesis produces amnesia (Holscher and Rose, 1992) and disrupts 
spatial learning and olfactory memory (Bohme et al., 1993; Kendrick et al., 1997). NO 
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has also been implicated in visual processing, discriminative learning, food and drinking 
behavior, thermoregulation and circadian rhythms, among other central functions 
(Esplugues, 2002). 
Physiological amounts of NO have been found to be neuroprotective, whereas higher 
concentrations are clearly neurotoxic (Calabrese et al., 2007). NO has been shown to 
mediate the neurotoxicity of glutamate (Dawson et al., 1991). Thus, in a situation where 
there is an excessive release of glutamate, such as during cerebral ischemia, this 
neurotransmitter exerts its actions via NMDARs, which promotes the entry of Ca2+ into 
the cell and triggers the activation of nNOS and the overproduction of NO. Peroxynitrite 
seems to be the major cytotoxic mediator in glutamate-induced damage (Lafon-Cazal et 
al., 1993; Tanaka et al., 1997; Fukuyama et al., 1998). The damage caused to DNA by 
NO and peroxynitrite appears to be a remarkable neurotoxic mechanism. NO is also 
involved in the etiology of neurologic conditions, including autoimmune and chronic 
neurodegenerative diseases. Thus, NO has been reported to contribute to the progression 
of Alzheimer's disease (Fernandez et al., 2010), Parkinson's disease (Del-Bel et al., 2011), 
Huntington’s disease (Butterfield et al., 2001) or amyotrophic lateral sclerosis (Urushitani 
and Shimohama, 2001).  
NO-signaling pathways also modulate cell proliferation, cell cycle arrest and 
apoptosis. Thus, low concentrations of NO seem to favor cell proliferation and 
antiapoptotic responses whereas higher levels of NO favor apoptosis (Napoli et al., 2013). 
Similarly, high levels of NOS expression appear to be cytostatic or cytotoxic for tumor 
cells, whereas low levels can have the opposite effect and promote tumour growth (Xu et 
al., 2002). The mitochondria is emerging as a key feature of peroxynitrite-mediated 
apoptosis. Permeability pore opening in response to peroxynitrite has been documented in 
isolated mitochondria (Scarlett et al., 1996; Brookes et al., 2004). Moreover, 
peroxynitrite-induced nitration of mitochondrial proteins has been reported to inactivate 
mitochondrial respiratory chain, reduce ATP production and promote cell death 
(Yamamoto et al., 2002). In addition to directly targeting the mitochondria, peroxynitrite 
can also activate cell death mechanisms through the modulation of various signal 
transduction processes, such as MAPKs (Shacka et al., 2006). Finally, exposure of cells to 
higher concentrations of the peroxynitrite has been associated with necrosis (Bonfoco et 
al., 1995, Virág et al., 2003), which is a complex process involving DNA damage and 
activation of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) (Szabo et al., 
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1996). On the other hand, NO plays several roles in immunity: as a toxic agent towards 
infectious organisms, an inducer or suppressor of apoptosis or an immunoregulator (for 
review see Coleman, 2001). 
NO/cGMP has long been known to be involved in smooth muscle relaxation and 
platelet aggregation. Thus, an impaired NO signaling represents a crucial pathogenic 
mechanism in cardiovascular diseases. Accumulating evidence suggests that alterations in 
NO synthesis and NO/sGC/cGMP signaling are key contributors to the pathogenesis of 
hypertension, one of the most common worldwide diseases (Escobales and Crespo, 2005; 
Wolin, 2005; Paravicini and Touyz, 2006). However, a role for NO and peroxynitrite in 
other cardiovascular conditions, such as stroke, myocardial infarction, chronic heart 
failure, diabetes or circulatory shock has also been reported (for review, Pacher et al., 
2007). Since NO enhances vascular smooth muscle relaxation, sGC stimulators could 
have unique clinical utility in the treatment of essential hypertension, pulmonary 
hypertension and associated cardiac and renal complications. Riociguat (BAY 63-2521) is 
the ﬁrst sGC stimulator that has been clinically developed. Clinical trials have shown that 
it significantly improves pulmonary vascular hemodynamics and increases exercise 
ability in patients with pulmonary arterial hypertension (Ghofrani et al., 2013). 
 
 
Figure 1.12. Some of the functions mediated by NO in vivo (Kim et al., 2014). 
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1.3  LOCUS COERULEUS (LC) 
 
1.3.1 Anatomy of the LC 
 
The LC is a compact cell group located in the brainstem. It consists of almost 
exclusively noradrenaline (NA)-containing neurons and represents the main 
noradrenergic nucleus in the central nervous system (CNS) (Foote et al., 1983). The first 
description of the LC was published by Reil in 1809, but the actual term “locus 
coeruleus” was proposed by the anatomists Wenzel and Wenzel in 1812 (reviewed by 
Russell, 1955). This Latin term means “blue spot” due to the melanin granules inside LC 
neurons, which provide a bluish shade to the nucleus.  
The noradrenergic nuclei in the brain include mainly the LC (A6 cell group) and 
several other less studied clusters of noradrenergic neurons (A1, A2, A5, A7) that 
primarily target subcortical regions (Dahlstrom and Fuxe, 1964; Bruinstroop et al., 2012). 
The LC is a dorsal pontine region placed bilaterally on the floor of the fourth ventricle 
and it is surrounded by the medial parabrachial nucleus, the mesencephalic trigeminal 
nucleus and the Barrington’s nucleus (Figure 1.13). The rat LC is composed by small 
number of neurons: approximately 1,500. Although it is generally accepted that NA is the 
main transmitter of LC neurons, the cell bodies also secret several neuropeptides, such as 
galanin, vasopressin, neuropeptide Y or somatostatin (for review, see Berridge and 
Waterhouse, 2003). 
 
Figure 1.13. Photomicrograph of Nissl-stained coronal 
section of the brainstem region containing the LC (Scale 
bar, 1 mm). Image modified from Bernuci et al. (2008). 
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1.3.1.1 Afferent projections to the LC 
 
The LC receives direct excitatory and inhibitory inputs. The major afferents to the 
LC arise from two structures: the lateral paragigantocellularis nucleus (PGi) and the 
nucleus prepositus hypoglossi (PrH) (Aston-Jones et al., 1986), both located in the rostral 
medulla. The PGi provides a potent excitatory amino acid input to the LC, whilst the PrH 
potently inhibits LC neurons by a GABAergic input (Aston-Jones et al., 1991). Both PrH 
and PGi endow the LC with enkephalinergic projections (Drolet et al., 1992). Moreover, 
the LC receives additional gabaergic afferents from the periaqueductal gray (PAG) and 
the ventrolateral preoptic hypothalamic area (Steininger et al., 2001), serotonergic 
afferents from the dorsal raphe nucleus (DRN) (Kim et al., 2004), dopaminergic inputs 
from the ventral tegmental area (VTA) (Maeda et al., 1994) and noradrenergic afferents 
from the bulbar/pontine nuclei and the contralateral LC (Singewald and Philippu, 1998). 
Corticotropin-releasing hormone (CRH) innervation is also present in the LC which 
comes from the Barrington's nucleus (Valentino et al., 1996) and orexin/hypocretin and 
histaminergic inputs that originate in the hypothalamus (Pollard et al., 1978; Horvath et 
al., 1999; de Lecea, 2010). 
On the other hand, a dense dendritic plexus has been reported to extend beyond the 
borders of the nucleus (Shipley et al., 1996). This pericoerulear region is the target for a 
large number of presynaptic fibers from several brain regions such as the prefrontal 
cortex, amygdala, hypothalamus or the DRN (Berridge and Waterhouse, 2003). 
GABAergic interneurons have been shown to be present in this pericoerulear region 
(Aston-Jones et al., 2004). 
 
1.3.1.2 Efferent projections from the LC 
 
LC gives rise to a broad, noradrenergic efferent network that innervates most of the 
major areas of the brain including the cerebral cortex, cerebellum, thalamus, 
hypothalamus, hippocampus, brainstem and dorsal and ventral horns of the spinal cord 
(Samuels and Szabadi, 2008, part I) (Fig. 1.14). The LC has long been considered a 
homogeneous assembly of NE-containing cells with broad and uniform actions 
throughout the cerebral cortex (Fallon and Loughlin, 1982; Berridge and Waterhouse, 
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2003). However, recent studies have challenged this notion and postulate that LC neurons 
exhibit a more heterogeneous and complex organization than previously thought 
(Chandler et al., 2014a, 2014b). According to this research, populations of LC neurons 
that communicate with the prefrontal cortex show different molecular phenotypes and 
electrophysiological properties in comparison with those LC neurons that project to the 
motor cortex. Thus, this heterogeneity might result in a differential noradrenergic 
modulation of these areas. Moreover, recent findings by Robertson et al. (2013) have 
shown that the insular cortex is innervated by non-LC derived NE terminals, challenging 
the longstanding notion that LC is the sole source of NA-containing fibers to the 
forebrain. 
 
 
 
Figure 1.14. Sagittal view of a monkey brain 
showing major efferent projections of the LC 
throughout the CNS (Aston-Jones and Cohen, 
2005). 
 
 
  
1.3.2 Physiology of the LC: intrinsic properties and physiological regulation 
 
In both anesthetized and unanesthetized animals LC neurons show some distinctive 
and representative electrophysiological properties, such as broad action potential spikes 
(2-4 ms) and a spontaneous, tonic activity characterized by relatively slow and regular 
firing rates (0.5-5 Hz). LC neurons respond to afferent stimuli by a phasic activity 
distinguished by burst discharges followed by a prolonged period of decreased firing 
(Cedarbaum and Aghajanian, 1976; Andrade et al., 1983; Andrade and Aghajanian, 1984; 
Berridge and Waterhouse, 2003). These two patterns of discharge, tonic and phasic, 
promote different modes of signal processing and behaviors (Aston-Jones and Cohen, 
2005). Moreover, both characteristics of LC discharge, the frequency and the pattern, are 
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determinants for NA release; bursts are more effective in increasing NA terminal release 
(Florin- Lechner et al., 1996).  
 
Figure 1.15. Characteristic extracellular waveforms of LC 
neurons recorded in vivo and in vitro, which consist of an 
initial positive component followed by a negative and a 
second positive deflection (Andrade et al., 1983). 
 
 
Probably, one of the most remarkable physiological characteristic of the LC is that its 
neurons fire action potentials spontaneously in vitro in the absence of any stimulation. 
This pacemaker activity depends on intrinsic membrane currents. One is an inward Na+ 
current that is active near the threshold for action potential generation. The second is a K+ 
current that is activated following the entry of calcium during the action potential and it is 
responsible for hyperpolarization (Williams et al., 1984, 1991).  
Multiple mechanisms modulate the spontaneous firing activity of LC cells. Firing 
rate of LC neurons is increased by activation of cAMP pathway (Wang and Aghajanian, 
1987). In addition, NA exerts its action through postsynaptic α2-adrenoceptors, which are 
coupled to Gi/o proteins and reduce the electrical activity of LC neurons by acting on 
GIRK channels (Egan et al., 1983; Arima et al., 1998). Likewise, activation of MOR 
inhibits the firing rate of LC cells by acting on GIRK channels (North et al., 1987) and 
inhibiting adenylyl cyclase activity and cAMP signaling (Duman et al., 1988). A role for 
5-HT receptors in LC cell activity has been reported. Thus, 5-HT1A receptors may 
mediate an inhibitory response on the LC (Bobker and Williams, 1989), although other 
authors have observed an excitatory regulation of LC neurons by 5-HT1A receptors 
(Szabo and Blier, 2001). Recent work has described that 5-HT3 promotes a decrease in 
the firing rate of LC neurons, by stimulating NA release (Ortega et al., 2012). Moreover, 
cannabinoids increase the spontaneous firing activity in the rat LC through CB1 
receptors, apparently by an indirect mechanism located at the peripheral level 
(Mendiguren and Pineda, 2006). Furthermore, activation of CB1 receptors enhances 
postsynaptic excitatory responses to NMDA in LC neurons (Mendiguren and Pineda, 
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2004). I1 and non-I1/I2-types imidazoline receptors have been described to stimulate NA 
cells (Pineda et al., 1993; Ugedo et al., 1998). CO2 has also been shown to maintain the 
tonic activity of LC neurons by decreasing intracellular pH, which closes inward rectifier 
potassium channels (Pineda and Aghajanian, 1997).  
Spontaneous activity is altered by both glutamatergic and gabaergic synaptic inputs 
(Williams et al., 1991). It has been described that LC neurons are only weakly excited by 
glutamatergic afferents during tonic activity (Kawahara et al., 1999). However, during the 
phasic mode periods concurrent with peripheral stimuli glutamatergic afferents turn 
physiologically active in LC neurons (Ennis et al., 1992). The excitatory response is 
mediated by glutamate receptors of both NMDA and non-NMDA type, but several 
studies indicate that, under control conditions, non-NMDA (AMPA) receptors exert a 
stronger influence on LC cells (Cherubini et al., 1988, Ennis et al., 1992). The inhibitory 
activity is triggered among others by GABA, acting mainly on GABAA receptors 
(Osmanovic and Shefner, 1990; Williams et al., 1991). 
A further remarkable electrical characteristic of LC neurons is the cell-to-cell 
coupling via gap junctions (Ishimatsu and Williams, 1996). This type of intercellular 
connection facilitates a fast communication between cells and it allows for coordination 
of the firing of LC neurons, since the entire nucleus fires simultaneously in response to 
sensory inputs (Christie et al., 1989; Nestler et al., 1999). Additionally, it has been 
reported that neurons and glia are electrically coupled in the LC (Álvarez-Maubecin et al., 
2000). 
 
1.3.3 Physiological and pathophysiological aspects of LC-NA system 
 
1.3.3.1 Involvement of the LC in physiological activities 
 
Given the fact that the LC receives and projects multiple inputs and outputs, this 
nucleus is involved in a wide variety of functions, controlling different physiological 
processes: 
 
- Sleep cycle and awakening: The LC is recognized as a major wakefulness-
promoting nucleus. The firing activity of LC neurons varies with stages of the sleep-
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waking cycle. Thus, LC neurons display the highest firing rates during wakefulness, 
they fire more slowly during slow-wave sleep and cease firing during rapid eye 
movement (REM) sleep (Aston-Jones and Bloom, 1981). Sleep process has been 
described to start with deactivation of waking-promoting neurons from the forebrain 
and brainstem (Takahashi et al., 2010). The wakefulness-promoting action of the LC 
is the consequence of its projections to most areas of the cerebral cortex and to 
alertness-modulating nuclei (Samuels and Szabadi, 2008, part II). A recent study has 
reported that the orexinergic hypothalamic neurons contacting with the LC are 
implicated in the stage succession during sleep-wakefulness cycle (Tortorella et al., 
2013). 
 
- Learning and memory: NA release in different parts of the brain is essential for 
the modulation of memory. Stimulation of LC neurons has been shown to increase 
NA release in terminal regions and also within the LC itself, enhancing memory 
formation and consolidation (Clayton and Williams, 2000; Gibbs et al., 2010). 
 
- Attention: Studies examining the activity of LC neurons in monkeys during 
performance of a task that required focused attention have indicated that LC cells 
exhibit phasic or tonic patterns of discharge, in a close correlation with good or 
poor performance on that task respectively (for review, see Aston-Jones et al., 
1999). It has been reported that phasic mode facilitates behavioral responses to 
specific tasks. Thus, phasic mode is associated with focused attention. Conversely, 
a tonic activity mode is associated with disconnection with the current task and a 
search for alternative behaviors (Aston-Jones and Cohen, 2005). 
 
- Pain regulation: The LC and the A5 and A7 cell groups in the pons have been 
implicated as a key component in the descending control of pain (Jones, 1991; 
Millan, 2002; Pertovaara, 2006). Thus, electrical or chemical stimulation of the 
LC has been shown to be analgesic in a number of acute pain models (Jones and 
Gebhart, 1986; Miller and Proudfit, 1990; West et al., 1993). However, the 
potential of the descending noradrenergic system to suppress pain has not been 
successfully approached therapeutically. Thus, the use of systemic α2-adrenergic 
agonists is limited by side effects including sedation and hypotension (Pertovaara, 
2006). Similarly, NA reuptake inhibitors, although moderately efficacious for 
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neuropathic pain (Finnerup et al., 2010), are also restricted by side effects. 
However, in a recent study, a novel acute pronociceptive effect of LC activation 
has been described (Hickey et al., 2014). They propose that distinct 
subpopulations of neurons in the LC drive opposing 
antinociceptive/pronociceptive actions.  
 
- Autonomic functions: The activation of the LC results in a well-defined pattern 
of autonomic changes: in tissues receiving a predominantly sympathetic 
innervation, there is an increase in activity, whereas in those receiving 
predominantly parasympathetic innervation, there is a decrease in activity (for 
review, Samuels and Szabadi, 2008, part II). Thus, activation of LC increases 
pupil diameter (Phillips et al., 2000), increases heart rate and blood pressure 
(Gurtu et al., 1984) and reduces salivation (Szabadi and Tavernor, 1999) among 
other functions. On the contrary, fall of blood pressure increases the firing rate of 
LC neurons (Curtis et al., 1993) and enhances the in vivo release of NA in the LC 
(Singewald et al., 1999). The LC is also implicated in the control of ventilation 
(for review, see de Carvalho et al., 2014). It is considered a central CO2/pH 
chemoreceptor site in amphibians and mammals (Gargaglioni et al., 2010; Santin 
and Hartzler, 2013) and more than 80% of its neurons are chemosensitive, 
responding to hypercapnia with an increased firing rate (Pineda and Aghajanian, 
1997). 
 
1.3.3.2 Involvement of the LC in pathophysiological activities 
 
- Anxiety and stress: NA is involved in neural mechanisms underlying fear and 
stress. Stress exposure is associated with an increase in firing of LC cells and with 
an increased release of NA in brain regions which receive innervation from the 
LC (Bremner et al., 1996; Tanaka et al., 2000). Increased firing of LC neurons has 
also been associated with behavioral manifestations of fear (Bremner et al., 1996). 
A recent study in vivo using a validated rat model of post-traumatic stress shows 
persistent changes in LC function, such as lower spontaneous LC activity, 
elevated phasic responses to a noxious event, decreased recovery from post-
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stimulus inhibition and increased tyrosine hydroxylase mRNA expression in the 
LC (George et al., 2013). 
 
- Sleep/arousal disorders: noradrenergic neurotransmission can initiate and 
maintain prolonged periods of alert waking (Berridge and Foote, 1996). 
Therefore, NA system can be considered as an appropriate target in the treatment 
of sleep and arousal disorders (insomnia and narcolepsy). A recent study has 
shown that the firing pattern of LC neurons was markedly altered in narcoleptic 
mice, and this change might be due to a functional change of GABAergic input to 
these cells (Tsujino et al., 2013). 
 
- Depression: An animal model that identifies the LC activity as a biological 
mediator of depression has been proposed (Weiss et al, 2005). It was developed 
after observing that many behavioral symptoms of depression appear in 
conjunction with an increased firing activity of LC neurons (Simson and Weiss, 
1988). In addition, long-term but not acute administration of certain selective 
serotonin reuptake inhibitors (SSRIs) antidepressants significantly decreases 
spontaneous LC cell activity (Szabo et al., 1999). Moreover, depression is 
associated with altered concentrations of several noradrenergic proteins in the LC. 
Thus, elevated levels of tyrosine hydroxylase (TH) (Zhu et al., 1999), increased 
agonist binding to α2-adrenergic receptors (Ordway et al., 2003) and reduced 
levels of norepinephrine transporters (Klimek et al., 1997) have been reported in 
major depressive subjects and in suicide victims. Moreover, long-term 
antidepressant treatment induces a significant desensitization of α2-adrenoceptors 
in the LC (Mateo et al., 2001). 
 
- Neurodegenerative diseases: The LC is impaired in Parkinson disease (PD), as 
revealed by the extensive cell loss occurring in PD patients (Forno, 1996). The LC 
has also been implicated in L-DOPA-induced dyskinesias, the main side effect of 
the dopaminergic treatment of PD (Miguelez et al., 2011). Finally, dysfunction of 
the LC/NA system has been associated with PD-related dementia (Del Tredici and 
Braak, 2013). However, LC loss is not only a feature of PD. It has been published 
that in both Parkinson and Alzheimer diseases the most severe neuronal loss is 
found in the LC in post-mortem human brain (Zarow et al., 2003). 
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- Opioid withdrawal: The NA system has been proposed to play an important role 
in the expression of some signs of opiate withdrawal. It has been suggested that 
the LC is the structure mediating the expression of the somatic syndrome of 
opioid withdrawal. Thus, there is an overactivation of LC neurons during 
morphine withdrawal that is associated with an elevated release of glutamate from 
excitatory afferent projections (Rasmussen, 1991; Maldonado, 1997). Moreover, 
chronic opioid administration upregulates the adenosine-5´-monophosphate 
(cAMP) pathway in the LC and this adaptation is also involved in the increase in 
electrical excitability of LC neurons (Nestler and Aghajanian, 1997; Lane-Ladd et 
al., 1997; Valverde et al., 2004; Parlato et al., 2010). This increased firing activity 
has also been associated with specific opioid withdrawal behaviors (Punch et al., 
1997). 
 
1.3.4 MOR in the LC 
 
The LC has long been used as a model to explore the cellular mechanisms underlying 
opioid tolerance and withdrawal (Nestler et al., 1994). The three classes of opioid 
receptors, MOR, DOR and KOR are present within the LC, but with distinct distribution. 
Thus, MORs are prominently localized at extrasynaptic sites on noradrenergic dendrites 
(Van Bockstaele et al., 1996). On the contrary, DORs are primarily located in the plasma 
membranes of presynaptic axon terminals (Van Bockstaele et al., 1997) and KORs are 
also presynaptically found to modulate diverse afferent signaling in the LC (Kreibich et 
al., 2008; Reyes et al., 2009).  
In the LC, acute binding of opioid agonists to the MOR leads to decreased adenylyl 
cyclase activity and cAMP signaling (Duman et al., 1988). Opioids also inhibit the 
spontaneous discharge of LC neurons by activating GIRK channels (Pepper and 
Henderson, 1980; Williams et al., 1982); specifically, these GIRK channels contain 
GIRK2 and GIRK3 subunits (Torrecilla et al., 2002). During chronic opioid exposure 
there is an up-regulation of the cAMP signaling pathway (adenylyl cyclase, PKA…). This 
increase becomes functionally evident during withdrawal (Nestler and Tallman, 1988; 
Kogan et al., 1992; Lane-Ladd et al., 1997; Mazei-Robison and Nestler, 2012), when the 
firing rate of LC neurons is significantly increased (Rasmussen et al., 1990). 
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As in other systems, sustained opioid exposure induces MOR desensitization in LC 
neurons (Harris and Williams, 1991). The degree of MOR desensitization and the 
differential involvement of regulatory events (phosphorylation, internalization, 
recycling…) depend on the opioid agonist used (see section 1.1.4). The opioid agonist 
ME induces a concentration-related desensitization of MOR responses in the LC (Harris 
and Williams, 1991; Santamarta et al., 2014). Inhibition of GRK2 activity in LC neurons 
has no effect on the acute desensitization induced by ME (Quillinan et al., 2011), but 
concurrent blockade of GRK2 and ERK 1 and 2 reduces ME-induced desensitization 
(Dang et al., 2009). In contrast, Arttamangkul et al. (2012) have reported that protein 
kinase inhibition by the nonselective inhibitor staurosporine does not reduce the extent of 
ME-induced desensitization, although it increases the rate of recovery from 
desensitization (resensitization, see section 1.1.4). 
Other opioid agonists such as methadone, fentanyl, oxymorphone, normorphine or 
etorphine have been reported to induce significant MOR desensitization in the LC 
(Alvarez et al., 2002; Virk and Williams, 2008). Morphine induces significantly less 
receptor desensitization than other MOR agonists in LC neurons (Alvarez et al., 2002; 
Bailey et al., 2003; Blanchet et al., 2003; Virk and Williams, 2008). Morphine leads to 
MOR desensitization in LC neurons under enhanced PKC activity (Bailey et al., 2004; 
2009a, 2009b). Furthermore, chronic administration of morphine induces tolerance to the 
inhibitory effect of ME in the LC (Santamarta et al., 2005). Levitt and Williams (2012) 
have reported that both desensitization and cellular tolerance are present in LC neurons 
from morphine-treated animals and that these processes can be distinguished by the time 
course of recovery and mechanism. Moreover, after chronic treatment with morphine, but 
not with methadone, there is a diminished recovery from acute ME-induced 
desensitization in LC neurons (Quillinan et al., 2011).  
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Opioids are effective for the treatment of pain. Unfortunately, their long-term utility 
is limited by the development of tolerance and dependence. The mechanisms underlying 
opioid tolerance are multifaceted and, despite extensive research, they have not been fully 
identified. Opioid receptors undergo several adaptations following sustained agonist 
exposure, including desensitization, internalization, recycling or down-regulation (see 
Introduction, section 1.1.4). Desensitization of MOR is thought to be an important initial 
step underlying tolerance and it depends on agonist identity (Williams et al., 2013). The 
LC, the main noradrenergic nucleus in the CNS, contains a high-density of MORs (van 
Bockstaele et al., 1996). Chronic administration of opioid agonists produces adaptive 
changes in this nucleus. Thus, the LC has long been used as a model to study the 
molecular mechanisms underlying opioid tolerance and dependence (Nestler et al., 1994; 
Mazei-Robison and Nestler, 2012). 
The signaling messenger NO modulates nociceptive processing and it is implicated in 
different pain states (Luo and Cizkova, 2000). In the LC, NO regulates the neuronal firing 
activity (Pineda et al., 1996; Torrecilla et al., 2007) and it is a key mediator in the 
mechanisms underlying MOR regulation following agonist exposure (Pineda et al., 1998). 
Previous results from our group have shown that in vitro administration of nNOS 
inhibitors attenuates ME-induced MOR desensitization in the LC (Torrecilla et al., 2001; 
Santamarta et al., 2014), whereas perfusion with NO donors enhances it (Llorente et al., 
2012). The NO system has been also implicated in neuronal adaptations occurring in vivo 
during opioid tolerance. NOS expression in the CNS is increased following morphine 
treatment (Machelska et al., 1997; Cuéllar et al., 2000; Wong et al., 2000). Co-treatment 
with the selective nNOS inhibitor 7-NI attenuates the development of tolerance to the 
electrophysiological effect of opioids on LC neurons and to the antinociceptive effect of 
morphine challenge in morphine-treated rats (Santamarta et al., 2005). In agreement, mice 
deficient in nNOS exhibit less analgesic tolerance after prolonged morphine exposure 
than control animals (Heinzen and Pollack, 2004). 
NO interacts with the enzyme sGC to form cGMP, which in turn, targets different 
effectors, such as PKGs (Francis et al., 2010). The LC has been shown to express sGC 
(Matsuoka et al., 1992; Furuyama et al., 1993), PKG (El-Husseini et al., 1995), as well as 
detectable concentrations of cGMP (Xu et al, 1998a; Vulliemoz et al., 1999). Previous 
studies performed in our laboratory have shown that perfusion with the PKG activator 8-
Br-cGMP completely restores ME-induced MOR desensitization from the blockade 
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elicited by the nNOS inhibitor 7-NI in LC neurons (M.T. Santamarta, Doctoral Thesis). 
Moreover, modulators of the enzyme sGC regulate the development and expression of 
morphine tolerance (Ozdemir et al., 2011; Durmus et al., 2014).  
On the other hand, NO reacts with oxygen derivatives to produce ROS, such as the 
powerful oxidant molecule peroxynitrite (Hughes, 2008). NO enhances MOR 
desensitization in the LC, in part, through a ROS-involving mechanism (Llorente et al., 
2012). ROS are also involved in the development of pain of several etiologies in vivo, 
including that associated with opiate-induced hyperalgesia and antinociceptive tolerance 
(Salvemini et al., 2011; Janes et al., 2012). Previous results from our group have shown 
that co-administration of the antioxidant Trolox together with ascorbic acid attenuates the 
development of antinociceptive tolerance in morphine-treated rats (Llorente J. Doctoral 
Thesis, unpublished data). Likewise, peroxynitrite decomposition catalysts reduce 
morphine-induced analgesic tolerance in mice (Muscoli et al., 2007; Batinić-Haberle et 
al., 2009).  
Taken together, these evidences establish a link between NO and opioid 
desensitization and tolerance. However, a detailed study of NO-dependent downstream 
signaling pathways (sGC/PKG and ROS) involved in MOR desensitization in LC neurons 
remains to be performed in vitro. In addition, it has to be further studied whether ROS are 
involved in the development of cellular tolerance induced by morphine in LC neurons. 
Although morphine causes significant behavioral tolerance in vivo, there is controversy 
about its ability to induce acute MOR desensitization in vitro. Some studies performed in 
LC neurons using intracellular recording techniques have reported that morphine is a very 
poor desensitizing agent (Alvarez et al., 2002; Bailey et al., 2003). However, others have 
observed a significant desensitization of MOR induced by morphine under activation of 
PKC (Bailey et al., 2004; 2009b; Arttamangkul et al., 2015). To date, morphine-induced 
MOR desensitization has not been characterized by extracellular recordings in vitro. In 
addition, the involvement of nNOS in morphine-induced acute MOR desensitization 
remains to be further studied in the LC. Finally, morphine is the prototypical MOR 
agonist used in tolerance studies, but we also hypothesize that nNOS and ROS may 
modulate the development of both cellular and antinociceptive tolerance induced by other 
opioid agonists (methadone and fentanyl). 
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The global aim of this study was to elucidate the involvement of NO-dependent 
pathways in the development of MOR desensitization in LC neurons in vitro and in the 
induction of cellular and analgesic tolerance in vivo induced by different opioid agonists. 
The specific objectives of the present study were: 
1. To characterize in vitro the NO-dependent downstream signaling pathways (i.e. 
cGMP and ROS) involved in ME-induced and NO-enhanced MOR desensitization 
in rat LC neurons by single-unit extracellular recordings. For this purpose, we 
tested the effect of different modulators of the sGC/PKG pathway and 
antioxidants.  
 
2. To investigate in vitro the involvement of nNOS in morphine-induced MOR 
desensitization in LC cells by single-unit extracellular recordings. For this 
purpose, we evoked an excitation of LC neurons with KCl to study the 
desensitization of MOR induced by morphine and we tested the effect of selective 
nNOS inhibitors. 
 
3. To investigate in vitro the involvement of nNOS and ROS in the induction of 
cellular tolerance induced by prolonged treatments with different opioids 
(morphine, methadone and fentanyl) in LC neurons. For this purpose, we studied 
by single-unit extracellular recordings the development of tolerance to the 
electrophysiological effects of an opioid agonist following prolonged treatments 
with different opioids (morphine, methadone and fentanyl) and we evaluated its 
regulation by a selective nNOS inhibitor and antioxidant agents. 
 
4. To explore in vivo the involvement of nNOS and ROS in the development of 
opioid analgesic tolerance. We examined by the tail-flick test the development of 
analgesic tolerance following prolonged treatments with different opioids 
(morphine, methadone and fentanyl) and we evaluated its regulation by a selective 
nNOS inhibitor and antioxidant agents.  
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3.1 MATERIALS 
 
3.1.1 Animals 
 
Male Sprague-Dawley rats (200-300 g) obtained from the animal house of the 
University of the Basque Country were used for the electrophysiological and behavioral 
assays. The animals were kept under controlled environmental conditions (22º C, 12-h 
light/dark cycle, humidity of 65-70%) and free access to food and water. All experimental 
procedures were conducted in accordance with the European Communities Council 
Directive on "Protection of Animals Used in Experimental and Other Scientific Purposes" 
of 24 November 1986 (86/609/EEC) and with institutional guidelines for animals used in 
research (Animal Care and Use Committee of the University of the Basque Country). All 
the efforts were made to minimize animal suffering and to reduce the number of animals 
used. 
3.1.2 Treatments 
 
a) Opioids 
For induction of morphine tolerance, rats were treated subcutaneously (s.c.) with a 
slow release emulsion containing free base morphine (200 mg/kg) for 72 h, as described 
by Santamarta et al. (2005) (see section 3.1.3b for preparation details). The emulsion was 
injected subcutaneously on the back of the rat under light anesthesia with chloral hydrate 
(200 mg/kg, intraperitoneally (i.p.)). Sham animals were implanted with the same vehicle 
emulsion without morphine. Behavioral or electrophysiological experiments were 
conducted 72h after administration of morphine or sham emulsions. 
Tolerance to fentanyl (0.2 mg/kg/day, 7 days) and methadone (60 mg/kg/day, 6 days) 
was induced by s.c. implantation of Alzet® 2ML1 osmotic pumps (Fig. 3.1), as described 
by Trujillo et al. (2004) and Quillinan et al. (2011), respectively. These pumps have a 2 
ml reservoir and deliver the drug at the rate of 10 µl/h. The required amount of the drug 
was dissolved in saline and introduced into the pump with a needle provided by the 
manufacturer. Rats were anaesthetized with isoflurane and a little incision was made in 
the mid-scapular region to place the minipump in the subcutaneous space. Sham animals 
were also implanted with a minipump filled with saline under the same experimental 
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conditions. As methadone requires high doses to induce tolerance, rats were given i.p. 
injections of methadone before minipump implantation as follows: the day before, rats 
received 5 mg/kg at 09:00 h and 7 mg/kg at 18:00 h. Next day, rats where administered 7 
mg/kg at 09:00 h and the minipump was finally inserted at 18:00 h. Behavioral or 
electrophysiological experiments were carried out on day 7 in methadone-treated rats (6 
days after minipump implantation) and on day 8 in fentanyl-treated rats (7 days after 
minipump implantation). 
b) Antioxidants and nNOS inhibitors 
Sham and morphine-treated animals were daily injected with the antioxidant U-
74389G (10 mg/kg, i.p.), Trolox (40 mg/kg, i.p.) or their vehichles (saline). Every time 
Trolox was administered, rats also received ascorbic acid (100 mg/kg, i.p.) (TX+AA) to 
prevent the oxidation of Trolox. Sham-, methadone- and fentanyl-receiving rats were 
intraperitoneally injected every day with U-74389G (10 mg/kg) or its vehicle (saline).  
In another set of experiments, sham-, methadone- and fentanyl-treated animals were 
intraperitoneally injected every 12 h with the nNOS inhibitor 7-NI (30 mg/kg) or its 
vehicle (peanut oil).  
  
 
3.1.3  Drugs and reagents 
 
a) Drug sources 
Opioids. Met5-enkephalin (ME) was purchased from Bachem (Bodendorf, Germany). The 
following drugs were obtained from Sigma-Aldrich Quimica S.A. (Madrid, Spain): 
Figure 3.1. Schematic illustration of an 
Alzet® minipump. The content is released 
because of the osmotic pressure difference 
between the compartment within the pump 
and the tissue environment in which the 
pump is implanted. Obtained from 
www.alzet.com. 
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fentanyl citrate salt, methadone hydrochloride and naloxone hydrochloride. Morphine 
base and morphine hydrochloride were purchased from Alcaliber (Madrid, Spain). 
Modulators of NO-dependent pathways. 8-Bromo-1H,4H-[1,2,4]oxadiazolo[3,4-
c][1,4]benzoxazin-1-one (NS 2028) and 3-[2-[(4-chlorophenyl)thiophenyl]-N-[4-
(dimethylamino)butyl]-2-propenamide hydrochloride (A 350619) were purchased from 
Tocris Bioscience (Bristol, UK). Ascorbic acid (AA), diethylamine NONOate 
diethylammonium salt (DEA/NO), 7-nitroindazole (7-NI), Rp-8-bromo-β-phenyl-1,N2-
ethenoguanosine 3′,5′-cyclic monophosphorothioate sodium salt (Rp-8-Br-PET-cGMPS) 
and S-methyl-L-thiocitrulline acetate salt (SMTC) were obtained from Sigma-Aldrich 
Quimica S.A. (Madrid, Spain). 21-[4- (2,6-di-1-pyrrolidinyl-4-pyrrimidinyl)-1-
piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione (Z)-2-butenedioate (U-74389G), 
melatonin and Trolox were purchased from Enzo Life Sciences, Inc. (New York, USA). 
2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-4,6 
pyrimidinediamine (BAY 418543) was obtained from Biotrend Chemikalien GmbH 
(Köln, Germany).  
Other drugs and chemicals. Chloral hydrate and γ-aminobutyric acid (GABA) were 
obtained from Sigma-Aldrich Quimica S.A. (Madrid, Spain). D-(-)-2-Amino-5-
phosphonopentanoic acid (D-AP5) and 6-Cyano-7-nitroquinoxaline-2,3-dione disodium 
salt (CNQX) were purchased from Tocris (Bristol, UK). Isoflurane was purchased from 
Esteve (Barcelona, Spain). 
 
b) Drug preparations 
In vitro 
For electrophysiological studies, DEA/NO was first dissolved in NaOH (25 mM; pH 
= 12) to prevent the spontaneous release of NO. Then, just before the assay, it was 
neutralized with HCl (1 M) and diluted in aCSF up to its final concentration. Trolox and 
7-NI were directly dissolved in aCSF before the experiment. 7- NI required prolonged 
sonication to facilitate homogeneity. The rest of the drugs used for in vitro perfusions, 
were prepared first as stock solutions in milliQ water (A 350619, CNQX, D-AP5, GABA, 
ME, morphine hydrocloride, naloxone, Rp-8-Br-PET-cGMP, SMTC), etanol (melatonin) 
or DMSO (NS 2028, U-74389G, BAY 418543), stored at –25 ºC and diluted in aCSF to 
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their final volume before the experiment. The maximum concentration of DMSO or 
etanol in the perfusion fluid was 0.1%, which was found not to affect the firing responses 
of LC neurons. 
The composition of the aCSF used was (in mM): NaCl 130, KCl 3, NaH2PO4 1.25, 
glucose 10, NaHCO3 21, CaCl2 2 and MgSO4 2. The aCSF was saturated with 95% O2/ 
5% CO2 for a final pH of ~7.34. In some assays, KCl (14 mM) was used. In those cases, 
the osmolarity of KCl was compensated with a lower concentration of NaCl (119 mM). 
 
In vivo 
For chronic treatments, a slow-release emulsion containing morphine base was 
prepared. The emulsion contained, appart from morphine, the following vehicle: mannide 
mono-oleate (Arlacel A), liquid paraffin and 0.9% NaCl (saline) (0.08:0.42:0.5, v/v/v). 
Morphine was mixed with the oils using a magnetic stirrer and then saline was added 
gradually to create an oil/water emulsion. 
 Methadone, fentanyl and ascorbic acid were dissolved in saline. 7-NI was dissolved 
in peanut oil. For chronic treatments, Trolox was dissolved in NaOH (1 M), neutralized 
with HCl (1 M) and diluted to the last volume with saline. U-74389G was dissolved in 
0.01 M HCl. The final pH prior to i.p administration was in all cases 6-7.  
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3.2 METHODS 
 
3.2.1 Electrophysiological procedures 
 
a) Brain slice preparation 
 
Rats were anaesthetized with chloral hydrate (400 mg/kg, i.p.) and decapitated. The 
brain was rapidly removed and placed in an ice-cold aCSF (4 °C), where NaCl was 
replaced with sucrose to improve neuronal viability (Aghajanian and Rasmussen, 1989). 
Coronal brainstem sections of 600 μm thickness containing the LC were cut using a 
vibratome (FHC Inc., Bowdoin, ME, USA) and a Valet blade (World Precision 
Instruments, Inc., Sarasota, FL, USA). Then, the slice was allowed to recover for 90 min 
in a glass containing oxygenated aCSF (95% O2 and 5% CO2). Next, the slice was 
carefully transferred to a modified Hass-type interface chamber and placed on an elevated 
polypropylene mesh covered with cellulose paper (Sigma-Aldrich Química, Madrid, 
Spain) and lens paper (Olympus Iberia, Barcelona, Spain). The slice was incubated at 
33ºC and continuously perfused with oxygenated aCSF through a system of threads and 
tubes at a flow rate of 1.5 ml/min (Fig. 3.2). Drugs were perfused in the bathing medium 
by switching to a drug-containing solution using a system of manually controlled three-
way valves. This system offered an excellent exchange of aCSF and drugs in the slice. 
 
 
 
 
 
 
 
 
 
b) Uni-extracellular recording of LC neurons 
  
Single-unit extracellular recordings of LC neurons were made as described 
previously (Mendiguren and Pineda, 2004). The recording electrode, an Omegadot glass 
Figure 3.2. The assembly of threads and tubes 
provides continuous perfusion to the slice 
containing the LC. 
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micropipette, was made with a horizontal pipette puller (Sutter Instruments Co., Novato, 
CA, USA). This instrument allows us to shape the micropipette tip by adjusting the 
parameters of heat or speed. The electrode was filled with 50 mM sodium chloride by a 
Yale spinal needle (0.5 x 90 mm, 25 G, Beckton Dickinson, Madrid, Spain), which was 
coupled to a Sartorius cellulose filter (0.20 μm, Filtros Anoia S.A., Barcelona, Spain). 
Once filled, the tip was broken back to a diameter of 2-5 μm for a final resistance of 3-5 
MΩ. Finally, the electrode was positioned on the LC by means of a binocular microscope 
(model C011, Olympus Iberia, Barcelona, Spain). This nucleus was visually identified in 
the rostral pons as a dark oval area on the lateral borders of the central gray and the 4th 
ventricle, just anterior to the genu of the facial nerve.   
 Then, the electrode was lowered at 4 µm intervals by a piezoelectric micropositioner 
(model 6000-ULN, Burleigh Instruments, Quebec, Canada), until the signal from one 
neuron was recognized from the background noise. Noradrenergic LC cells were 
identified by their spontaneous discharge activity, the regular, slow firing rate and the 
long-lasting biphasic positive-negative waveforms (Andrade and Aghajanian, 1984). As 
summarized in Figure 3.3, the extracellular signal from the electrode was passed through 
a high-input impedance headstage (HS- 2A, Axon Instruments, Foster City, CA, U.S.A.) 
that acted as a signal filter and, together with the amplifier (Axoclamp-2A, Axon 
Instruments, Foster City, CA, U.S.A.), amplified the signal (x 10). Next, the signal passed 
through a post-amplifier (Cibertec S.A., Spain), which further filtered and amplified the 
signal (x 1-500). The signal was then monitored by an oscilloscope (Hameg Instruments, 
Germany) and an audio-analyzer (Cibertec S.A., Spain). Individual (single-unit) neuronal 
spikes were isolated from the background noise with a window discriminator (Cibertec 
S.A., Madrid, Spain) and the firing rate was analyzed by a PC-based custom-made 
software (HFCP®, Cibertec S.A., Spain), which generated histogram bars representing 
the cumulative number of spikes in consecutive 10 s bins. To maintain the slice at a 
physiological temperature (33-34 ºC) a thermoregulatory system was used (Cibertec S.A., 
Madrid, Spain). All the extracellular-recording equipment was connected to a ground 
wire to prevent electrical interference.  
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Figure 3.3. Schematic illustration of extracellular electrophysiological procedures 
 
3.2.2 Measurement of analgesic tolerance to opioids: tail-flick technique 
 
The antinociceptive effect of morphine hydrocloride was measured by the tail-flick 
test (Le Bars et al., 2001), which evaluates the response of the animal to a thermal 
nociceptive stimulus (Fig. 3.4). First, the rat was placed in a Plexiglas trap covered with a 
cloth for 20 min to allow the animal to some degree of habituation and to minimize the 
stress due to manipulation. Then, a beam of light was focused on the middle third of the 
tail. When the animal removed the tail with an energetic movement, the time (latency) 
was recorded. Three basal measures were taken from each animal at three different points 
of the tail, with a 15 s interval between measures. The mean of these three values was 
used as the result. The light intensity was initially adjusted with naive animals so that the 
basal latency (tbasal) was close to 3 s. Next, the rat was injected with a challenge dose of 
morphine hydrocloride (10 mg/kg, i.p.) and the latency (treaction) was tested again 30 min 
later to measure the effect of the opioid. This dose of morphine was selected based on 
previous experiments that observed a near maximal effect. This strong effect of morphine 
was appropriate to achieve a measurable tolerance after chronic opioid treatments. To 
Microelectrode 
Slice containing the LC 
Hass-type interface chamber 
Post-amplifier 
Oscilloscope 
Window 
discriminator 
Audioanalyzer PC 
Amplifier 
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minimize tail skin damage, a cut-off latency time (tmax) was set at 10 s. Antinociception 
was expressed as a percentage of the maximal possible effect (M.P.E) according to the 
following formula (see section 3.2.4 for details): 
 
M. P. E (%) =  
𝑡𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 − 𝑡𝑏𝑎𝑠𝑎𝑙
𝑡𝑚𝑎𝑥 − 𝑡𝑏𝑎𝑠𝑎𝑙
· 100 
 
 
 
Figure 3.4. The antinociceptive effect of morphine was measured by the tail-flick test, which evaluates the 
response of the animal to a thermal nociceptive stimulus. 
 
3.2.3 Pharmacological procedures 
 
a) Characterization of the NO-dependent signaling pathways involved in ME-
induced MOR desensitization in spontaneously active LC neurons in vitro 
Acute MOR desensitization in LC neurons was studied by measuring the inhibitory 
effect of a short application of a test concentration of ME (0.8 μM, 1 min) before (basal 
effect) and 5 min after perfusion with a high concentration of ME (3 or 10 μM, 10 min), 
according to the following scheme: 
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Figure 3.5. Scheme of the protocol used to evaluate the degree of opioid desensitization induced by ME in 
spontaneously firing LC neurons. The acute effect of ME (0.8 μM, 1 min) was tested before (Ebasal) and 5 
min after (Epost) inducing desensitization with ME (3 or 10 μM, 10 min). The decrease in ME (0.8 μM, 1 
min) effect was taken as a measure of the degree of desensitization (Modified from Santamarta et al., 2014). 
ME concentrations were chosen on the basis of previous studies (Harris and 
Williams, 1991; Torrecilla et al., 2001; Santamarta et al., 2014). To avoid variability 
between groups, we only recorded cells that showed slow spontaneous firing rates 
between 0.4 and 1.5 Hz, as well as strong inhibitory effects induced by ME (0.8 µM, 1 
min) (higher than 80%).  
To characterize the involvement of NO-dependent pathways (sGC/PKG and ROS) in 
ME-induced desensitization, the following drugs were perfused for at least 20-30 min 
before inducing desensitization with ME (3 or 10 µM) and then during the whole 
desensitization assay: 
 sGC activators: A-350619 (30 μM) and BAY 418543 (1 μM) 
 sGC inhibitor: NS 2028 (10 μM and 30 μM) 
 PKG inhibitor: Rp-8-Br-PET-cGMP (1 μM) 
 Antioxidants: melatonin (100 μM), Trolox (200 μM), U-74389G (10 μM)  
In some assays, the NO donor DEA/NO (100 µM) was previously perfused to 
explore whether the sGC inhibitor NS 2028 (10 μM) regulated ME-induced 
desensitization. Finally, in one series of experiments, Trolox (200 µM) was administered 
together with NS 2028 (10 μM) to further evaluate the involvement of both sGC/cGMP 
and ROS pathways in MOR desensitization.  
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The desensitization induced by ME (3 µM) was used to investigate the effect of sGC 
activators, since we have previously demonstrated that this model is sensitive to the 
potentiation induced by NO (Llorente et al., 2012). Moreover, we induced desensitization 
with a higher concentration of ME (10 µM) to study the effect of sGC/PKG inhibitors or 
antioxidants, because this protocol is sensitive to the blockade of MOR desensitization 
induced by the NOS inhibitor 7-NI (Torrecilla et al., 2001; Santamarta et al., 2014). 
b) Involvement of nNOS in morphine- and ME-induced MOR desensitization in 
KCl-excited LC neurons in vitro 
The desensitization model that we have previously used in spontaneously firing 
neurons (see Fig. 3.5) was particularly suitable to study the desensitization induced by 
ME because it rapidly washes out from the preparation, so that the effect of a test 
concentration of ME (0.8 µM, 1 min) can be evaluated several times in the same neuron 
within few minutes. However, that protocol is not suitable to evaluate morphine effects 
repeatedly in the same neuron, since it does not quickly wash out from slices (Levitt and 
Williams, 2012). For those reasons, we quantified the extent of receptor desensitization 
induced by morphine by evoking a positive DC shift (a shift in the resting potential/ 
equilibrium potential in the positive direction) with KCl (14 mM)-containing aCSF, so 
that LC cells were excited to 2.0 – 7.3 Hz and morphine effects could be continously 
monitored. In these assays, NaCl was equiosmotically replaced with KCl. All the 
experiments were performed in the presence of CNQX (a non-NMDA glutamate receptor 
antagonist, 30 μM) and D-AP5 (a NMDA receptor antagonist, 100 μM) to avoid the 
interference of KCl-induced glutamate release on MOR desensitization. In each of the 
experiments, GABA (1 mM) was tested as an internal control before and after the 
desensitization with ME (10 μM, 10 min) or morphine (30 μM, 10 min).  
ME and morphine effects on KCl-excited LC neurons were characterized by 
performing concentration-effect curves for the inhibitory effects of ME (0.1-25.6 µM, 2x, 
1 min) and morphine (0.1-30 µM, 3x, 5 min) on the firing rate of LC neurons from rat 
brain slices. 
To characterize the acute desensitization of MOR induced by ME or morphine under 
these experimental conditions, two possible designs were used: 
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- First, we compared the inhibitory effect of a supramaximal concentration of ME 
(25.6 μM, 1 min) before and 3-5 min after inducing desensitization with ME (10 
μM, 10 min) or morphine (30 μM, 10 min). Once the last test concentration of ME 
(25.6 μM, 1 min) was applied, naloxone (1 µM) was perfused to reverse the 
morphine-induced hyperpolarization and to return the firing rate to control 
conditions. The decrease in the ME (25.6 μM, 1 min) effect after ME (10 μM) or 
morphine (30 μM) was taken as a measure of the degree of desensitization (see 
Fig. 3.6). With the purpose of comparisons, in some experiments, we used ME 
(0.8 μM, 1 min) as a test concentration before and after inducing desensitization 
with ME (10 μM, 10 min). These assays were similar to those described in section 
3.2.3a (see Fig. 3.5), but in the presence of KCl (14 mM). 
 
 
 
Figure 3.6. Scheme of one of the experimental designs used to evaluate the degree of opioid 
desensitization induced by ME or morphine in LC neurons under KCl-evoked excitation. The 
acute effect of ME (0.8 or 25.6 µM) was tested before and after inducing desensitization with ME 
(10 µM, 10 min) or morphine (30 µM, 10 min). The inhibitory effect induced by morphine was 
reversed by naloxone (1 µM). The decrease in the effect of ME (25.6 μM, 1 min) was taken as a 
measure of the degree of desensitization. All the experiments were performed in the presence of 
CNQX (non-NMDA glutamate receptor antagonist, 30 μM) and D-AP5 (NMDA receptor 
antagonist, 100 μM) to avoid the interference of KCl-induced glutamate release on MOR 
desensitization. 
 
- Second, we measured the maximal response to ME (25.6 µM) at two times during 
a prolonged application of ME (10 µM, 10 min) or morphine (30 µM, 10 min): (1) 
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40-60 s after initiating the 10 min ME (10 µM) or morphine (30 µM) perfusion 
and (2) just after finishing it (see Fig. 3.7). Finally, naloxone (1 µM) was applied 
to reverse morphine-induced effects. The decrease in the ME (25.6 μM, 1 min) 
effect after ME (10 μM) or morphine (30 μM) was taken as a measure of the 
degree of desensitization. 
In all cases, the application of the supramaximal test concentration of ME (25.6 μM) 
was limited to 1 min and a washout period of approximately 10 min was set between 
applications in order to reduce the induction of desensitization by test ME applications 
alone. 
 
Figure 3.7. Scheme of one of the experimental designs used to evaluate the degree of opioid desensitization 
induced by ME or morphine in LC neurons under KCl-evoked excitation. The maximal effect induced by 
ME (25.6 µM) was tested during the continuous perfusion with ME (10 µM, 10 min) or morphine (30 µM, 
10 min). The inhibitory effect induced by morphine was reversed by naloxone (1 µM). The decrease in the 
effect of ME (25.6 μM, 1 min) was taken as a measure of the degree of desensitization. All the experiments 
were performed in the presence of CNQX (non-NMDA glutamate receptor antagonist, 30 μM) and D-AP5 
(NMDA receptor antagonist, 100 μM) to avoid the effects of KCl-induced glutamate release on MOR 
desensitization. 
On the other hand, previous experiments have shown that administration of nNOS 
inhibitors attenuate the development of ME-induced MOR desensitization in 
spontaneously firing LC neurons in vitro (Santamarta et al., 2014). Here, we evaluated the 
effect of nNOS inhibitors on ME- and morphine-induced acute desensitization of MOR 
under KCl-induced activation. Thus, SMTC (10 µM) was perfused together with 7-NI 
(100 µM) for 20 min before starting the experiment and during the entire desensitization 
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assay with ME (10 μM, 10 min) or morphine (30 µM, 10 min). MOR desensitization in 
the presence of nNOS inhibitors was explored under the two experimental designs of 
MOR desensitization. 
c) Involvement of nNOS and ROS generation in the development of tolerance to 
the inhibitory effect of ME on LC cells after chronic treatment with morphine, 
methadone and fentanyl 
It has been previously shown that co-treatment with the nNOS inhibitor 7-NI 
attenuates the development of cellular tolerance in LC neurons from morphine-treated 
rats (Santamarta et al., 2005). To examine whether nNOS is involved in the development 
of tolerance by chronic treatments with other opioid agonists, such as methadone or 
fentanyl, rats treated with the opioid (methadone or fentanyl) or the sham were also co-
treated with 7-NI or its vehicle. To further investigate the involvement of ROS in the 
development of cellular tolerance, sham- and opioid-treated rats were co-treated with the 
antioxidants TX+AA, U-74389G or their vehicles (see section 3.1.2 for treatment details).  
To evaluate the development of tolerance, concentration-effect curves for the 
inhibitory effect of ME were performed as described by Santamarta et al. (2005) in LC 
neurons from sham- and opioid-treated rats, co-treated with 7-NI or the antioxidants. 
Thus, increasing concentrations of ME (0.05-12.8 µM, 2x, 1 min) were perfused at 5-min 
intervals until a maximal effect was reached. To avoid variability between groups, we 
only recorded cells that showed slow spontaneous firing rates between 0.4 and 1.5 Hz.  
d) Involvement of nNOS and ROS generation in the development of tolerance to 
the analgesic effects of morphine after chronic treatments with morphine, methadone 
and fentanyl 
Previous experiments have shown that in vivo administration of the nNOS inhibitor 
7-NI attenuates the development of analgesic tolerance in morphine-treated rats 
(Santamarta et al., 2005). Moreover, co-treatment with TX+AA also attenuates the 
development of analgesic tolerance normally induced by morphine treatment (Llorente J., 
Doctoral Thesis, unpublished data). To study whether the nNOS is involved in the 
development of antinociceptive tolerance by chronic treatments with other opioid 
agonists, such as methadone and fentanyl, rats treated with the opioid (methadone or 
fentanyl) were co-treated with the nNOS inhibitor 7-NI or with its vehicle. To further 
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explore the involvement of ROS, sham and opioid-treated rats were co-treated with the 
antioxidant U-74389G or its vehicle (see section 3.1.2 for treatment details). Then, the 
antinociceptive response was measured by the tail-flick test (Le Bars et al., 2001), as 
explained in the section 3.2.2. 
3.2.4 Data analysis and statistics  
 
In electrophysiological experiments neuronal firing rate (FR) was collected in 10 s 
bin frequency histograms, where each bar represents the accumulated neuronal discharges 
in 10 seconds (spikes/10 s). The firing rate of LC cells was recorded before (baseline) and 
after the test application of the agonist (ME 0.8 – 12.8 μM, 1 min). Thus, the inhibitory 
effect (E) induced by ME (0.8 µΜ, 1 min) (Fig. 3.8) was calculated as the percentage of 
reduction of firing rate from baseline, according to the following formula:  
 
𝐸 (%) =  
𝐹𝑅𝑝𝑟𝑒 − 𝐹𝑅𝑝𝑜𝑠𝑡
𝐹𝑅𝑏𝑎𝑠𝑎𝑙
· 100 
 
Where: 
- E is the inhibitory effect of (ME 0.8 – 12.8 μM, 1 min) in percentages. 
- FRbasal is the average firing rate for 60 at the beginning of the recording. 
- FRpre is the average firing rate for 60 s before each ME application. 
- FRpost is the average firing rate for 90 s after ME application, ruling out the 30-40 
s that approximately take the drugs to reach the slice through the perfusion 
system. 
 
Figure 3.8. Representative example of a 
firing-rate recording from a LC neuron 
showing the inhibitory effect of a test 
concentration of ME (0.8 µM, 1 min). The 
vertical line refers to the neuronal firing rate 
and the horizontal line represents the period 
of ME application. The time scale 
corresponds to 1 min. 
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In those experiments in which the effect of opioids was tested under KCl (14 mM)-
evoked excitation of LC neurons (Fig. 3.9) the inhibitory effect (E) induced by the test 
concentrations of ME (0.8 µM or 25.6 µM, 1 min) or GABA (1 mM, 1 min) was 
calculated by the same equation with the parameters being defined as follows: 
 
- E is the inhibitory effect of ME (0.8 µM or 25.6 µM, 1 min) or GABA (1 mM, 1 
min) in percentages.  
- FRbasal is the average firing rate for 60 s at the beginning of the recording. 
- FRpre is the average firing rate for 60 s before each ME or GABA test application. 
- FRpost is the average firing rate for 30 s at the peak time after ME or GABA test 
application. 
 
 
Figure 3.9. Representative example of a firing-rate 
recording from a LC neuron. The recording shows the 
inhibitory effect of a test concentration of ME (25.6 µM, 
1 min). The vertical line refers to the KCl-excited firing 
rate and the horizontal line represents the period of ME 
application. The time scale corresponds to 1 min. 
 
 
When naloxone (1 µM) was perfused to reverse morphine-induced effects (Fig. 3.10) 
the inhibitory effect (E) induced by the test concentration of ME (25.6 µM, 1 min) was 
calculated as follows: 
𝐸 (%) =  
𝐹𝑅𝑛𝑎𝑙𝑜𝑥. − 𝐹𝑅𝑝𝑜𝑠𝑡
𝐹𝑅𝑏𝑎𝑠𝑎𝑙
· 100 
 
 Where: 
- E is the inhibitory effect of ME (25.6 µM, 1 min) in percentages. 
- FRbasal is the average firing rate for 60 s at the beginning of the recording. 
- FRpost is the average firing rate for 30 s at the peak time after ME (25.6 µM, 1 
min) application, just before naloxone. 
- FR nalox is the average firing rate for 60 s after naloxone (1 µM) application, once 
the firing rate returned to a plateau.  
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Figure 3.10. Representative example of a firing-rate 
recording from a LC neuron. The recording shows the 
inhibitory effect of a test concentration of ME (25.6 µM, 
1 min) and the naloxone (1 µM)-induced reversal of the 
inhibitory effect. The vertical line refers to the KCl-
evoked firing rate and the horizontal line represents the 
period of ME application. The time scale corresponds to 1 
min. 
 
 
In both in vitro models of acute MOR desensitization (the spontaneous firing rate 
model and the KCl-evoked firing excitation model), the degree of agonist-induced 
desensitization was calculated as follows:  
 
𝑑𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑑𝑒𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑧𝑎𝑡𝑖𝑜𝑛 (%) =  [1 −
𝐸𝑝𝑜𝑠𝑡
𝐸𝑏𝑎𝑠𝑎𝑙
] · 100 
 
Where:  
- Ebasal is the inhibitory effect of the test concentration of the agonist (ME 0.8 µM, 
25.6 µM or GABA 1 mM, 1 min) before perfusing the desensitizing 
concentrations of the opioid agonists (ME 3 and 10 µM; morphine 30 µM; 10 
min) (Figures 3.5 and 3.6). In those experiments in which ME (25.6 µM, 1 min) 
was applied during a continuous opioid perfusion, Ebasal is the initial inhibitory 
effect of ME (25.6 µM, 1 min) applied 40-60 s after starting the perfusion with 
ME (10 μM) or morphine (30 μM) (Figure 3.7). 
 
- Epost is the inhibitory effect of the test concentration of the agonist (ME 0.8 µM, 
25.6 µM or GABA 1 mM, 1 min) 3-5 min after finishing the desensitization with 
ME (3 µM or 10 µM, 10 min) or morphine (30 µM, 10 min) ) (Figures 3.5 and 
3.6). In those experiments in which ME (25.6 µM, 1 min) was applied during a 
continuous opioid perfusion, Epost is the final inhibitory effect of ME (25.6 µM, 1 
min) applied immediately at the end of the 10 min perfusion with ME (10 μM) or 
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morphine (30 μM) and calculated with respect to the naloxone reversal (Figure 
3.7). 
To construct concentration-effect curves, we perfused increasing concentrations of 
ME until a maximal effect was reached. Curve fitting analysis was performed to obtain 
the best simple nonlinear fit to the following three-parameter logistic equation: 
𝐸 (%) =  
𝐸𝑚𝑎𝑥
1 + (
𝐸𝐶50
𝐴 )
𝑛 · 100 
Where: 
- E is the effect induced by each concentration of the agonist. 
- A is the concentration of the agonist (μM). 
- Emax is the maximal effect achieved.  
- EC50 is the concentration of the agonist needed to elicit a 50% of the maximal 
effect (μM). 
- n is the slope factor of the concentration-effect curve. 
These parameters were determined by nonlinear analysis. Then, EC50 values were 
transformed to the corresponding logarithmic data to convert them to a Gaussian 
distribution (Carpenter, 1986) and the corresponding statistical test was applied to the 
converted log units. 
In behavioral experiments, analgesia was calculated as a percentage of the maximal 
possible effect (M.P.E.) (as explained in section 3.2.2) 
 
M. P. E (%) =  
𝑡𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 − 𝑡𝑏𝑎𝑠𝑎𝑙
𝑡𝑚𝑎𝑥 − 𝑡𝑏𝑎𝑠𝑎𝑙
· 100 
Where: 
-  tbasal is the time at which the animal withdrew the tail, before the morphine 
challenge. 
- treaction is the time at which the animal withdrew the tail after the morphine 
challenge. 
- tmax is the cut-off time, which was set at 10 s. 
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Analyses were performed by the software GraphPad Prism (version 5.0 for 
Windows), SPSS statistics (version 22.0 for Windows) and Microsoft Excel 2013. Data 
are expressed as mean ± S.E.M. For statistical evaluation, the following analyses were 
applied: 
- Paired Student’s t test: when the values were compared within the same cell or the 
same animal, before and after a pharmacological intervention. 
- Two-sample Student’s t test: when the values were compared between two 
independent groups. 
-  One-way analysis of variance (ANOVA) was used when values were compared 
between more than two groups. In case of significative results, the differences 
between two specific groups were further evaluated by a Tukey’s post-hoc test. In 
some cases, analysis of covariance (ANCOVA) was performed to statistically 
control an external variable which might affect the results, followed by a Tukey’s 
test. 
A probability level of 0.05 was accepted as significantly different. 
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4.1 STUDY 1: CONTRIBUTION OF NITRIC OXIDE-DEPENDENT 
GUANYLATE CYCLASE AND REACTIVE OXYGEN SPECIES SIGNALING 
PATHWAYS TO DESENSITIZATION OF µ-OPIOID RECEPTORS IN THE RAT 
LOCUS COERULEUS 
 
Involvement of soluble guanylate cyclase/cyclic GMP in opioid-induced MOR 
desensitization in the LC  
We have previously reported that different NO donors enhance ME (3 µM)-induced 
MOR desensitization (Llorente et al., 2012). It is well known that NO targets the heme 
group of the sGC, elevating cGMP concentrations (Ignarro et al., 1991). To study the 
involvement of sGC/cGMP pathway in the effect of NO donors on MOR desensitization, 
we tested the effect of DEA/NO, a nucleophile complex that spontaneously releases NO 
in aqueous solution, in the presence of the sGC inhibitor NS 2028. As expected, perfusion 
with ME (3 µM, 10 min) desensitized the inhibitory effect of ME (0.8 µM) by 30 ± 6% (n 
= 5, p < 0.05), whereas DEA/NO (100 µM) enhanced ME (3 µM)-induced MOR 
desensitization by 65 ± 18% (n = 5, p < 0.05 vs control) (Figs. 4.1A, B and D). The firing 
activity of LC cells was also elevated by DEA/NO (100 µM) perfusion (firing rate 
increase: 101 ± 14%, n = 5, p < 0.05; compare baselines in Figs. 4.1A and B), which is in 
agreement with previous studies showing a neuronal hyperactivity induced by NO donors 
(Llorente et al., 2012; Pineda et al., 1996). More importantly, administration of NS 2028 
(10 µM) fully prevented both DEA/NO (100 µM)-induced enhancement of MOR 
desensitization (n = 5, p < 0.05, DEA/NO + NS 2028 vs DEA/NO) (Figs. 4.1C and D) 
and DEA/NO (100 µM)-elicited hyperactivity of LC neurons (firing rate changed by 
DEA/NO, with NS 2028: -9 ± 5%, n = 5, p < 0.005 vs without NS 2028, see above). NS 
2028 (10 µM) itself did not modify MOR desensitization (n = 3) (Fig. 4.1D). Finally, no 
changes were found in the acute effect of ME (0.8 µM) between the different groups (ME 
effect, control: 86 ± 3%, n = 5; NS 2028: 90 ± 2%, n = 3; DEA/NO: 87 ± 5%, n = 5; and 
DEA/NO + NS 2028: 92 ± 2%, n = 5). These data suggest the contribution of sGC in the 
enhancement of MOR desensitization and hyperactivity of LC cells induced by NO 
donors.  
Results 
  
 
66 
 
Figure 4.1. Effect of DEA/NO and DEA/NO + NS 2028 on ME (3 µM, 10 min)-induced MOR 
desensitization. A, B, C. Representative examples of firing-rate recordings of LC cells showing the effect of 
ME (0.8 µM, 1 min) before and 5 min after application of ME (3 µM, 10 min) in control slices (A), in slices 
perfused with DEA/NO (100 µM (B) or DEA/NO (100 µM) + NS 2028 (10 µM) (C). The horizontal bars 
indicate the period of drug applications and the vertical lines show the number of spikes recorded every 10 
s. D. Bar histograms show the mean ± S.E.M of ME (3 µM, 10 min)-induced desensitization in the absence 
(n = 5) or the presence of NS 2028 (10 μM, n = 3), DEA/NO (100 μM, n = 5) or NS 2028 (10 μM) + 
DEA/NO (100 μM) (n = 5). Desensitization degrees were calculated as percentage values (see Data 
analysis and statistics). Note that DEA/NO markedly enhanced MOR desensitization and NS 2028 fully 
prevented the enhancement of MOR desensitization induced by DEA/NO. *p < 0.05 when compared with 
the control group (two-sample Student’s t test), and † p < 0.05 when compared with the DEA/NO group 
(two-sample Student’s t test). 
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To further explore the involvement of sGC/cGMP pathway in MOR desensitization, 
we evaluated the direct effect of different sGC modulators on ME (3 and 10 µM)-induced 
desensitization. Perfusion with the sGC activators A 350619 (30 μM) and BAY 418543 
(1 μM) enhanced by 93 ± 15% and 90 ± 6%, respectively, ME (3 µM)-induced MOR 
desensitization (n = 5, p < 0.01 vs control; and n = 5, p < 0.005 vs control; respectively) 
(Figs. 4.2A, B and C). BAY 418543 (1 μM) also elevated the firing activity of LC 
neurons by a 51 ± 16% (n = 5, p < 0.05). There was no change in the acute effect of ME 
(0.8 µM) between the different groups (ME effect, A 350619: 88 ± 3%, n = 5; BAY 
418543: 94 ± 2%, n = 5). On the other hand, perfusion with a higher concentration of ME 
(10 µM, 10 min) caused a greater degree of MOR desensitization, with a strong decrease 
in ME (0.8 µM) effect (desensitization: 61 ± 3%, n = 8, p < 0.005) (Figs. 4.3A and C). 
Unexpectedly, administration of two different concentrations of the sGC inhibitor NS 
2028 (10 and 30 μM) failed to modify ME (10 µM)-induced MOR desensitization, so that 
desensitization remained significant (n = 6, p < 0.005; and n = 3, p < 0.005) (Figs. 4.3B 
and C). 
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Figure 4.2. Effect of A 350619 and BAY 418543 on ME (3 µM, 10 min)-induced desensitization. A, B. 
Representative examples of firing-rate recordings of LC cells showing the effect of ME (0.8 µM, 1 min) 
before and 5 min after application of ME (3 µM, 10 min) in slices perfused with A 350619 (30 µM) (A) or 
BAY 418543 (1 µM) (B). The horizontal bars indicate the period of drug applications and the vertical lines 
show the number of spikes recorded every 10 s. C. Bar histograms show the mean ± S.E.M of ME (3 µM, 
10 min)-induced desensitization in the presence of A 350619 (30 μM, n = 5) or BAY 418543 (1 μM, n = 5). 
Desensitization degrees were calculated as percentage values (see Data analysis and statistics). Note that A 
350619 and BAY 418543 markedly enhanced MOR desensitization. *p < 0.01 and **p < 0.005 when 
compared with the control group (two-sample Student’s t test). 
 
Involvement of cGMP-dependent protein kinase in opioid-induced MOR 
desensitization in the LC 
Previous studies from our group have reported that perfusion with the PKG activator 
8-Br-cGMP completely restores ME-induced MOR desensitization from the blockade 
elicited by the nNOS inhibitor 7-NI in LC neurons (M.T. Santamarta, Doctoral Thesis). 
To further explore the involvement of PKG in acute desensitization of MOR, we tested 
the highly selective PKG inhibitor Rp-8-Br-PET-cGMP (1 μM). Unexpectedly, 
administration of the PKG inhibitor Rp-8-Br-PET-cGMP (1 μM) failed to modify the 
degree of ME (10 µM)-induced desensitization. Thus, desensitization induced by ME (10 
µM) in the presence of or Rp-8-Br-PET-cGMP (1 μM) was significant (n = 4, p < 0.005) 
(Fig. 4.3C). 
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Figure 4.3. Effect of NS 2028 and Rp-8-Br-PET-cGMP on ME (10 µM, 10 min)-induced desensitization. 
A, B. Examples of firing-rate recordings of LC cells showing the effect of ME (0.8 µM, 1 min) before and 5 
min after application of ME (10 µM, 10 min) in control slices (A) and in slices perfused with NS 2028 (10 
µM) (B). The horizontal bars indicate the period of drug applications and the vertical lines show the number 
of spikes recorded every 10 s. C. Effect of NS 2028 and Rp-8-Br-PET-cGMP on MOR desensitization 
induced by ME (10 µM, 10 min). Bars represent the mean ± S.E.M. of n experiments. Desensitization 
degrees were calculated as percentage values (see Data analysis and statistics). Note that ME (10 µM)-
induced desensitization was not changed in the presence of NS 2028 (10 µM or 30 µM, n = 6 and n = 3, 
respectively) or Rp-8-Br-PET-cGMP (1 µM, n = 4). 
 
Involvement of reactive oxygen species in opioid-induced MOR desensitization in the 
LC  
NO reacts with oxygen derivatives to produce reactive nitrogen species and ROS 
(Davis et al., 2001), which have been shown to contribute to NO-induced enhancement of 
MOR desensitization in the LC (Llorente et al., 2012). We further explored whether ROS 
would itself mediate ME (10 µM)-induced desensitization by administration of three 
structurally unrelated antioxidants. Perfusion of either of the antioxidants U-74389G (10 
µM), melatonin (100 µM) or Trolox (200 µM) failed to modify the degree of ME (10 
µM)-induced desensitization (n = 4, n = 4 and n = 4, respectively) when compared to the 
corresponding control group (Figs. 4.4A and C). However, perfusion of the antioxidant 
Trolox (200 µM) together with the sGC inhibitor NS 2028 (10 μM) attenuated by 37 ± 
6% (n = 5, p < 0.005 vs control) ME (10 µM)-induced desensitization (Figs. 4.4B and C). 
This combination (Trolox 200 µM + NS 2028 10 μM) slightly reduced the firing rate of 
LC neurons (firing rate change: -22 ± 4%, n = 5, p < 0.005), although the basal firing rate 
after the combination was not different from that in control (basal firing rate before 
desensitization, control: 0.72 ± 0.09, n = 8; Trolox + NS 2028: 0.67 ± 0.13, n = 5). 
Finally, no changes were found in the acute ME (0.8 µM) effect between the two groups 
(ME effect, control: 93 ± 1%, n = 8; Trolox + NS 2028: 91 ± 3%, n = 5). This indicates 
that ROS and sGC/cGMP signaling cascades may be required for induction of MOR 
desensitization, but either of these pathways independently may be enough to mediate it. 
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Figure 4.4. Effect of Trolox, Trolox + NS 2028, U-74389G and melatonin on ME (10 µM, 10 min)-induced 
desensitization. A, B. Representative examples of firing-rate recordings of LC cells showing the effect of 
ME (0.8 µM, 1 min) before and 5 min after application of ME (10 µM, 10 min) in slices perfused with 
Trolox (200 µM) (A) or Trolox (200 µM) + NS 2028 (10 µM) (B). Drugs were bath applied for the time 
indicated by the horizontal bars. Vertical lines represent the number of spikes recorded every 10 s. C. Bar 
histograms show the mean ± S.E.M of ME (10 µM)-induced desensitization in the absence (n = 8, control) 
or the presence of U-74389G (10 μM, n = 4), melatonin (100 μM, n = 4), Trolox (200 μM, n = 4) or Trolox 
(200 μM) + NS 2028 (10 μM) (n = 5). Desensitization degrees were calculated as percentage values (see 
Data analysis and statistics). Note that in the presence of Trolox + NS 2028 MOR desensitization was 
markedly attenuated. *p < 0.005 compared with the control group (two-sample Student’s t test).  
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4.2 STUDY 2: STUDY OF THE INVOLVEMENT OF NEURONAL NITRIC 
OXIDE SYNTHASE IN MORPHINE-INDUCED DESENSITIZATION OF µ-
OPIOID RECEPTORS IN THE RAT LOCUS COERULEUS 
 
Characterization of acute inhibitory effects of ME and morphine on KCl-excited LC 
neurons in vitro 
A sustained perfusion with KCl (14 mM) increased by 6 fold the firing rate of LC 
neurons (firing rate before KCl: 0.80 ± 0.04 Hz; after KCl: 4.29 ± 0.16 Hz, n = 52, p < 
0.005). In order to characterize the acute inhibitory effects of ME and morphine, 
increasing concentrations of ME (0.1-25.6 µM, 2x, 1 min) or morphine (0.1-30 µM, 3x, 5 
min) were perfused in the slice (Figs. 4.5A and B). No differences were found in the KCl-
excited basal firing rate between groups (basal firing rate, before ME: 3.08 ± 0.44 Hz, n = 
5; before morphine: 3.27 ± 0.56 Hz, n = 5). The pEC50 value for ME effect obtained by 
nonlinear analysis was 6.12 ± 0.02 (EC50 = 0.75 µM, n = 5), whereas the pEC50 for 
morphine effect was 6.41 ± 0.09 (EC50 = 0.39 µM, n = 5). The maximum inhibitory 
effects (Emax) induced by ME and morphine were 81 ± 8% and 55 ± 5% from the KCl-
excited basal firing rate, respectively (Figs. 4.5C and D). GABA promoted a 100% 
inhibition from baseline in all cases. These results indicate that morphine behaves as 
partial agonist at the MOR in LC neurons. 
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Figure 4.5. Characterization of acute ME and morphine effects under KCl-evoked activation of LC neurons 
in vitro. A, B. Examples of firing-rate recordings of LC cells showing the inhibitory effect of ME (A) and 
morphine (B). Each horizontal bar represents the period of application of each ME (0.1 - 25.6 μM, 2x) or 
morphine concentration (0.1 - 30 μM, 3x) and the vertical lines show the number of spikes recorded every 
10 s. C, D. Concentration-effect curves for the inhibitory effect of ME (C) and morphine (D) in KCl-
excited LC neurons. The horizontal axis represents the logarithms of ME and morphine concentrations in 
linear scale. The vertical axis expresses the reduction in the firing rate of LC neurons as a percentage from 
the KCl-induced basal firing rate. Symbols are the mean ± SEM of ME or morphine effects at each 
concentration obtained from n animals. The lines through the data are the theoretical curves constructed 
from the mean of the individual concentration-effect curve parameters, as estimated by nonlinear regression 
(see Materials and Methods for details). 
Results 
  
 
76 
Characterization of acute MOR desensitization induced by ME and morphine in LC 
neurons  
First, we evaluated the effect of short applications of two test concentrations of ME 
(0.8 µM or 25.6 µM, 1 min) before and after perfusing with a high, desensitizing 
concentration of ME (10 μM, 10 min) or morphine (30 µM, 10 min). ME (0.8 μΜ) is a 
concentration that is close to the EC50 in this KCl model and ME (25.6 µΜ) allows us to 
see changes in the maximum response. Thus, after finishing the ME (10 μM, 10 min) 
administration, the inhibitory effect of ME (0.8 µM) was desensitized by 55 ± 3% (n = 5, 
p < 0.005), whereas the effect of ME (25.6 µM) was reduced by 26 ± 3% (n = 5, p < 
0.005) (Figs. 4.6A, C and G). On the other hand, after finishing the morphine (30 μM, 10 
min) perfusion, the inhibitory effect of (25.6 µM) was desensitized by 39 ± 4% (n = 5, p < 
0.005) (Figs. 4.6D and G). This degree of desensitization was higher than that induced by 
ME (10 μM) (p < 0.05, Fig. 4.6G). As morphine (30 µM) produces a near maximal 
receptor occupancy and does not quickly wash out from the slice, we had to use the 
supramaximal test concentration of ME (25.6 µM) to measure maximal activity of MOR. 
For that reason, ME (0.8 µΜ) was not tested in morphine experiments. After inducing 
desensitization with morphine, naloxone was applied to return to control firing rate values 
in the absence of MOR activation. In fact, the firing rate after naloxone (1 µM) was not 
different when compared to the firing rate before desensitization (firing rate, before 
desensitization: 4.1 ± 0.5 Hz, n = 5; after naloxone (1 μM): 4.0 ± 0.5 Hz, n = 5).  
Second, we compared the maximal response to ME (25.6 µM) applied at two times 
during a continuous application of ME (10 µM, 10 min) or morphine (30 µM, 10 min). 
By this approach the inhibitory effect of ME (25.6 µM, 1 min) was desensitized by 36 ± 
4% (n = 5, p < 0.05) following ME (10 µM, 10 min) perfusion and by 32 ± 5% (n = 5, p < 
0.01) after morphine (30 µM, 10 min) (Figs. 4.6E, F and G). The firing rate after 
naloxone (1 μM) did not differ from the firing rate before desensitization (firing rate, 
before desensitization: 4.7 ± 0.4 Hz, n = 5; after naloxone (1 μM): 4.5 ± 0.4 Hz, n = 5).  
In each desensitization experiment, GABA (1 mM) was tested as an internal control. 
The inhibitory effect of GABA (1 mM, 1 min) was close to 100% from baseline (>95%) 
both before and after perfusion with ME (10 µM, 10 min) (n = 15) (Figs. 4.6B and G) or 
morphine (30 µM, 10 min) (n = 9) (Fig. 4.6G). 
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Figure 4.6 Characterization of acute desensitization of MOR induced by ME and morphine in KCl-excited 
LC neurons in vitro. A, B, C. Examples of firing-rate recordings of LC cells showing the effect of ME (0.8 
μM, 1 min) (A), GABA (1 mM, 1 min) (B) or ME (25.6 μM, 1 min) (C) before and after inducing 
desensitization with ME (10 μM, 10 min). D, Example of firing-rate recording of a LC neuron showing the 
effect of ME (25.6 μM, 1 min) before and after inducing desensitization with morphine (30 μM, 10 min). E, 
F. Examples of firing-rate recordings of LC cells showing the effect of ME (25.6 μM, 1 min) applied at two 
times during a sustained perfusion with ME (10 μM, 10 min) (E) or morphine (30 μM, 10 min) (F). The 
horizontal bars indicate the period of drug applications and the vertical lines show the number of spikes 
recorded every 10 s. G. Bar histograms show the mean ± S.E.M of ME (10 μM)-, or morphine (30 μM)-
induced desensitization. Different test concentrations and experimental designs were used (see 
Pharmacological procedures). GABA was used as an internal control. All the experiments were performed 
in the presence of the glutamate receptor antagonists CNQX (30 μM) and D-AP5 (100 μM). Desensitization 
degrees were calculated as percentage values (see Data analysis and statistics). Note that significant 
reductions in the effect of ME (0.8 μM, 1 min) or ME (25.6 μM, 1 min) were observed when applied before 
and after or during ME (10 μM, 10 min) (n = 5, in all cases), but the degree of desensitization was greater 
when it was quantified by ME (0.8 μM). Likewise, substantial reduction in ME (25.6 μM) effect was 
observed when applied before and after (n = 5) or during (n = 5) morphine (30 μM, 10 min). The 
desensitization induced by morphine (30 μM) was greater than that induced by ME (10 μM) when the test 
concentration was applied before and after. The effect of GABA (1 mM) was unaltered after perfusion with 
either ME (10 μM) or morphine (30 μM) (n = 15 and n = 9, respectively). *p < 0.05, **p < 0.01 and **p < 
0.005 when the effect of the test concentration of ME after desensitization was compared to the basal effect 
by a paired Student’s t test. #p < 0.005 when compared to the ME (0.8 μM) group by a two-sample 
Student’s t test; †p < 0.05 when compared to the corresponding ME (10 μM) group by a two-sample 
Student’s t test.  
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Effect of neuronal NOS inhibitors on acute MOR desensitization induced by ME 
and morphine  
It has been shown that nNOS contributes to ME-induced MOR desensitization in 
spontaneously active LC neurons (Santamarta et al., 2014). To further study the 
involvement of nNOS on morphine (30 µM)-induced desensitization, we perfused a 
combination of two nNOS inhibitors 7-NI (100 µM) and SMTC (10 µM). Perfusion with 
the nNOS inhibitors did not alter the firing rate of LC neurons (firing rate change: 2 ± 
1%, n = 17). Moreover, acute effects of both test concentrations of ME (0.8 and 25.6 µM) 
in the presence of nNOS inhibitors were not different from those in the control group 
(change in acute effect, ME (0.8 µM): 15 ± 7%, n = 5; ME (25.6 µM): 5 ± 7%, n = 15). 
 As in spontaneously firing neurons, administration of nNOS inhibitors in KCl-
excited LC neurons reduced by 27 ± 6% (n = 5, p < 0.05 vs control) the desensitization 
induced by ME (10 μM) when ME (0.8 µM) was applied before and after inducing 
desensitization (Figs. 4.7A and E). In addition, nNOS inhibitors blocked the 
desensitization by 58 ± 8% (n = 5, p < 0.005 vs control) when ME (25.6 µM) was applied 
before and after ME (10 μM), (Figs. 4.7B and E). Finally, nNOS inhibitors reduced by 43 
± 8% (n = 5, p < 0.05 vs control) the desensitization when ME (25.6 µM) was applied 
during ME (10 μM), (Figs. 4.7D and E). The basal firing rate in the presence of nNOS 
inhibitors was not significantly different when compared to the control group (basal firing 
rate, control: 4.35 ± 0.26 Hz, n = 15; in the presence of nNOS inhibitors: 4.92 ± 0.32 Hz, 
n = 15). GABA (1 mM, 1 min) caused a 100% reduction from baseline before and after 
inducing desensitization (n = 14) (Figs. 4.7C and E). These results reaffirm that nNOS 
contributes to ME-induced MOR desensitization in rat LC neurons. 
Results 
  
 
80 
 
 
 
 
Results 
   
81 
Figure 4.7. Effect of nNOS inhibitors on acute MOR desensitization induced by ME in KCl-excited LC 
neurons in vitro. A, B, C. Representative examples of firing-rate recordings of LC cells showing the effect 
of ME (0.8 μM, 1 min) (A), ME (25.6 μM, 1 min) (B) or GABA (1 mM, 1 min) (C) applied before and after 
inducing desensitization with ME (10 μM, 10 min) in the presence of 7-NI (100 μM) and SMTC (10 μM). 
D. Example of firing-rate recording of LC cell showing the effect of ME (25.6 μM, 1 min) applied at two 
times during a sustained perfusion with ME (10 μM, 10 min) in the presence of 7-NI (100 μM) and SMTC 
(10 μM). The horizontal bars indicate the period of drug applications and the vertical lines show the number 
of spikes recorded every 10 s. E. Bar histograms show the mean ± S.E.M of ME (10 μM)-induced 
desensitization in the absence and in the presence of nNOS inhibitors. Different test concentrations and 
experimental designs were used (see Pharmacological procedures). GABA was used as an internal control. 
All the experiments were performed in the presence of the glutamate receptor antagonists CNQX (30 μM) 
and D-AP5 (100 μM). Desensitization degrees were calculated as percentage values (see Data analysis and 
statistics). Note that nNOS inhibitors attenuated ME (10 μM)-induced desensitization when it was 
quantified by ME (0.8 μM, n = 5), or ME (25.6 μM) applied before and after (n = 5) or during ME 10 µM 
(n = 5). In contrast, GABA (1 mM) effect was not affected (n = 14). *p < 0.05 and **p < 0.005 when 
compared to the corresponding control group by two-sample Student’s t test. 
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On the contrary, perfusion with 7-NI (100 μM) together with SMTC (10 μM) failed 
to alter morphine (30 μM)-induced desensitization. Thus, desensitization induced by 
morphine (30 μM) in the presence of nNOS inhibitors was significant (n = 5, p < 0.005) 
(Figs. 4.8A and B). No differences were found between the firing rate before morphine 
(30 μM) and after naloxone (1 μM) (firing rate before morphine (30 μM): 5.0 ± 0.2 Hz, n 
= 5; firing rate after naloxone (1 μM): 4.8 ± 0.3 Hz, n = 5). GABA (1 mM) promoted a 
100% inhibition from baseline before and after inducing desensitization (n = 5) (Figs. 
4.8A and B). These results suggest that nNOS is not involved in acute MOR 
desensitization induced by morphine in LC neurons. 
 
Figure 4.8. Effect of nNOS inhibitors on acute MOR desensitization induced by morphine in KCl-excited 
LC neurons in vitro. A. Representative example of a firing-rate recording of LC cell showing the effect of 
ME (25.6 μM, 1 min) applied at two times during a sustained perfusion with morphine (30 μM, 10 min) in 
the presence of 7-NI (100 μM) and SMTC (10 μM). The horizontal bars indicate the period of drug 
applications and the vertical lines show the number of spikes recorded every 10 s. B. Bar histograms show 
the mean ± S.E.M of morphine (30 μM)-induced desensitization in the absence and in the presence of 
nNOS inhibitors. GABA was used as an internal control. All the experiments were performed in the 
presence of the glutamate receptor antagonists CNQX (30 μM) and D-AP5 (100 μM). Desensitization 
degrees were calculated as percentage values (see Data analysis and statistics). Note that nNOS inhibitors 
failed to block morphine (30 μM)-induced desensitization (n = 5). The effect of GABA (1 mM) was not 
affected by morphine perfusion (n = 5).  
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4.3 STUDY 3: EFFECT OF NEURONAL NITRIC OXIDE SYNTHASE 
INHIBITION AND ANTIOXIDANTS ON THE DEVELOPMENT OF 
TOLERANCE BY DIFFERENT OPIOID AGONISTS IN THE RAT LOCUS 
COERULEUS.  
 
Effect of chronic treatments with morphine, methadone and fentanyl on 
concentration-effect curves for ME in rat LC neurons 
To evaluate the development of tolerance, concentration-effect curves for the 
inhibitory effect of ME were performed. It has been reported that the firing rate of LC 
neurons is elevated in brain slices from opioid-treated rats (Kogan et al., 1992). In this 
study we attempted to minimize the differences in firing rates among groups by 
performing concentration-effect curves only in cells that displayed standard spontaneous 
firing rates in the range of 0.4-1.5 Hz (mean ± SEM: 0.80 ± 0.02 Hz, n = 95). This 
procedure attempted to avoid the possibility that a change in the spontaneous activity of 
LC cells could influence the quantification of opioid effects. Thus, the firing rate of LC 
neurons from morphine-, methadone- and fentanyl-treated animals was not different when 
compared to the corresponding sham groups (Tables 4.1 and 4.2). Morphine treatment 
(200 mg/kg, s.c., 72 h) induced a strong degree of tolerance in the LC, which was 
revealed by a substantial rightward shift in the concentration-effect curves for ME and an 
increase in the EC50 of about 4 fold, as compared to the corresponding sham group (p < 
0.005) (Figs. 4.9A and 4.10A; Table 4.2). Similarly, chronic treatment with methadone 
(60 mg/kg/day, s.c., 6 days) induced a rightward shift in the concentration-effect curves 
for ME and increased by about 2 fold the EC50 value when compared to the 
corresponding sham group (p < 0.005) (Figs. 4.9B and 4.10B; Table 4.2). Finally, chronic 
treatment with fentanyl (0.2 mg/kg/day, s.c., 7 days) also caused a rightward shift in the 
concentration-effect curves for ME with an increase of the EC50 of about 3 fold, as 
compared to the corresponding sham group (p < 0.005) (Figs. 4.9B and 4.10C; Table 4.2). 
These results indicate that morphine, methadone and fentanyl induce different degrees of 
tolerance to the inhibitory effect of ME in LC neurons. In all groups, the maximal effect 
of ME was 100% of baseline, which corresponded with an absolute inhibition from the 
basal firing rate. 
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Figure 4.9. Effect of chronic treatments with morphine, methadone or fentanyl on the acute ME effect in rat 
LC neurons. Rats were treated for 72 h with a morphine (n = 5) or sham emulsion (n = 5). Another group of 
animals were treated for 6 days with methadone (n = 7), 7 days with fentanyl (n = 5) or sham (n = 5) 
minipumps. A, B. Representative examples of firing-rate recording of LC cells from rats receiving the 
following treatments: sham (emulsion) or morphine (A), sham (minipump), methadone or fentanyl (B). 
Each horizontal bar represents the period of application of each ME concentration (0.05 - 12.8 μM, 2x) and 
the vertical lines show the number of spikes recorded every 10 s. The inhibitory effect induced by each 
application was calculated as a percentage from the basal firing rate. Note that greater concentrations of ME 
are needed to inhibit the neuron activity in rats treated with morphine, methadone and fentanyl, compared 
with sham animals, indicative of tolerance. 
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Figure 4.10. Concentration-effect curves for the inhibitory effect of ME in LC neurons from rats treated 
chronically with morphine, methadone or fentanyl. Rats were treated for 72 h with a morphine (n = 5) or 
sham emulsion (n = 5). Another group of animals were treated for 6 days with methadone (n = 7), 7 days 
with fentanyl (n = 5) or sham (n = 5) minipumps. A, B, C. Concentration-effect curves for the inhibitory 
effect of ME in LC neurons from rats receiving morphine (A), methadone (B), fentanyl (C) or sham 
treatment. The horizontal axis represents the logarithms of ME concentrations (0.05 - 12.8 μM, 2x) in linear 
scale. The vertical axis expresses the reduction in the firing rate of LC neurons as a percentage from the 
basal firing rate. Symbols are the mean ± SEM of ME effect at each concentration obtained from n animals. 
The lines through the data are the theoretical curves in each group constructed from the mean of the 
individual concentration-effect curve parameters, as estimated by nonlinear regressions (see Materials and 
Methods for details and Table 4.2 for mean values). Note that administration of morphine, methadone or 
fentanyl induces a shift to the right of the ME curves, representative of tolerance. In all groups, the maximal 
effect of ME was 100% of baseline, which corresponded with an absolute inhibition from the basal firing 
rate. 
 
Effect of the nNOS inhibitor 7-NI on opioid tolerance in rat LC neurons 
In vivo administration of the nNOS inhibitor 7-NI has been shown to attenueate the 
development of cellular tolerance in LC neurons from morphine-treated rats (Santamarta 
et al., 2005). Herein, we tested the effect of 7-NI on the tolerance induced by chronic 
treatments with other opioid agonists such as methadone and fentanyl. Co-administration 
of 7-NI in methadone- and fentanyl-treated rats (methadone/7-NI group and fentanyl/7-NI 
group) failed to prevent the development of tolerance. Thus, the pEC50 values of 
concentration-effect curves for ME in the methadone/7-NI or fentanyl/7-NI group were 
statistically lower than those in the corresponding sham group (p < 0.005 vs sham/7-NI; 
in both cases), but they were not different from the corresponding vehicle groups (i.e., vs 
methadone/vehicle and fentanyl/vehicle) (Fig. 4.11; Table 4.1). 7-NI administration in 
sham-treated animals (sham/7-NI group) did not modify the concentration-effect curves 
for ME in the LC as compared to the sham-vehicle group (Fig. 4.11; Table 4.1). No 
differences were found in the basal firing rate among groups (Table 4.1). Therefore, 
unlike morphine (Santamarta et al., 2005), the neuronal NOS inhibitor 7-NI fails to affect 
the development of opioid tolerance after methadone or fentanyl treatments. 
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Table 4.1. Effect of 7-nitroindazole (7-NI) on the basal firing rate and the inhibition 
induced by ME in the LC of sham- and opioid-treated rats. 
 
1Animals were co-treated for 6 days with methadone or 7 days with fentanyl by an osmotic minipump and 
7-NI injections (methadone/7-NI group, fentanyl/7-NI group), or with their vehicles (sham/vehicle group, 
sham/7-NI group, methadone/vehicle group, and fentanyl/vehicle group). 
2Parameters of concentration-effect curves for ME were estimated in each experiment by nonlinear 
regression. pEC50 values (negative logarithm of the concentration needed to elicit a 50% of maximal effect) 
and slope factors are shown as mean ± SEM of n experiments. Maximal effect values were 100% in all 
cases. *p < 0.005 when compared to the corresponding sham group (one-way ANOVA followed by a post-
hoc Tukey’s test). 
Concentration-effect curves
2
Treatment groups
1 Basal firing rate (Hz) pEC50 (M) (EC50, µM) Slope factor n
Sham (minipump)
     Vehicle (peanut oil) 0.74 ± 0.03 6.66 ± 0.03 (0.22) 1.15 ± 0.07 5
     7-NI 0.69 ± 0.06 6.84 ± 0.04 (0.15) 0.93 ± 0.07 5
Methadone
     Vehicle (peanut oil) 0.75 ± 0.06 6.29 ± 0.09* (0.52) 0.96 ± 0.03 5
     7-NI 0.57 ± 0.02 6.43 ± 0.04* (0.37) 1.02 ± 0.13 5
Fentanyl
     Vehicle (peanut oil) 0.96 ± 0.08 6.23 ± 0.05* (0.58) 1.03 ± 0.09 6
     7-NI 0.82 ± 0.10 6.38 ± 0.05* (0.42) 0.97 ± 0.04 5
Results 
   
89 
 
Figure 4.11. Effect of 7-nitroindazole (7-NI) on the concentration-effect curves for the inhibitory effect of 
ME and pEC50 values for ME in LC neurons from methadone- and fentanyl-treated rats. Animals were co-
treated with methadone or fentanyl minipumps and 7-NI injections for 6 and 7 days, respectively 
(methadone/7-NI group, n = 5; fentanyl/7-NI group, n = 5) or with their vehicles (sham/vehicle group, n = 
5; sham/7-NI group, n = 5; methadone/vehicle group, n = 5 and fentanyl/vehicle group, n = 6). A, B. 
Concentration-effect curves for the inhibitory effect of ME in LC neurons from rats receiving 7-NI together 
with methadone (A), fentanyl (B) or sham treatment. The horizontal axis represents the logarithms of ME 
concentration (0.05 - 12.8 μM, 2x) in linear scale. The vertical axis expresses the reduction in the firing rate 
of LC neurons as a percentage from the basal firing rate. Symbols are the mean ± SEM at each ME 
concentration obtained from n rats. The lines through the data are the theoretical curves in each group 
constructed from the mean of the individual concentration-effect curve parameters, as estimated by 
nonlinear regressions (see Materials and Methods for details and Table 4.1 for mean values). C, D. Ordinate 
represents pEC50 values for ME effect in sham-, methadone- or fentanyl-treated rats. Bars are mean ± 
S.E.M. of n rats. Note that administration of methadone and fentanyl induces a rightward shift to the right 
of the ME curves, but co-administration of the nNOS inhibitor 7-NI does not prevent this change. In all 
groups, the maximal effect of ME was 100% of baseline, which corresponded with an absolute inhibition 
from the basal firing rate. *p < 0.005 when compared to the corresponding sham group (one-way ANOVA 
followed by a post-hoc Tukey’s test). 
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Effect of antioxidants on opioid tolerance in rat LC neurons 
Previous results from our group have shown that the co-administration of the free 
radical scavenger Trolox together with ascorbic acid (TX+AA) blocked partially the 
development of analgesic tolerance in morphine-treated rats (J. Llorente, Doctoral Thesis, 
unpublished data). To verify these results with other antioxidants and other opioid 
agonists, we evaluated the effect of co-administration of TX+AA or U-74389 on the 
development of tolerance in morphine-, methadone- and fentanyl-treated animals. In 
agreement with previous results, co-administration of the vitamin E analogue Trolox, 
together with ascorbic acid in morphine-treated rats (morphine/TX+AA group) attenuated 
the development of cellular tolerance, which was shown by a blockade of the rightward 
shift of the concentration-effect curve in this group. Thus, the pEC50 value for ME effect 
in the morphine/TX+AA group did not differ statistically from the value in the 
sham/TX+AA group, but it was significantly less than that in the morphine/vehicle group 
(p < 0.05), indicating that the blockade of morphine tolerance by TX+AA was complete 
(Figs. 4.12A and C; Table 4.2). In contrast, TX+AA administration in sham-treated 
animals (sham/TX+AA) did not modify the concentration-effect curves for ME in the LC, 
as compared to the sham/vehicle group (Figs. 4.12A and C; Table 4.2). Likewise, co-
treatment with U-74389G, a structurally unrelated antioxidant in morphine-treated rats 
(morphine/U-74389G group), attenuated the development of morphine tolerance, revealed 
by a blockade of the rightward shift of the concentration-effect curves in this group and 
an overlap with sham curves, indicating that the blockade was also complete. Hence, the 
pEC50 for ME effect in the morphine/U-74389G group was not different from that in the 
sham/U-74389G group, but was significantly less than that in the morphine/vehicle group 
(p < 0.01) (Figs. 4.12B and C; Table 4.2). Administration of U-74389G in sham animals 
(sham/U-74389G) failed to modify the concentration-effect curves for ME when 
compared to the sham/vehicle group (Figs. 4.12B and C; Table 4.2). Moreover, no 
differences were found in the basal firing rate among groups (Table 4.2). 
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Table 4.2. Effect of antioxidants (Trolox + ascorbic acid and U-74389G) on the basal 
firing rate and the inhibition induced by ME in the LC of sham- and opioid-treated 
rats. 
 
 
1Animals were co-treated for 72 h with a morphine emulsion, for 6 days with methadone and 7 days with 
fentanyl by an osmotic minipump and Trolox + ascorbic acid or U-74389G injections (morphine/TX+AA 
group, morphine/U-74389G group, methadone/U-74389G group, fentanyl/U-74389G group), or with their 
vehicles (sham/vehicle group, sham/TX+AA group, sham/U-74389G group, morphine/vehicle group, 
methadone/vehicle group and fentanyl/vehicle group). 
2Parameters of concentration-effect curves for ME were estimated in each experiment by nonlinear 
regression. pEC50 values (negative logarithm of the concentration needed to elicit a 50% of maximal effect) 
and slope factors are shown as mean ± SEM of n experiments. Maximal effect values were 100% in all 
cases. *p < 0.05, **p < 0.01 and ***p < 0.005 when compared to the corresponding sham group. †p < 0.05 
and ††p < 0.01 when compared to the corresponding vehicle group (one-way ANOVA followed by a post-
hoc Tukey’s test). 
Concentration-effect curves
2
Treatment groups
1 Basal firing rate (Hz) pEC50 (M) (EC50, µM) Slope factor n
Sham (emulsion)
     Vehicle (saline) 0.87 ± 0.05   6.66 ± 0.05 (0.22) 1.01 ± 0.05 5
     TX+AA 0.71 ± 0.04   6.58 ± 0.10 (0.26) 1.06 ± 0.06 5
     U-74389G 0.72 ± 0.05   6.52 ± 0.01 (0.30) 1.14 ± 0.05 5
Morphine
     Vehicle (saline) 1.05 ± 0.14   6.02 ± 0.10*** (0.95) 0.91 ± 0.04 5
     TX+AA 0.89 ± 0.09   6.41 ± 0.11
† (0.39) 0.92 ± 0.06 5
     U-74389G 0.85 ± 0.06   6.42 ± 0.08
†† (0.38) 1.03 ± 0.09 5
 
 
Sham (minipump)
     Vehicle (saline) 0.78 ± 0.04   6.64 ± 0.03 (0.23) 1.05 ± 0.08 5
     U-74389G 0.78 ± 0.03   6.58 ± 0.06 (0.27) 1.06 ± 0.05 5
Methadone
     Vehicle (saline) 0.81 ± 0.06   6.31 ± 0.05*** (0.49) 1.05 ± 0.04 7
     U-74389G 0.68 ± 0.09   6.34 ± 0.04* (0.45) 1.16 ± 0.10 7
Fentanyl
     Vehicle (saline) 0.93 ± 0.09   6.19 ± 0.03*** (0.64) 1.02 ± 0.11 5
     U-74389G 0.81 ± 0.09   6.19 ± 0.09** (0.65) 1.04 ± 0.11 5
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Figure 4.12. Effect of Trolox + ascorbic acid (TX+AA) and U-74389G on the concentration-effect curves 
for the inhibitory effect of ME and pEC50 values for ME in LC neurons from morphine-treated rats. 
Animals were co-treated for 72 h with a morphine emulsion and TX+AA or U-74389G injections 
(morphine/TX+AA group, n = 5; morphine/U-74389G group, n = 5) or with their vehicles (sham/vehicle 
group, n = 5; morphine/vehicle group, n = 5; sham/TX+AA group, n = 5; sham/U-74389G group, n = 5). A, 
B. Concentration-effect curves for the inhibitory effect of ME in LC neurons from morphine-treated rats 
receiving TX+AA (A) or U-74389G (B). The horizontal axis represents the logarithms of ME concentration 
(0.05 - 12.8 μM, 2x) in linear scale. The vertical axis expresses the reduction in the firing rate of LC 
neurons as a percentage from the basal firing rate. Data points are the mean ± SEM at each ME 
concentration obtained from n animals. The lines through the data are the theoretical curves in each group 
constructed from the mean of the individual concentration-effect curve parameters, as estimated by 
nonlinear regressions (see Materials and Methods for details and Table 4.2 for mean values). C. Ordinate 
represents pEC50 values for ME effect in sham- and morphine-treated animals. Bars are mean ± S.E.M. of 
n rats. Note that administration of morphine induces a strong shift to the right of the ME curves, and co-
administration of antioxidants TX+AA and U-74389G blocks this rightward displacement. In all groups, the 
maximal effect of ME was 100% of baseline, which corresponded with an absolute inhibition from the 
basal firing rate. *p < 0.005, when compared to the corresponding sham group, †p < 0.05 and ††p < 0.01, 
when compared to the vehicle group (one-way ANOVA followed by a post-hoc Tukey’s test). 
 
On the contrary, co-treatment with U-74389G in rats treated chronically with 
methadone or fentanyl (methadone/U-74389G and fentanyl/U-74389G group) did not 
prevent the development of cellular tolerance induced by these opioids, so that the 
concentration-effect curves from either methadone/U-74389G or fentanyl/U-74389G 
group were overlapped with those from their respective vehicle groups 
(methadone/vehicle and fentanylvehicle, respectively). Thus, the pEC50 values for ME 
effect in the methadone/U-74389G or fentanyl/U-74389G groups were statistically 
different from the corresponding sham group (sham/ U-74389G; p < 0.05 and p < 0.01, 
respectively), but they were not different from the corresponding vehicle groups 
(methadone/vehicle and fentanyl/vehicle, respectively) (Fig. 4.13; Table 4.2). U-74389G 
administration in sham animals (sham/U-74389G) failed to modify the concentration-
effect curves for ME when compared to the sham/vehicle group (Fig. 4.13; Table 4.2). No 
differences were found in the basal firing rate among groups (Table 4.2). 
Taken together, these data indicate that antioxidants reduce the development of 
cellular tolerance after morphine, but not methadone or fentanyl, and therefore, ROS 
seem to be differentially involved in opioid-induced cellular tolerance in the LC. 
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Figure 4.13. Effect of U-74389G on the concentration-effect curves for the inhibitory effect of ME and 
pEC50 values for ME in LC neurons from methadone- or fentanyl-treated rats. Animals were co-treated with 
methadone or fentanyl minipumps for 6 and 7 days, respectively, and U-74389G injections (methadone/U-
74389G group, n = 7; fentanyl/U-74389G group, n = 5) or with their vehicles (sham/vehicle group, n = 5; 
sham/U-74389G group, n = 5; methadone/vehicle group, n = 7 and fentanyl/vehicle group, n = 5). A, B. 
Concentration-effect curves for the inhibitory effect of ME in LC neurons from rats receiving U-74389G 
together with methadone (A), fentanyl (B) or sham treatment The horizontal axis represents the logarithms 
of ME concentration (0.05 - 12.8 μM, 2x) in linear scale. The vertical axis expresses the reduction in the 
firing rate of LC neurons as a percentage from the basal firing rate. Symbols are the mean ± SEM at each 
ME concentration obtained from n rats. The lines through the data are the theoretical curves in each group 
constructed from the mean of the individual concentration-effect curve parameters, as estimated by 
nonlinear regressions (see Materials and Methods for details and Table 4.2 for mean values). C, D. Ordinate 
represents pEC50 values for ME effect in sham-, methadone- and fentanyl-treated rats. Bars are mean ± 
S.E.M. of n rats. Note that administration of methadone of fentanyl induces a rightward shift to the right of 
the ME curves, but co-administration of the antioxidant U-74389G does not block this change. In all 
groups, the maximal effect of ME was 100% of baseline, which corresponded with an absolute inhibition 
from the basal firing rate. *p < 0.05, **p < 0.01 and ***p < 0.005 when compared to the corresponding 
sham group (one-way ANOVA followed by a post-hoc Tukey’s test).   
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4.4 STUDY 4: ROLE OF NEURONAL NITRIC OXIDE SYNTHASE AND 
REACTIVE OXYGEN SPECIES IN THE DEVELOPMENT OF 
ANTINOCICEPTIVE TOLERANCE INDUCED BY DIFFERENT OPIOID 
AGONISTS 
 
Development of tolerance for morphine-induced antinociception in morphine-, 
methadone- and fentanyl-treated animals 
In nontreated animals, morphine challenge (10 mg/ kg, i.p.) increased by more than 
three times the tail-flick latency, which corresponded with an average antinociceptive 
effect of 98 ± 1% (M.P.E.; basal latency = 2.99 ± 0.05 s; n = 104). To explore the 
development of opioid analgesic tolerance, the tail-flick test was performed in animals 
treated with different opioids (morphine, methadone and fentanyl). As expected, before 
opioid treatments the basal latencies and the antinociceptive effects induced by a 
challenge dose of morphine were not significantly different between groups. 
After morphine treatment, basal latencies were not different between sham 
(emulsion) and morphine-treated animals (Fig. 4.14A; Table 4.3). Morphine challenge 
increased by four times the latency in sham animals when compared to the basal latency 
(p < 0.005). In contrast, it failed to change the latency in morphine-treated animals (Fig. 
4.14A; Table 4.3). Thus, the analgesic effects induced by morphine challenge were 
statistically different between sham and morphine-treated animals, so that post-hoc 
analysis showed that morphine challenge induced a less pronounced analgesic effect in 
the morphine/vehicle group than it did in the sham/vehicle group (p < 0.005) (Fig. 4.14C; 
Table 4.3), which indicated the development of tolerance. 
On the other hand, basal latencies were found to be significantly different between 
sham (minipump) and methadone-treated rats (p < 0.005) (Table 4.4; compare 
methadone/vehicle vs sham/vehicle group). In sham animals, morphine challenge 
increased by four times the latency (p < 0.005 vs basal latency) and in methadone-treated 
rats it increased the latency by two times (p < 0.005 vs basal latency) (Fig. 4.14B; Table 
4.4). The analgesic effects induced by a challenge dose of morphine were significantly 
different between sham and methadone-treated rats even when the basal latency values 
were used as a covariate by ANCOVA. Thus, morphine challenge caused a less 
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antinociceptive effect in the methadone/vehicle group than in the sham/vehicle group, 
representative of tolerance (p < 0.005) (Fig. 4.14C; Table 4.4). 
Finally, basal latencies were not significantly different between sham (minipump) 
and fentanyl-treated rats. The challenge dose of morphine in fentanyl-treated rats 
increased more than three times the latency when compared to the basal latency (p < 
0.005). This increase was not different when compared to that in the sham group (Fig. 
4.14B; Table 4.4). Hence, the antinociceptive effect of morphine challenge in the 
fentanyl/vehicle group did not differ from that in the sham/vehicle group (ig. 4.14C; 
Table 4.4). Therefore, unlike morphine and methadone, this protocol of fentanyl infusion 
did not induce significant tolerance. 
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Figure 4.14. Development of tolerance for morphine-induced antinociception in morphine-, methadone- 
and fentanyl-treated animals. A, B. Bar histograms show the mean ± S.E.M of the latency before (basal) 
and after a challenge dose of morphine in sham (emulsion) (n = 10), sham (minipump) (n = 10), morphine- 
(n = 9), methadone- (n = 9) and fentanyl-treated animals (n = 6). Basal latencies were statistically different 
between methadone and sham groups &p < 0.005 when compared to the corresponding sham/vehicle group. 
Note that morphine challenge significantly increased the latency in sham-, methadone- and fentanyl-treated 
rats, but not in morphine-treated animals. *p < 0.005 when compared to the corresponding basal latency by 
a paired Student’s t test, and #p < 0.005, when compared to the corresponding sham group by two-sample 
Student’s t test. C. Bar histograms represent the mean ± S.E.M of the maximum possible effect (M.P.E.) in 
sham (emulsion) (n = 10), sham (minipump) (n = 10) morphine- (n = 9), methadone- (n = 9) and fentanyl-
treated animals (n = 6). Note that morphine and methadone treatments reduce the analgesic effect of 
morphine challenge, indicative of tolerance. $p < 0.005 when compared to the corresponding sham group by 
two-sample Student’s t test. †p < 0.005 when compared to the morphine group by two-sample Student’s t 
test. 
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Effect of the antioxidant U-74389G on morphine-induced analgesic tolerance 
We have previously shown that the co-administration of the selective nNOS inhibitor 
7-NI prevents the antinociceptive tolerance induced by a subchronic morphine treatment 
(3 days) in rats (Santamarta et al., 2005). Moreover, previous experiments have shown 
that co-administration of the vitamin E analogue Trolox and ascorbic acid (TX+AA) 
partially prevents the development of morphine analgesic tolerance (J. Llorente Doctoral 
Thesis, unpublished results). Likewise, in our work, co-treatment with U-74389G (10 
mg/kg/day), a structurally unrelated antioxidant, partially prevented the development of 
tolerance in morphine-treated rats. Hence, the antinociceptive response of the challenge 
dose of morphine in the morphine/U-74389G group was significantly greater than that in 
the morphine/vehicle group (p < 0.005), but smaller than that in the corresponding sham 
group (Fig. 4.15; Table 4.3). On the other hand, subchronic administration of U-74389G 
in sham-treated animals (sham/U-74389G group) failed to affect the morphine-induced 
analgesic effect, as compared to the sham/vehicle group (Fig. 4.15; Table 4.3). 
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Table 4.3. Effect of U-74389G on the tail-flick latencies and the analgesic response of 
sham- and morphine-treated rats. 
 
1Animals were co-treated for 72 h with a morphine emulsion and U-74389G injections (morphine/U-
74389G group), or with their vehicles (sham/vehicle group, sham/U-74389G group and morphine/vehicle 
group). 
2Basal latency values refer to the time until tail removal before administration of the morphine challenge. 
Data are shown as mean ± SEM of n experiments. After chronic treatments, basal latencies were not 
statistically different between groups.  
3Latency values refer to the time until tail removal after administration of the morphine challenge. Data are 
shown as mean ± SEM of n experiments. Latencies were statistically different when compared to basal 
latencies in all groups except in morphine/vehicle group. *p < 0.005 (paired Student’s t test). 
4M.P.E is the percentage of the maximal possible effect (see Materials and Methods). Data are shown as 
mean ± SEM of n experiments. Note that morphine treatment attenuates the analgesic effect of morphine 
challenge and co-administration of U-74389G partially blocks this change. $p < 0.005, when compared to 
the corresponding sham group (ANOVA followed by a post-hoc Tukey’s test), †p < 0.005 when compared 
to the corresponding vehicle group (ANOVA followed by a post-hoc Tukey’s test).  
 
 
Treatment groups
1
Basal latency (s)
2
Latency (s)
3
M.P.E (%)
4 n
Sham (emulsion)
     Vehicle (saline) 2.66 ± 0.14         9.41 ± 0.33*  92.41 ± 4.23 10
     U-74389G 2.57 ± 0.14         9.93 ± 0.06*  99.08 ± 0.73 7
Morphine
     Vehicle (saline) 3.19 ± 0.26         3.94 ± 0.30  13.77 ± 4.38
$ 9
     U-74389G 2.80 ± 0.14         7.20 ± 0.65*  61.74 ± 8.85
$† 8
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Figure 4.15. Effect of U-74389G on the on the antinociception induced by a challenge dose of morphine in 
sham-, and morphine-treated rats. Bar histograms show the mean ± S.E.M of the maximum possible effect 
(M.P.E.) in rats co-treated with the morphine emulsion and U-74389G (morphine/U-74389G group, n = 8) 
or with their vehicles (sham-vehicle group, n = 10; morphine-vehicle group, n = 9; sham/U-74389G group, 
n = 7). Note that morphine treatment reduces the analgesic effect of morphine challenge and co-
administration of U-74389G partially blocks this change. $p < 0.005, as compared to the corresponding 
sham group; †p < 0.005, as compared to the corresponding vehicle group (ANOVA followed by a post-hoc 
Tukey’s test). 
 
Effect of the neuronal nitric oxide synthase inhibitor 7-NI and the antioxidant U-
74389G on methadone-induced analgesic tolerance 
To study the role of neuronal NOS in the antinociceptive tolerance induced by other 
opioid agonists, we tested the effect of 7-NI in the group of rats receiving methadone. As 
noted above, basal latencies were found to be significantly higher (p < 0.05) in 
methadone/vehicle than in sham/vehicle groups (Table 4.4). However, in animals 
cotreated with 7-NI, basal latencies were not different between methadone and sham 
broups. Co-administration of the nNOS inhibitor 7-NI (30 mg/kg/12 h) in rats treated 
chronically with methadone failed to modify the development of analgesic tolerance, even 
when the basal latency values were used as a covariate by ANCOVA. Thus, the analgesic 
effect induced by morphine challenge in the methadone/7-NI group did not differ from 
that in the methadone/7-NI vehicle group, but it was lower than that in sham/7-NI group 
(Fig. 4.16A; Table 4.4). Chronic treatment with 7-NI failed to change the morphine 
challenge-induced effect, as compared the sham/7-NI group with the sham/7-NI vehicle 
group (Fig. 4.16A; Table 4.4).  
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To further explore the involvement of ROS, methadone-treated animals were co-
treated with the antioxidant U-74389G (10 mg/kg/day). As mentioned, basal latencies 
were significantly higher in methadone/vehicle than in sham/vehicle groups, but this 
difference was not significant between methadone and sham animals after co-treatment 
with U-74389G. Co-treatment with U-74389G in methadone-treated rats failed to modify 
the development of analgesic tolerance, even when the basal latency values were used as 
a covariate by ANCOVA. Thus, the analgesic response after a challenge dose of 
morphine in the methadone/U-74389G group was not different from that in the 
methadone/U-74389G vehicle group, but it was lower than that in sham/U-74389G group 
(Fig. 4.16B; Table 4.4). Chronic treatment with U-74389G failed to affect the morphine 
challenge-induced analgesic effect, as compared the sham/ U-74389G group with the 
sham/ U-74389G vehicle group (Fig. 4.16B; Table 4.4). 
Taken together, these data indicate that NO/ROS pathways play a key role in the 
development of morphine-, but not methadone-induced analgesic tolerance and therefore, 
these pathways seem to be differentially involved in opioid-induced analgesic tolerance in 
vivo.  
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Table 4.4. Effect of 7-nitroindazole (7-NI) and U-74389G on the tail-flick latencies 
and the analgesic response of sham and methadone-treated rats.
 
1Animals were co-treated for 6 days with methadone by an osmotic minipump and 7-NI or U-74389G 
injections (methadone/7-NI group, methadone/U-74389G group) or with their vehicles (sham/7-NI vehicle 
group, sham/U-74389G vehicle group, sham/7-NI group, sham/U-74389G group, methadone/7-NI vehicle 
group and methadone/U-74389G group). Another group of animals were co-treated for 7 days with fentanyl 
by an osmotic minipump. 
2Basal latency values refer to the time until tail removal before administration of the morphine challenge. 
Data are shown as mean ± SEM of n experiments. After chronic treatments, basal latencies were 
statistically different between groups. &p < 0.05 and &&p < 0.005 when compared to the corresponding 
sham/vehicle group (one-way ANOVA followed by a post-hoc Tukey’s test). 
3Latency values refer to the time until tail removal after administration of the morphine challenge. Data are 
shown as mean ± SEM of n experiments. Latencies were statistically different when compared to basal 
latencies in all groups. *p < 0.005 (paired Student’s t test). 
4M.P.E is the percentage of the maximal possible effect (see Materials and Methods). Data are shown as 
mean ± SEM of n experiments. Note that chronic methadone treatment attenuates the analgesic effect of 
morphine challenge, but co-administration of either 7-NI or U-74389G failed to block this effect, even 
when the basal latency values were used as a covariate. $p < 0.005 when compared to the corresponding 
sham group (ANCOVA followed by a post-hoc Tukey’s test). Chronic treatment with fentanyl does not 
alter the analgesic effect of morphine challenge. 
Treatment groups
1
Basal latency (s)
2
Latency (s)
3
M.P.E (%)
4 n
Sham (minipump)
     7-NI vehicle (peanut oil) 2.64 ± 0.14 9.87 ± 0.10* 98.29 ± 1.29 7
     7-NI 2.93 ± 0.14 9.74 ± 0.14* 96.43 ± 2.00 7
     U-74389G vehicle (saline) 2.59 ± 0.14 9.79 ± 0.11* 97.31 ± 1.43 10
     U-74389G 2.66 ± 0.17 9.90 ± 0.06* 98.75 ± 0.73 7
Methadone
     7-NI vehicle (peanut oil)   3.24 ± 0.07
&
6.61 ± 0.41* 49.48 ± 6.40
$
9
     7-NI 2.86 ± 0.16 5.51 ± 0.61* 37.77 ± 8.12
$
8
     U-74389G vehicle (saline)      3.32 ± 0.09
&&
6.51 ± 0.45* 47.98 ± 6.40
$
9
     U-74389G 3.01 ± 0.07 5.99 ± 0.52* 42.45 ± 7.41
$
7
Fentanyl
     Vehicle (saline) 2.90 ± 0.11 9.58 ± 0.18* 94.14 ± 2.66 6
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Figure 4.16. Effect of 7-NI and U-74389G on the on the antinociception induced by a challenge dose of 
morphine in sham-, and methadone-treated rats. A. Bar histograms show the mean ± S.E.M of the 
maximum possible effect (M.P.E.) in rats co-treated with methadone and 7-NI (methadone/7-NI group, n = 
8) or with their vehicles (sham/vehicle group, n = 7; methadone/vehicle group, n = 9; sham/7-NI group, n = 
7). B. Bar histograms show the mean ± S.E.M of the maximum possible effect (M.P.E.) in rats co-treated 
with methadone minipumps and U-74389G (methadone/U-74389G group, n = 7) or with their vehicles 
(sham/vehicle group, n = 10; methadone/vehicle group, n = 9; sham/U-74389G group, n = 7). Note that 
chronic methadone treatment reduces the analgesic effect of morphine challenge, but co-administration of 
either 7-NI or U-74389G fails to block this change. $p < 0.005, as compared to the corresponding sham 
group (ANCOVA followed by a post-hoc Tukey’s test).  
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5.1 STUDY 1: CONTRIBUTION OF NITRIC OXIDE-DEPENDENT 
GUANYLATE CYCLASE AND REACTIVE OXYGEN SPECIES SIGNALING 
PATHWAYS TO DESENSITIZATION OF µ-OPIOID RECEPTORS IN THE RAT 
LOCUS COERULEUS 
 
Previous electrophysiological experiments have shown that NO regulates MOR 
desensitization in the LC (Torrecilla et al., 2001; Llorente et al., 2012; Santamarta et al., 
2014). We have used single-unit extracellular recording techniques in brain slices to 
characterize the NO-dependent pathways (i.e., sGC and ROS) involved in MOR 
desensitization in the LC in vitro. Our results confirm that ME (3–10 μM) causes a 
concentration-related desensitization of MOR in the LC, so that the inhibitory effect of 
ME (0.8 μM) was markedly reduced. ME (3 μM)-induced MOR desensitization was 
enhanced by perfusion with the NO donor DEA/NO, whereas this enhancement was 
blocked by the sGC inhibitor NS 2028. Accordingly, ME (3 μM)-induced MOR 
desensitization was enhanced by two activators of sGC, A 350619 and BAY 418543. In 
contrast, ME (10 μM)-induced desensitization was not modified by inhibition of sGC 
with NS 2028 or PKG with Rp-8-Br-PET-cGMP. Perfusion with the antioxidants Trolox, 
melatonin or U-74389G failed to change ME (10 μM)-induced desensitization, but a 
combination of an antioxidant (Trolox) with a sGC inhibitor (NS 2028) was able to 
attenuate ME (10 μM)-induced desensitization.  
To study MOR desensitization in the LC, we measured the inhibitory effect of a test 
concentration of the opioid agonist ME (0.8 μM). ME was used as an indicator of MOR 
function, because it exerts a full inhibition of the firing activity of LC neurons almost 
exclusively through MOR (Williams and North, 1984; McPherson et al., 2010). 
Moreover, ME effect can be tested several times in the same cell, since it rapidly washes 
out from the tissue after bath perfusion. Therefore, MOR desensitization can be readily 
measured by extracellular recordings after recovery of the firing from ME-induced 
inhibition. Our results confirm that sustained application of ME (3 and 10 μM) causes 
MOR desensitization in the LC, expressed as a concentration-related decline in the test 
ME effect (30% and 61%, respectively). This protocol including variable desensitization 
degrees (i.e., by ME 3 and 10 μM) allowed us to investigate possible regulation of this 
phenomenon by activators or inhibitors of sGC pathway. Similar degrees of MOR 
desensitization by ME (3 and 10 µM) have been described by both intracellular electrodes 
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measuring ion currents (Harris and Williams, 1991) and extracellular electrodes recording 
cell firing rates (Llorente et al., 2012; Santamarta et al., 2014). The firing activity 
recorded by extracellular techniques may be considered as a closer physiological end-
point of MOR desensitization at the synaptic level of the neuron.  
ME (3 μM)-induced MOR desensitization was enhanced by 65% in the presence of 
the NO donor DEA/NO. Likewise, previous electrophysiological experiments in vitro 
have shown that the NO donor sodium nitroprusside also enhances MOR desensitization 
in the LC (Llorente et al., 2012). The main direct target of NO is the sGC, which 
catalyzes the production of cGMP from GTP (Kots et al., 2009; Hoffmann and Chen, 
2014). The LC has been reported to express the α1 and ß1 subunits of the sGC (Matsuoka 
et al., 1992; Furuyama et al., 1993; Pifarré et al., 2007) and, accordingly, detectable 
concentrations of cGMP are measured in the LC (Xu et al., 1998a; Vulliemoz et al., 
1999). Herein, ME (3 µM)-induced MOR desensitization in LC neurons was enhanced by 
~90% after perfusion with two structurally unrelated sGC activators, A 350619 or BAY 
418543. Both activators enhance the catalytic function of sGC in an NO-independent 
manner, although they can also act synergically with NO (Mayer and Koesling, 2001; 
Stasch et al. 2002). BAY 418543 lacks any effect on phosphodiesterase activity (Stasch et 
al., 2002). Accordingly, we found that DEA/NO-induced enhancement of MOR 
desensitization was prevented by NS 2028, an irreversible inhibitor of NO-dependent 
sGC activation in homogenates and slice preparations of the brain (Olesen et al., 1998). A 
high concentration of NO in the LC as that reached during DEA/NO administration could 
be obtained when nNOS expression is elevated in this nucleus, as described by chronic 
morphine treatments (Cuéllar et al., 2000). None of the drugs targeting the NO/sGC 
pathway in the present work (DEA/NO, NS 2028, A 350619 or BAY 418543) altered the 
acute effects of ME (0.8 μM) (before desensitization). Therefore, our data indicate that 
activation of sGC signaling can enhance MOR desensitization and also mediate the 
enhancement of MOR desensitization induced by raising the NO concentration in the LC. 
Other authors have reported in vivo that treatment with sGC activators enhances the 
development and expression of analgesic tolerance to morphine (Ozdemir et al., 2011) 
and administration of sGC inhibitors prevents the development of analgesic tolerance to 
morphine (Xu et al., 1998b; Durmus et al., 2014).  
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As discussed above, perfusion with high concentrations of ME (10 μM) induce a 
near-maximal degree of MOR desensitization in the absence of NO enhancers (“high 
MOR desensitization”) (Harris and Williams, 1991; Santamarta et al., 2014). Previous in 
vitro reports have described that lowering the endogenous production of NO by different 
neuronal-selective NOS inhibitors also attenuates the development of high MOR 
desensitization in the LC (Torrecilla et al., 2001; Santamarta et al., 2014). Likewise, 
inhibition of nNOS in vivo has been described to reduce the induction of morphine 
tolerance (Highfield and Grant, 1998; Santamarta et al., 2005) and morphine withdrawal 
(Pineda et al., 1998) in the LC. A high amount of type II PKG mRNA, one of the main 
cGMP targets (Kots et al., 2009), has been detected in the LC (El-Husseini et al., 1995). 
We have previously observed that high MOR desensitization is restored from 7-NI-
induced blockade by addition of 8-Br-cGMP (M.T. Santamarta, Doctoral Thesis), a cell 
permeable cGMP analogue with high potency for type II PKG activation (Pöhler et al., 
1995). This suggests that downstream regulation of cGMP/PKG pathway by NO may 
account for the effect of nNOS inhibitors on high MOR desensitization in the LC. 
Interestingly, sGC activity and type II PKG expression are up-regulated by morphine 
treatments in mice (Muraki et al., 1982; Liang and Clarck, 2004) and, therefore, the 
contribution of cGMP to MOR desensitization mediated by endogenous NO could be 
functionally relevant in vivo. Paradoxically, we did not detect any change in the extent of 
high MOR desensitization after independent administrations of high concentrations of the 
sGC inhibitor NS 2028 (10–30 μM) or the PKG inhibitor Rp-8-Br-PET-cGMP (1 μM). 
These drugs have been previously used as effective inhibitors of cGMP/PKG signaling. 
Thus, NS 2028 inhibits brain sGC activity in vitro with higher potency than ODQ 
(Garthwaite et al., 1995; Olesen et al., 1998). Rp-8-Br-PET-cGMP is a cell-permeable, 
potent inhibitor of PKG that shows 300-fold higher selectivities for PKG than for PKA 
(Smolenski et al., 1998). Similarly, intracerebroventricular administration of the PKG 
inhibitor KT-5823 fails to alter morphine tolerance in vivo (Bernstein and Welch, 1997).  
On the other hand, ROS have been reported to regulate MOR desensitization in the 
LC (Llorente et al., 2012). We found no change in the degree of high MOR 
desensitization (ME 10 μM) after separate administrations of antioxidant agents (U-
74389G, melatonin or Trolox). U-74389G and melatonin are two lipid-soluble 
antioxidants that protect against the effects induced by ROS (Khalil et al., 1998; Noda et 
al., 1999; Taherzadeh et al., 2006), whereas Trolox is a cell-permeable vitamin E 
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derivative that prevents oxidative stress in rat models (Balogh et al., 2005). In contrast, 
combined administrations of a sGC inhibitor (NS 2028) and an antioxidant agent (Trolox) 
significantly attenuated the development of high MOR desensitization, whereas they did 
not affect the acute effect of ME. Therefore, these results indicate that endogenous 
production of NO from nNOS purportedly caused by high ME concentrations would 
induce MOR desensitization by independent activation of sGC/PKG and ROS signaling 
pathways. Either of these cascades would be enough by itself to trigger the induction of 
high MOR desensitization by endogenous NO, so that both pathways should be 
simultaneously blocked to observe a reduced desensitization. The mechanism by which 
NO is generated and the exact NO-dependent events regulated by sGC/PKG and ROS 
remain as yet to be elucidated. Thus, NO-dependent activation of PKG has been 
speculated to mediate MOR desensitization by phosphorylating a substrate that affects 
MOR/G protein interaction or by counteracting the opioid effect on nonselective cation 
channels (Santamarta et al., 2014). Furthermore, several oxidative mechanisms have been 
proposed to regulate MOR desensitization, including possible ROS-induced activation of 
PKC (Llorente et al., 2012).  
It has been reported that NO modulates the firing activity of LC neurons by 
activation of sGC, the subsequent increase of cGMP levels and stimulation of PKG (Xu et 
al., 1998a; Pineda et al., 1996). Our work demonstrates that DEA/NO elevates by about 
100% the firing rate of LC neurons and this excitatory effect is prevented by 
administration of the sGC inhibitor NS 2028. Furthermore, a 51% elevation of the 
spontaneous firing rate of LC cells was obtained after sGC stimulation with BAY 418543 
and a slight reduction of the firing activity was observed after a combined perfusion with 
a sGC inhibitor (NS 2028) and an antioxidant (Trolox). Therefore, data obtained from the 
present work are compatible with an excitatory regulation of the firing activity of LC 
neurons by NO through the sGC/PKG pathway.  
Morphine dependence and withdrawal are associated with neuroadaptive changes in 
the neuronal NOS activity (Vaupel et al., 1997). During conditions in which nNOS 
expression is raised (such as during morphine dependence), NO concentrations would be 
expected to be higher (Cuéllar et al., 2000). Our results demonstrate that submaximal 
MOR desensitization induced by an intermediate concentration of ME (3 μM) can be 
enhanced by raising the concentrations of NO and by activating the sGC in the LC. NO-
induced enhancement appears to be blocked by a sGC inhibitor. Our previous work has 
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shown that antioxidant agents attenuate the enhancement of MOR desensitization induced 
by high concentrations of NO in the LC (Llorente et al., 2012). Removal of ROS also 
prevents the appearance of analgesic tolerance caused by opioids (Muscoli et al., 2007). 
Therefore, these data indicate that a combined activation of both signaling cascades, 
cGMP and ROS, may be needed to enhance MOR desensitization by high NO levels in 
this nucleus, so that inhibition of either of these pathways would disrupt the enhancement 
induced by NO. On the other hand, strong MOR desensitization obtained by high ME 
concentrations (10 μM) can be blocked by a combination of an antioxidant and a sGC 
inhibitor. Therefore, we conclude that endogenous NO derived from nNOS activity may 
mediate the development of strong MOR desensitization through downstream regulation 
of independent sGC/PKG and ROS pathways in the LC. Hypothetically, a 
pharmacological protection against NO-derived cGMP and ROS generation would result 
in prevention of opiate tolerance and maintaining a better control of pain with chronic 
opiates. 
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5.2 STUDY 2: STUDY OF THE INVOLVEMENT OF NEURONAL NITRIC 
OXIDE SYNTHASE IN MORPHINE-INDUCED DESENSITIZATION OF µ-
OPIOID RECEPTORS IN THE RAT LOCUS COERULEUS  
 
The ability of morphine to induce rapid MOR desensitization in native LC neurons 
has been a matter of debate (Alvarez et al., 2002; Bailey et al., 2003, 2009b). In addition, 
NO has been shown to regulate ME-induced MOR desensitization in the LC in vitro 
(Torrecilla et al., 2001; Llorente et al., 2012; Santamarta et al., 2014) and morphine-
induced tolerance in this nucleus in vivo (Santamarta et al., 2005). However, the 
contribution of NO to MOR desensitization induced by non-peptide opioid agonists in 
vitro is unknown. In the present study, we used single-unit extracellular recordings in 
KCl-excited LC neurons from rat brain slices to characterize the desensitization of MOR 
induced by morphine and ME. We further explored the involvement of the neuronal NOS 
isoform in acute MOR desensitization. Our results show that morphine (30 μM) causes 
significant desensitization of MOR in the LC, so that the inhibitory effect of a 
supramaximal test concentration of ME (25.6 μM, applied before and after, or during the 
opioid perfusion) was markedly reduced. As expected, ME (10 μM) also induced 
substantial desensitization of MOR, since the inhibitory effect of ME (0.8 or 25.6 μM) 
was diminished. The inhibitory effect of GABA (1 mM) was unaltered after application 
of either ME (10 µM) or morphine (30 µM). Perfusion with a combination of two 
selective nNOS inhibitors (7-NI and SMTC) attenuated the induction of MOR 
desensitization induced by ME but, in contrast, it failed to alter the desensitization 
induced by morphine. 
As previously mentioned, to study MOR desensitization, we evoked an excitation of 
LC neurons with KCl (14 mM). This procedure allows us to continously monitor 
morphine effects and, at the same time, to assess supramaximal test concentrations of ME 
by extracellular recording techniques. This would not have been feasible in spontaneously 
firing LC neurons from brain slices, since morphine would induce a complete inhibition 
of the firing activity that would not recover to baseline values. Apart from the 
postsynaptic action, it has been shown that KCl depolarizes nerve terminals, which 
triggers GABA and glutamate release in slice preparations (Liachenko et al., 1999). To 
avoid the interference of the KCl-induced glutamate release on MOR desensitization, all 
the experiments were performed in the presence of D-AP5 and CNQX (NMDA and non-
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NMDA glutamate receptor antagonist, respectively), as described by Mendiguren and 
Pineda (2007). Under these experimental conditions, most of the excitation of LC cells by 
KCl is due to postsynaptic changes in membrane potassium equilibrium. Thus, we first 
characterized the acute inhibitory effects of ME and morphine on KCl-excited neurons. 
Concentration-effect curves showed that morphine has a smaller maximum inhibitory 
effect (Emax) than ME, which is consistent with previous studies that have shown that 
morphine behaves as partial agonist at the MOR in LC neurons (Osborne et al., 2000; 
Bailey et al., 2003). The EC50 value for the inhibitory effect of ME effect in the presence 
of high K+ was found to be slightly shifted to the right as compared to that from 
spontaneously firing LC neurons (Santamarta et al., 2005) or by intracellular electrodes 
under voltage-clamp mode in the LC (Osborne and Williams, 1995). Likewise, the EC50 
value for morphine in the presence of high K+ is shifted rightward when compared to that 
reported using intracellular recording techniques in LC neurons (Chiu et al., 1993). This 
is likely due to a positive DC shift in the potassium equilibrium potential promoted by 
high concentrations of extracellular K+ and the fact that we are able to follow the effect of 
ME or morphine at membrane potentials close to the reversal potential for K+ (where 
GIRK channels show rectification). 
To study MOR desensitization in the present study, we measured changes in the 
inhibitory effect of two test concentrations of the opioid agonist ME (0.8 or 25.6 μM). 
ME inhibits LC cell activity with high efficacy and almost exclusively through MOR 
(Williams and North, 1984). Moreover, it rapidly washes out from the slice so that MOR 
desensitization can be easily measured by extracellular recordings once the firing 
recovers from ME-induced inhibition. The use of an intermediate concentration of ME 
(0.8 µM), close to the EC50 value, allowed us to detect any minimal change in the 
sensitivity of MOR associated with ME-induced desensitization. On the contrary, 
application of a supramaximal test concentration of ME (25.6 µM) made it possible to 
study reductions in the maximal activity of MOR associated with ME-induced 
desensitization (Osborne and Williams, 1995). In the case of morphine, as a concentration 
of 30 µM produces near maximal receptor occupancy, we had to use the supramaximal 
test concentration of ME (25.6 µM) to measure maximal activity of MOR, overcoming 
morphine’s slow rate of receptor dissociation in the slice preparation.  
As expected, ME (10 μM) strongly desensitized the inhibition induced by a test 
application of ME (0.8 μM). This degree of desensitization was found to be similar to that 
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reported in spontaneously firing LC neurons (Llorente et al., 2012; Santamarta et al., 
2014). In addition, ME (10 μM) desensitized the inhibition induced by a supramaximal 
concentration of ME (25.6 μM), applied before and after the opioid perfusion. However, 
this degree of desensitization was less strong than that quantified by ME (0.8 µM), as a 
supramaximal test concentration is less sensitive to detect changes in MOR 
responsiveness associated with desensitization. Finally, the inhibitory effect of ME (25.6 
μM), applied at two times during ME (10 μM, 10 min) administration, was also 
desensitized to a similar extent to that observed when the ME test was applied before and 
after. 
On the other hand, morphine caused significant MOR desensitization, since the effect 
of ME (25.6 μM), applied before and after morphine (30 μM) perfusion, was significantly 
reduced. In fact, the degree of desensitization induced by morphine was stronger than that 
induced by ME under the same experimental design. This is likely because MOR 
signaling starts recovering once the sustained perfusion of ME finishes, whereas it does 
not recover for a long time after morphine perfusion. Likewise, morphine (30 μM) 
desensitized the inhibitory effect of ME (25.6 μM), when it was tested at two times during 
the opioid perfusion. Interestingly, the degree of desensitization induced by morphine 
using the latter protocol was not different from that induced by ME. This finding seems to 
contradict previous electrophysiological experiments that showed that morphine induces 
significantly weaker MOR desensitization than higher efficacy opioid agonists such as 
ME in LC neurons in vitro (Alvarez et al., 2002; Bailey et al., 2003). Interestingly, these 
authors have reported that morphine-induced desensitization is enhanced by concomitant 
activation of PKC (Bailey et al., 2004; Arttamangkul et al., 2015). In our assays, high K+ 
concentration may facilitate calcium entry through voltage-dependent calcium channels 
(Meier et al., 1988), which has been shown to elevate PKC activity in different systems 
(Sakai et al., 1997; Dupont et al., 2000; Ratz and Miner, 2009). Other kinases such as 
CaMKII have been also reported to negatively regulate MOR signaling and to contribute 
to morphine-induced desensitization, tolerance and dependence (Mestek et al., 1995; 
Sánchez-Blázquez et al., 2008; Tang et al., 2006; Navidhamidi et al., 2012), with their 
activity being increased in a calcium-dependent manner (Kim et al., 2000; Song et al., 
2010). However, it is unclear if they interact directly or indirectly with MOR in LC 
neurons (Wang and Wang, 2006; Feng et al., 2011; Arttamangkul et al., 2015). Given that 
the mean firing rate after KCl (14 mM) was ~4 Hz, we can speculate that these kinases 
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would be activated during KCl perfusion to a similar extent to that observed in waking 
animals, since tonic LC discharge rates up to 5 Hz are typically observed during normal 
waking in rats and monkeys (Foote et al., 1980; Berridge and Waterhouse, 2003).  
On the contrary, our results suggest that, even in conditions where increased PKC 
activity would be expected (high K+), ME-induced desensitization was not found to be 
stronger than in control tissues. In agreement, a recent study using intracellular recordings 
in LC neurons has reported that PKC activators do not affect the desensitization induced 
by a saturating concentration of ME (30 µM), when the test was applied before and after 
the ME perfusion (Arttamangkul et al., 2015). Finally, we observed that the inhibitory 
effect of GABA, which was tested as an internal control, was ~100% and was not affected 
by either morphine or ME perfusion. GABA has been shown to induce stronger inhibitory 
effects at depolarized than at hyperpolarized membrane potentials on LC neurons 
(Osmanovic and Shefner, 1990), but these actions are not changed by opioid agonists. 
The NO system has been shown to modulate MOR signaling in the LC. We have 
previously reported that NO enhances ME-induced MOR desensitization (Llorente et al., 
2012). Independent administration of 7-NI and SMTC, two structurally unrelated 
molecules that selectively inhibit the neuronal NOS isoform (Babbedge et al., 1993; 
Furfine et al., 1994), attenuated ME-induced MOR desensitization in spontaneously firing 
LC neurons in vitro (Santamarta et al., 2014). In the present study, nNOS inhibition by a 
combined perfusion with 7-NI and SMTC attenuated ME-induced MOR desensitization 
in KCl-excited LC neurons, which confirms the involvement of nNOS in this process. In 
addition, NO has been shown to play a critical role in the adaptations induced by chronic 
morphine administration. Thus, morphine treatment leads to an increased NOS expression 
in the central nervous system (Cuéllar et al., 2000; Wong et al., 2000). In vivo 
administration of 7-NI prevents the development of tolerance in morphine-treated rats 
(Santamarta et al., 2005) and reduced the hyperactivity of LC neurons typically found 
after chronic morphine exposure (Pineda et al., 1998). Morphine-induced analgesic 
tolerance has been also shown to be attenuated by NO-activated sGC/cGMP-dependent 
mechanisms (Ozdemir et al., 2011; Durmus et al., 2014) and ROS generation (Muscoli et 
al., 2007; Batinić-Haberle et al., 2009). Surprisingly, perfusion with the nNOS inhibitors 
7-NI and SMTC failed to alter morphine-induced desensitization of MOR in vitro in our 
work. These results suggest that acute inhibition of neuronal NO synthesis does not affect 
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morphine-induced MOR desensitization in vitro, whereas it attenuates the induction of 
tolerance in vivo. 
The mechanisms by which nNOS might be differentialy involved in ME-, but not 
morphine-induced MOR desensitization are unknown. Results obtained in our laboratory 
have indicated that NO mediates the development of ME-induced MOR desensitization 
through independent regulation of downstream sGC/PKG and ROS pathways in the LC 
(see Results, Study 1). One of the most remarkable differences between ME and 
morphine is that ME causes robust receptor internalization (Arttamangkul et al., 2008; 
2012), whereas morphine fails to induce efficient internalization in adult rat LC neurons 
or HEK293 cells (Finn and Whistler, 2001; Alvarez et al., 2002; Bailey et al., 2003; 
Arttamangkul et al., 2008). It can be hypothesized that NO might act disrupting 
reinsertion of internalized receptors back into the plasma membrane, which would agree 
with the fact that morphine-induced desensitization is unaffected by nNOS inhibitors, 
since morphine does not promote efficient receptor endocytosis and recycling of the 
MOR. 
On the other hand, the mechanisms by which nNOS inhibitors would attenuate 
morphine-induced cellular tolerance in LC neurons and morphine-induced analgesic 
tolerance, without affecting acute desensitization are unclear. One of the possibilities may 
involve alterations in MOR turnover in LC neurons, which has been suggested to underlie 
opioid tolerance (Dang and Christie, 2012). Thus, previous results from our group have 
reported that chronic treatment with morphine leads to a disruption in MOR functional 
recovery from complete receptor inactivation with β-funaltrexamine in the LC. Our 
preliminary data indicate that this modification of MOR turnover may be mediated by NO 
(M.T. Santamarta, Doctoral Thesis, unpublished data). In adition, several events 
dependent on NO signaling pathways have been reported to mediate in vivo morphine-
induced antinociceptive tolerance, including glutamatergic activation (Sánchez-Blázquez 
et al., 2013), neuronal apoptosis (Bonfoco et al, 1995) or glial activation and induction of 
proinflammatory processes (Little et al., 2013). Thus, nNOS inhibitors could alleviate 
morphine tolerance in vivo by attenuating some of these processes, without altering 
morphine-induced desensitization.  
In conclusion, the present study shows that morphine and ME induce acute MOR 
desensitization in LC neurons. On the basis of previous studies, we can hypothesize that 
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morphine-induced desensitization could be mediated by high firing rate-dependent 
activation of PKC and/or CaMKII, to a similar extent as in vivo, but the exact mechanism 
has yet to be determined. Selective nNOS inhibition attenuates the induction of MOR 
desensitization by the opioid agonist ME, but it failed to alter the desensitization 
promoted by morphine. These results highlight the agonist-selective acute regulation of 
MOR by nNOS. Further studies are needed to investigate the underlying mechanisms. 
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5.3 STUDY 3: EFFECT OF NEURONAL NITRIC OXIDE SYNTHASE 
INHIBITION AND ANTIOXIDANTS ON THE DEVELOPMENT OF 
TOLERANCE BY DIFFERENT OPIOID AGONISTS IN THE RAT LOCUS 
COERULEUS 
 
The NO system has been involved in the underlying mechanisms of acute 
desensitization of MOR (Torrecilla et al., 2001; Llorente et al., 2012; Santamarta et al., 
2014) and in the development of morphine-induced tolerance (Santamarta et al., 2005). 
The aim of this work was to investigate the role of neuronal NOS and NO-derived ROS in 
the development of tolerance induced by three different opioid agonists: morphine, 
methadone and fentanyl. For that purpose, we performed uni-extracellular recordings of 
LC neurons to test the effect of the nNOS inhibitor 7-NI and the ROS scavengers TX+AA 
and U-74389G on the induction of tolerance by chronic treatments with these three opioid 
agonists. Chronic treatments with morphine, methadone and fentanyl resulted in cellular 
tolerance in LC neurons, which was revealed by a rightward shift of 2-4 fold in the 
concentration-effect curves for the inhibitory effect of ME. Co-treatment with TX+AA 
and U-74389G attenuated the tolerance to the electrophysiological effect of ME induced 
by morphine. On the contrary, co-treatment with 7-NI or with U-74389G failed to modify 
the cellular tolerance induced by methadone or fentanyl. 
It has been described that basal firing rates of LC neurons are significantly higher in 
slices from morphine-treated animals (Kogan et al., 1992), although they fire at control 
rates in morphine-treated rats that have been acutely pretreated with 7-NI (Pineda et al., 
1998). In the present study, concentration-effect curves for ME were performed only in 
LC cells that spontaneously fired at slow rates (between 0.4 and 1.5 Hz, as in control 
animals), to avoid a biased quantification of opioid effects influenced by differences in 
the spontaneous activity of LC neurons. We used ME as an indicator of MOR function in 
the LC because it is a potent agonist that acts almost exclusively through MOR (Williams 
and North, 1984). Furthermore, it rapidly washes out after perfusion, which allows us to 
characterize the effect easily by extracellular recordings. Morphine tolerance was induced 
by s.c. implantation of an oily emulsion containing morphine base (200 mg/kg, a single 
administration, 72 h). These emulsions have been described to provide a slow drug 
release and prolonged exposure to the opioid (Salem and Hope, 1999). According to the 
time course described in mice, the emulsion promotes a rise in morphine concentration in 
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serum 3–12 h after implantation and a gradual clearance of morphine over 4–5 days 
(Garzón and Sánchez-Blázquez, 2001). In the present study, morphine caused a 4-fold 
shift to the right in the concentration-effect curves for ME in the LC. This degree of 
cellular tolerance is comparable to that reported previously in LC neurons in vitro, using 
the same morphine protocol (Santamarta et al., 2005). Likewise, in a previous study in the 
LC in vivo, we reported a 4-fold rightward shift in the morphine dose-effect curves after 
intraperitoneal administration of morphine hydrochloride solutions (10–100 mg/kg per 
injection, 15 injections, 5 days) (Pineda et al., 1998). However, Highfield and Grant 
(1998) implanted several slow-release pellets (75 mg morphine base per pellet, 6 pellets, 
6 days) and found a 2-fold rightward shift in the concentration-effect curves for morphine 
in LC cells. 
Chronic treatment with methadone osmotic pumps (60 mg/kg/day, 6 days) caused a 
2-fold shift to the right in the concentration-effect curves for ME in the LC. Likewise, 
Quillinan et al. (2011) observed a 2-fold shift to the right in the concentration-effect 
curves for ME measured by intracellular recordings in LC cells using the same 
methadone administration protocol. Methadone has been reported to cause 
antinociception in the tail flick and hot plate tests with a potency similar to that of 
morphine when given s.c. to rats (Giusti et al., 1997; He et al., 2009). Furthermore, the 
peak hyperpolarization caused by methadone (30 µM) is approximately the same as the 
hyperpolarization induced by morphine (30 µM) measured by extracellular recordings in 
LC neurons (Alvarez et al., 2002). The dose of methadone that is delivered daily by the 
pump is comparable to that estimated to be released daily by the morphine emulsion (~66 
mg/kg/day), but elicited a less profound degree of cellular tolerance. In behavioral 
experiments chronic methadone treatment has been also reported to cause a less strong 
degree of antinociceptive tolerance than morphine when given at equianalgesic doses 
(Enquist et al., 2012). In our results, morphine treatment exerted a stronger degree of 
cellular tolerance than methadone in LC neurons (see above). Studies comparing different 
MOR agonists have found that those that induce robust receptor endocytosis and 
recycling tend to produce reduced analgesic tolerance and dependence (Whistler et al., 
1999). Morphine has a poor ability to promote internalization and recycling of the MOR 
(Alvarez et al., 2002; Arttamangkul et al., 2008), whereas methadone efficiently 
internalizes the MOR in different systems (Keith et al., 1998; Alvarez et al., 2002; Celver 
et al., 2004; Koch et al., 2005; Arttamangkul et al., 2008). In agreement with this 
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hyphothesis, mice with genetically modified MORs that have the ability to spontanelusly 
internalize and recycle develop a reduced tolerance to morphine (Kim et al., 2008). 
Similarly, animals with mutant MORs that show enhanced receptor degradation after 
endocytosis, developed stronger antinociceptive tolerance after methadone treatment 
(Enquist et al., 2012). 
On the other hand, chronic treatment with fentanyl minipumps (0.2 mg/kg/day, 7 
days) resulted in a 3-fold shift to the right in the concentration-effect curves for ME in LC 
neurons. Fentanyl has been reported to be up to 100 times more potent than morphine at 
producing analgesia (Vardanyan and Hruby, 2014). Surprisingly, this fentanyl 
administration protocol did not cause antinociceptive tolerance (see Results, Study 4). 
Paronis and Holtzman (1992) also observed that fentanyl (0.24 mg/kg/day) infused for 7 
days by osmotic pumps failed to induce significant analgesic tolerance in rats. However, 
fentanyl has been found to induce analgesic tolerance when given at a dose of 0.04 mg/kg 
(s.c., 4 times a day, 3 days) in mice (Popik et al., 2000) and also at much higher doses, 
such as 2.4 mg/kg/day (72 h) or 3.2 mg/kg/day (5 days) by subcutaneously implanted 
pumps in neonatal rats and mice (Raehal and Bohn, 2011; Thornton and Smith, 1997). In 
our study, fentanyl elicited a weaker degree of cellular tolerance than morphine (see 
above). As it happens with methadone, fentanyl induces endocytosis and recycling of the 
MOR (Celver et al., 2004), which was been associated with a less potential to induce 
tolerance.  
Thus, it can be hypothesized that differences between opioids in their ability to 
induce receptor internalization and recycling may contribute, at least in part, to the 
different degrees of cellular tolerance observed in this study. In contrast, other studies 
show that β-arrestin2 knockout mice, in which MOR endocytosis is presumably unpaired, 
fail to develop both cellular tolerance (Dang et al., 2011) and antinociceptive tolerance 
after morphine (Bohn et al., 2000), but not after methadone or fentanyl treatments (Raehal 
and Bohn, 2011). Interistingly, the impaired MOR recycling that was found in wild-type 
LC neurons from morphine-treated rats was attenuated in β-arrestin2 knockout animals 
(Quillinan et al., 2011). Thus, β-arrestin2 may disrupt the ability of receptors to recycle 
after endocytosis, and therefore, contribute to the development of tolerance. 
Interactions between the opioid system and the NO cascade have been described in 
the brain (Pasternak et al., 1995; Sánchez-Blázquez et al., 2013). Thus, NOS activity and 
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expression in the central nervous system is up-regulated after chronic morphine 
administration (Machelska et al., 1997; Cuéllar et al., 2000). Previous data from our 
laboratory have shown that perfusion with non-selective and selective NOS inhibitors 
attenuates acute MOR desensitization induced by ME in LC cells in vitro (Torrecilla et 
al., 2001; Santamarta et al., 2014). Moreover, the nNOS inhibitor 7-NI attenuates the 
development of cellular and antinociceptive tolerance in morphine-treated rats 
(Santamarta et al., 2005). Likewise, nNOS-, but not eNOS-deficient mice, exhibit weak 
analgesic tolerance to morphine when compared to wild type animals (Heinzen and 
Pollack, 2004). NOS inhibitors also attenuated the withdrawal-induced hyperactivity of 
LC cells (Pineda et al., 1998). 7-NI is a heterocyclic compound that hardly distinguishes 
between nNOS and eNOS in brain homogenate preparations, but it exhibits a marked 
selectivity for neuronal NOS in intact cell models or in vivo (Babbedge et al., 1993; 
Hobbs et al., 1999), which is likely due to specific targets of 7-NI that are only present in 
neurons (Alderton et al., 2001; Handy and Moore, 1998). NO reacts with oxygen 
derivatives to produce ROS, such as the powerful oxidant peroxynitrite (Davis, 2001). 
ROS have been reported to regulate MOR desensitization in the LC (Llorente et al., 
2012). In this study, we found that TX+AA (40 and 100 mg/kg/day, respectively, i.p.) and 
U-74389G (10 mg/kg/day, i.p.), attenuated morphine-induced cellular tolerance to the 
inhibitory effect of ME on LC neurons. Trolox is a cell-permeable vitamin E derivative 
with powerful antioxidant properties (Balogh et al., 2005). Ascorbic acid is a potent 
antioxidant and ROS chelator by itself, but we used it as a Trolox recycler from oxidation 
(Guo and Packer, 2000). Vitamin E (40 mg/kg) and ascorbic acid (100 mg/kg) are 
effective in preventing oxidative damage in the rat brain (Delwing et al., 2005). U-
74389G is a 21-aminosteroid that potently inhibits ROS-mediated peroxidation and it has 
been shown to reduce cerebral superoxide anion concentration following brain injury 
(Villa and Gorini, 1997; Fabian et al., 1998). Similarly, TX+AA and U-74389G have 
been shown to block partially the development of antinociceptive tolerance induced by 
morphine (see Results, Study 4). In agreement, other ROS scavengers such as melatonin 
(Raghavendra and Kulkarni, 2000), alpha-lipoic acid (Abdel-Zaher et al., 2013) or 
metalloporphyrins (Muscoli et al., 2007; Batinić-Haberle et al., 2009) attenuate the 
development of morphine-induced antinociceptive tolerance.  
The mechanisms by which NO modulates morphine-induced tolerance via ROS 
generation remain unclear. One possible mechanism might be ROS-mediated activation 
Discussion   
    
122 
 
of PKC. Opioids can induce a sustained increase in ROS (Koch et al., 2009) and PKC can 
be activated by raising the concentrations of ROS (Palumbo et al., 1992; Knapp and 
Klann, 2002). In the LC, PKC-induced phosphorylation enhances MOR desensitization 
induced by morphine without changing α2-adrenoceptor desensitization (Bailey et al., 
2004). There is also good evidence that PKC-dependent mechanisms play a significant 
role in the development of morphine analgesic tolerance (Zeitz et al., 2001; Smith et al., 
2003; Newton et al., 2007). Molecular data have reported that in brain areas such as the 
PAG, morphine-activated MOR increases NO concentrations via the Akt-nNOS pathway 
and activates PKC, which stimulates the activity of NMDARs (Sánchez-Blázquez et al., 
2010). This increased NMDAR activity would induce the phosphorylation and 
uncoupling of MORs via nNOS/CaMKII pathway, which results in the development of 
morphine analgesic tolerance (Sánchez-Blázquez et al., 2013). Indeed, NMDAR 
antagonists and nNOS and CaMKII inhibitors attenuate opioid tolerance and withdrawal 
(Elliott et al., 1994; Herman et al., 1995). Future studies should test this hypothesis and 
the possible involvement of other kinases such as c-Jun N-terminal kinase (Melief et al., 
2010). 
Conversely, our results show that 7-NI and antioxidants did not affect the 
development of tolerance in rats treated chronically with methadone or fentanyl. 
Similarly, behavioral experiments showed that 7-NI and U-74389G failed to alter the 
development of antinociceptive tolerance in methadone-treated rats (see Results, Study 
3). It has been described that methadone is a weak noncompetitive NMDAR antagonist 
(Ebert et al., 1998) and might counteract maladaptive changes in glutamate transmission. 
This might explain, at least in part, the less strong degree of cellular tolerance after 
methadone treatment and the lack of effects of NO/ROS modulators on methadone-
induced tolerance. Methadone and fentanyl may induce cellular tolerance by different 
mechanisms and cellular pathways from those described for morphine, as they trigger 
internalization and recycling of the MOR. Further assays should unmask the mechanisms 
underlying methadone- and fentanyl-induced adaptations. In conclusion, our results show 
that chronic treatments with morphine, methadone and fentanyl induce different degrees 
of cellular tolerance in LC neurons. In addition, in vivo administration of antioxidant 
agents attenuates the development of morphine-, but not methadone- or fentanyl-induced 
cellular tolerance. Therefore, NO/ROS pathways seem to be differentially involved in 
opioid cellular tolerance. Taken together, our results highlight the interest of a 
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pharmacological protection against NO-derived ROS generation to attenuate the 
development of morphine tolerance and maintain a better control of pain.  
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5.4 STUDY 4: ROLE OF NEURONAL NITRIC OXIDE SYNTHASE AND 
REACTIVE OXYGEN SPECIES IN THE DEVELOPMENT OF 
ANTINOCICEPTIVE TOLERANCE INDUCED BY DIFFERENT OPIOID 
AGONISTS 
 
In this study, we evaluated by the tail-flick technique the development of analgesic 
tolerance after chronic treatments with three different MOR agonists. We present 
behavioral evidence for a role of NO/ROS pathway in morphine-, but no other opioids-
induced antinociceptive tolerance. Thus, morphine and methadone treatments induced 
tolerance to the antinociceptive effect of a challenge dose of morphine. In contrast, no 
tolerance to morphine effect was observed in fentanyl-treated animals. Co-administration 
of the antioxidant U-74389G partially prevented the development of antinociceptive 
tolerance in morphine-treated animals. On the contrary, co-treatment with neither the 
nNOS inhibitor 7-NI nor the antioxidant U-74389G affected the development of 
antinociceptive tolerance in methadone-treated rats.  
Morphine tolerance was induced by subcutaneous implantation of an oily emulsion 
containing morphine base (200 mg/kg, a single administration, 72 h). Morphine base 
containing emulsions provide a slow drug release and prolonged exposure to the opioid 
(Salem and Hope, 1999). According to the time course described in treated mice, the oily 
emulsion promotes a rise in morphine concentration in serum 3–12 h after implantation 
and a gradual clearance of morphine over 4–5 days (Garzón and Sánchez-Blázquez, 
2001). This morphine administration protocol has been reported to efficiently induce both 
analgesic and cellular tolerance in rats (Santamarta et al., 2005). The degree of tolerance 
was similar to that observed by Goodchild et al. (2009) who induced tolerance by a s.c. 
sustained release morphine emulsion (125 mg/kg/day, 2 days) in rats. Likewise, chronic 
administration of s.c. morphine (10 mg/kg, twice daily, 5 days) showed a similar degree 
of antinociceptive tolerance in thermal and mechanical test paradigms (Raghavendra et 
al., 2004). 
Chronic treatment with methadone-filled osmotic pumps (60 mg/kg/day, 6 days) 
induced a less strong degree of tolerance. In agreement, chronic methadone treatment has 
been reported to cause substantially less antinociceptive tolerance than morphine when 
given at equianalgesic doses (Enquist et al., 2012). The dose was selected based on 
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previous studies where cellular tolerance was observed in LC neurons (Quillinan et al., 
2011). Methadone has been reported to produce antinociception in the tail flick and hot 
plate tests with a potency similar to that of morphine when given s.c. to rats (Giusti et al., 
1997; He et al., 2009). The dose of methadone that is daily administered by the osmotic 
pump in the present study is similar to that estimated to be released by the morphine 
emulsion (~66 mg/kg/day), yet induces a less profound degree of tolerance. Methadone 
has been found to induce analgesic tolerance at higher doses, such as 96 mg/kg/day (s.c., 
5 days) (Raehal and Bohn, 2011) and also at much lower doses, such as 3 mg/kg/day (s.c., 
4 days) in mice (Enquist et al., 2012). However, no tolerance was observed with 4 mg/kg 
(s.c., twice daily, 5 days) (Kim et al., 2008). It has been proposed that the degree of 
tolerance that an agonist can induce is inversely related to its ability to induce receptor 
internalization (Whistler et al., 1999). It could be hypothesized that in the present study 
methadone causes a less strong degree of tolerance because it induces endocytosis and 
recycling of the MOR, whereas morphine is less effective (Keith et al., 1998; Alvarez et 
al., 2002; Celver et al., 2004; Koch et al., 2005). Indeed, in an animal model in which the 
MOR is genetically modified to enhance receptor degradation after endocytosis, mice 
show a stronger degree of antinociceptive tolerance after methadone treatment (Enquist et 
al., 2012). In agreement, transgenic mice with genetically modified MORs that have the 
ability to internalize and recycle develop a reduced tolerance to morphine (Kim et al., 
2008).  
 On the other hand, chronic treatment with fentanyl pumps (0.2 mg/kg/day, 7 days) 
did not cause antinociceptive tolerance. Fentanyl has been reported to be up to 100 times 
more potent than morphine as an analgesic (Vardanyan and Hruby, 2014). The dose of 
fentanyl used in the present study is sufficient to activate the MOR and promote 
behavioral changes and neuronal adaptations, as it was found to produce locomotor 
sensitization (Trujillo et al., 2004) and cellular tolerance in LC neurons (see Results, 
Study 3). In another study, fentanyl (0.24 mg/kg/day) infused for 7 days by osmotic 
pumps also failed to induce significant analgesic tolerance in rats (Paronis and Holtzman, 
1992). However, it was found to cause tolerance when given at a dose of 0.04 mg/kg (s.c., 
4 times a day, 3 days) in mice (Popik et al., 2000) and also at much higher doses, such as 
2.4 mg/kg/day (72 h) or 3.2 mg/kg/day (5 days) by subcutaneously implanted pumps in 
neonatal rats and mice (Thornton and Smith, 1997; Raehal and Bohn, 2011). Our results 
suggest that fentanyl, at doses expected to activate MOR and promote neuronal 
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adaptations, is resistant to tolerance induction. Fentanyl induces endocytosis and 
recycling of the MOR (Celver et al., 2004), which was been associated with a less 
potential to induce tolerance. Furthermore, it could be hypothesized that the absence of 
antinociceptive tolerance may be the result of other adaptations in the whole animal 
caused by fentanyl that may counteract the development of cellular tolerance, as observed 
in LC neurons (see Results, Study 3). 
Thus, we propose that the different magnitudes of tolerance among opioid agonists, 
may be explained, at least in part, by their different abilities to induce receptor 
internalization and recycling. However, β-arrestin2 knockout mice have been shown to 
develop attenuated analgesic tolerance to morphine but not to fentanyl or methadone 
(Bohn et al., 2000, 2002; Raehal and Bohn, 2011), which seems to contradict this 
hypothesis. Interistingly, Quillinan et al., (2011) showed that in morphine-treated rats 
recovery from acute ME-induced desensitization and receptor recycling was diminished, 
an effect that was not present in animals lacking β-arrestin2. Thus, it can be hypothesized 
that β-arrestin2 may disrupt the ability of receptors to recycle after endocytosis, which 
would contribute to tolerance development. 
Previous studies have implicated the NO system in the adaptations triggered by 
chronic morphine treatment. Thus, chronic treatment with morphine has been found to 
increase NOS activity and expression in the brain and spinal cord (Machelska et al., 1997; 
Bhargava et al., 1998; Cuéllar et al., 2000). Our previous studies show that in vivo 
administration of the nNOS inhibitor 7-NI attenuates the development of cellular and 
analgesic tolerance in morphine-treated rats (Santamarta et al., 2005). Likewise, at the 
cellular level, non-selective and selective NOS inhibitors block opioid-induced MOR 
desensitization in vitro (Torrecilla et al., 2001; Santamarta et al., 2014). 7-NI hardly 
distinguishes between nNOS and eNOS in brain homogenate preparations, but it exhibits 
a marked selectivity for neuronal NOS in intact cell models (Babbedge et al., 1993), 
which seems to be due to specific targets of 7-NI that are only present in neurons (Handy 
and Moore, 1998; Alderton et al., 2001). In agreement, following sustained morphine 
administration, nNOS-, but not eNOS-deficient mice, exhibit weak analgesic tolerance 
development when compared to wild type animals (Heinzen and Pollack, 2004). It is well 
known that NO reacts with oxygen derivatives to produce ROS, such as the powerful 
oxidant peroxynitrite (Davis, 2001). Previous results obtained in our laboratory have 
indicated that the vitamin E analogue Trolox and U-74389G separately attenuated the 
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enhancement of MOR desensitization induced by NO donors in LC neurons (Llorente et 
al., 2012). Moreover, Trolox, administered together with ascorbic acid (TX+AA), blocked 
partially the development of antinociceptive tolerance in morphine-treated rats (J 
Llorente, Doctoral Thesis, unpublished data). Similarly, in the present study U-74389G 
blocked partially the development of analgesic tolerance induced by a subchronic 
treatment with morphine and it did not alter the animal pain threshold. The 21-
aminosteroid U-74389G, whose molecular structure is unrelated to that of Trolox, 
potently inhibits ROS-mediated lipid peroxidation and has a strong antioxidant activity 
(Villa and Gorini, 1997; Fabian et al., 1998). Thus, we can assume that reduction of 
morphine tolerance by U-74389G is the consequence of prevention of ROS-induced 
effects. In agreement, targeting peroxynitrite by metalloporphyrins blocks the 
development of morphine-induced antinociceptive tolerance in mice (Muscoli et al., 
2007; Batinić-Haberle et al., 2009). Likewise, antioxidant agents such as melatonin or 
alpha-lipoic acid have been reported to attenuate the development of morphine tolerance 
(Raghavendra and Kulkarni, 2000; Abdel-Zaher et al., 2013). Mice lacking NOX1, a 
major source of ROS formation, exhibited weaker analgesic tolerance induced by 
repeated administration of morphine than wild type animals (Ibi et al., 2011). NOX2 
knockout mice developed antinociceptive tolerance similar to wild type mice after 3 days 
of continuous morphine, but showed restored morphine analgesia on day six, whereas 
wild type mice mice continued to develop tolerance (Doyle et al., 2013). In 
electrophysiological experiments, TX+AA and U-74389G separatedly blocked the 
development of cellular tolerance in LC neurons from morphine-treated rats (see Results, 
Study 3). 
The mechanisms by which ROS modulate opioid tolerance remain unclear. The 
potent ROS peroxynitrite has emerged as a pivotal component of opioid antinociceptive 
tolerance and pain. (Salvemini and Neumann, 2009; Little et al., 2012). Thus, there are 
some mechanisms by which ROS formation might contribute to opioid tolerance. 
Peroxynitrite has been shown to alter glutamate homeostasis within the dorsal horn of the 
spinal cord by the post-translational nitration of key proteins involved in maintaining a 
normal glutamate balance, such as NMDARs, glutamate transporters or glutamine 
synthase (Trotti et al., 1996; Zanelli et al., 2000, 2002). Nitration of these proteins by 
peroxynitrite would lead to a constant potentiation of the glutamatergic system. There is 
general agreement that dysfunction of the NMDAR/NO pathway is a key component of 
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nociception. It has been described that morphine activation of MOR increases NO 
production via the Akt-nNOS pathway and activates PKC, which stimulates the activity 
of NMDARs (Sánchez-Blázquez et al., 2010). This increased NMDAR activity would 
induce the phosphorylation and uncoupling of MORs via nNOS/CaMKII pathway, which 
results in the development of morphine analgesic tolerance (Sánchez-Blázquez et al., 
2013). In agreement, NMDAR antagonists and nNOS and CaMKII inhibitors attenuate 
opioid tolerance and dependence (Elliott et al., 1994; Herman et al., 1995). A second 
alternative would involve ROS-mediated activation of PKC (Palumbo et al., 1992; Knapp 
and Klann, 2000). Indeed, morphine tolerance is attenuated by administration of PKC 
inhibitors, or when PKC expression is reduced (Zeitz et al., 2001; Smith et al., 2003; 
Newton et al., 2007). A third potential ROS-dependent mechanism underlying tolerance 
might be glial activation and the consequent induction of proinflammatory processes. 
Chronic administration of morphine promotes neuroimmune activation as evidenced by 
activation of spinal cord glial cells and production of proinflammatory cytokines (Song 
and Zhao, 2001; Watkins et al., 2005, 2007; Zeng et al., 2014). The induction of those 
proinflammatory molecules would be relevant in the development of morphine tolerance, 
since the glial modulators propentofylline (Raghavendra et al., 2004), minocycline (Cui et 
al., 2008) or paeoniflorin (Jiang et al., 2014) attenuate morphine-induced antinociceptive 
tolerance. The possible mechanisms by which chronic morphine induces glial cell 
activation and cytokine production are not known, but a role for peroxynitrite as a 
signaling molecule involved in this process has been reported (Little et al., 2013). 
Resveratrol, a potent anti-inflammatory and antioxidant molecule, has been reported to 
attenuate morphine analgesic tolerance by inhibiting microglial activation and down-
regulating NMDAR expression in the spinal cord (Han et al., 2014; Tsai et al., 2012). A 
fourth ROS-related mechanism might involve neuronal cell death, which is present in 
morphine-induced antinociceptive tolerance (Mao et al., 2002; Sharifipour et al., 2014). 
Chronic morphine exposure causes apoptosis within the spinal cord dorsal horn (Mao et 
al., 2002) and increases supraspinal apoptosis in the cortex and amygdala in neonatal rats 
(Bajic et al., 2013). The mechanisms involved in morphine-induced apoptosis remain 
unclear, but ROS seem to take part in this process. Thus, low concentrations of 
peroxynitrite trigger apoptotic death, whereas higher concentrations induce necrosis 
(Bonfoco et al., 1995; Virág et al., 2003). The nuclear enzyme poly(ADP-ribose) 
polymerase (PARP) has been shown to contribute to peroxynitrite-induced neuronal cell 
death in the spinal cord in vitro (Scott et al., 2004). Inhibitors of PARP, which is involved 
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in different paradigms of cell death (Aredia and Scovassi, 2014), prevent the development 
of morphine antinociceptive tolerance (Mayer et al., 1999). 
On the other hand, we show that 7-NI and U-74389G did not affect the development 
of antinociceptive tolerance in methadone-treated rats. These findings are in agreement 
with electrophysiological experiments (see Results, Study 3), where 7-NI and U-74389G 
failed to alter the development of cellular tolerance in LC neurons from methadone-
treated rats. These results suggest that the NO system is not involved in methadone-
induced adaptations. Methadone has been described to behave as a weak noncompetitive 
NMDAR antagonist (Ebert et al., 1998). This ability of methadone to antagonize NMDA 
receptors and counteract maladaptive changes in glutamate transmission might explain, at 
least in part, the reduced tolerance after methadone treatment and lack of effects of 
NO/ROS modulators on methadone-induced tolerance. Further studies are needed to 
unmask the mechanisms underlying methadone-induced adaptations. 
In conclusion, our results show that morphine treatment induces a stronger degree of 
antinociceptive tolerance than methadone in rats, whereas fentanyl was resistant to 
tolerance induction. In addition, in vivo administration of antioxidant agents partially 
prevents the development of morphine-, but not methadone-induced analgesic tolerance, 
suggesting that the NO/ROS pathway is differentially involved in opioid antinociceptive 
tolerance. We provide pharmacological basis for the potential use of antioxidants as 
useful co-adjuvants in the management of chronic pain to prevent or, at least, attenuate 
the development of morphine analgesic tolerance. 
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1. NO enhances ME-induced MOR desensitization in LC neurons by a mechanism 
that is blocked by sGC inhibition and mimicked by sGC activators. Although 
isolated inhibition of sGC/PKG pathways or ROS generation itself does not affect 
MOR desensitization in the LC, simultaneous inhibition of both sGC and ROS 
attenuates MOR desensitization. These results suggest that sGC/cGMP and ROS 
pathways independently mediate MOR desensitization and underlie the enhancing 
effect of NO on MOR desensitization in LC neurons. 
 
2. ME and morphine induce acute desensitization of MOR in a model of KCl-evoked 
excitation of LC neurons in vitro, quantified by applying a test concentration of 
ME either before-after or during the desensitization period. These results contrast 
with literature reports that do not have shown any morphine-induced MOR 
desensitization by intracellular or patch-clamp recording techniques. 
 
3. Neuronal NOS inhibitors attenuate ME-, but not morphine-induced MOR 
desensitization in LC neurons in vitro. This suggests a differential role of NO in 
mediating the acute desensitization of MOR induced by different opioid agonists. 
 
4. Prolonged treatments with morphine, methadone and fentanyl induce a shift of the 
concentration-effect curves for ME to the right, with an increase of the EC50 of 4, 
2 and 3 folds, respectively, in LC neurons in vitro. This indicates that treatments 
with MOR agonists with different intrinsic efficacies cause variable degrees of 
cellular tolerance in LC cells.  
 
5. Co-administration of antioxidants in morphine-treated animals prevents the 
development of tolerance to ME effects in LC neurons in vitro. Conversely, co-
treatments with a neuronal NOS inhibitor or antioxidant agents fail to affect the 
induction of cellular tolerance in methadone- or fentanyl-treated animals. These 
results indicate a differential involvement of NO/ROS pathways in opioid 
tolerance in vivo after prolonged treatments with morphine, methadone and 
fentanyl. 
 
6. Prolonged treatments with morphine and methadone cause tolerance to the 
analgesic effect of morphine, but the degree of tolerance induced by methadone is 
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weaker than that induced by morphine. On the contrary, no analgesic tolerance is 
observed after chronic fentanyl treatment. This indicates that MOR agonists with 
different intrinsic efficacies cause variable degrees of antinociceptive tolerance. 
Furthermore, the degree of opioid tolerance depends on the response measured, as 
suggested by the differential results observed with analgesic vs 
electrophysiological techniques (see fifth conclusion). 
 
7. Co-administration of antioxidant agents in morphine-treated animals attenuates 
the development of tolerance to the antinociceptive effect of a challenge dose of 
morphine. In contrast, co-treatments with a neuronal NOS inhibitor or an 
antioxidant agent fail to affect the development of antinociceptive tolerance 
induced by methadone. These findings suggest that NO/ROS pathways are 
differentially involved in opioid tolerance, as measured by an in vivo function. 
 
Taken together, these results provide functional data supporting the involvement of 
neuronal NO and its downstream signaling pathways in the adaptations induced by 
opioids after acute or chronic exposure. We demonstrate that opioid agonists 
commonly prescribed in clinics for pain treatment have different profiles with 
respect to MOR regulation and promote agonist-specific activation of NO-related 
pathways.  
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Abstract 
Nitric oxide (NO) is involved in desensitization of µ-opioid receptors (MOR) in the 
locus coeruleus (LC). We used extracellular recordings in vitro to unmask the NO-
dependent pathways involved in MOR desensitization in the rat LC. Perfusion with ME 
(3 and 10 μM) reduced ME (0.8 μM) effect in a concentration-related manner, indicative 
of MOR desensitization. ME (3 μM)-induced desensitization was enhanced by the NO 
donor DEA/NO (100 µM) and the soluble guanylate cyclase (sGC) activators A 350619 
(30 μM) or BAY 418543 (1 μM). DEA/NO-induced enhancement was blocked by the 
sGC inhibitor NS 2028 (10 μM). The neuronal NO synthase inhibitor 7-NI (100 µM) 
reduced ME (10 μM)-induced desensitization, an effect that was prevented by the cGMP-
dependent protein kinase (PKG) activator 8-Br-cGMP (100 and 300 μM). Paradoxically, 
ME (10 μM)-induced desensitization was not modified by several sGC inhibitors (NS 
2028 and ODQ), PKG inhibitors (H8 and Rp-8-Br-PET-cGMP) or antioxidant agents 
(Trolox, U-74389G and melatonin), but it was attenuated by a combination of a sGC 
inhibitor (NS 2028 10 μM) and an antioxidant (Trolox 200 µM). Our results suggest that 
MOR desensitization in the LC may be mediated or regulated by NO through sGC and 
reactive oxygen species signaling pathways.  
 
Keywords: nitric oxide; µ-opioid receptor; locus coeruleus; cyclic guanosine 
monophosphate; slice; firing.  
Abbreviations: A350619, 3-[2-[(4-chlorophenyl)thiophenyl]-N-[4-(dimethylamino)butyl]-
2-propenamide hydrochloride; aCSF, artificial cerebrospinal fluid; BAY 418543, 2-[1-
[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-4,6 
pyrimidinediamine; cGMP, cyclic guanosine monophosphate; 8-Br-cGMP, 8-
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bromoguanosine 3′,5′-cyclic monophosphate; DEA/NO, diethylamine NONOate; H8, N-
(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide; LC, locus coeruleus; ME, Met5-
enkephalin; MOR, µ-opioid receptor; 7-NI, 7-nitroindazole; NO, nitric oxide; NOS, nitric 
oxide synthase; nNOS, neuronal nitric oxide synthase; NS 2028, 8-bromo-1H,4H-
[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one; ODQ, 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one; PKG, cGMP-dependent protein kinase; ROS, reactive oxygen 
species; Rp-8-Br-PET-cGMP, Rp-β-phenyl-1,N2-etheno-8-bromoguanosine 3′,5′-cyclic 
monophosphorothioate; S.E.M., standard error of the mean; sGC, soluble guanylate 
cyclase; U-74389G, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrrimidinyl)-1-piperazinyl]-pregna-
1,4,9(11)-triene-3,20-dione(Z)-2-butenedioate. 
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1. Introduction  
Opioids have long been used to alleviate severe, acute and chronic pain due to their 
high analgesic efficacy. However, the major limitation of their long-term use is the 
development of tolerance and dependence. Despite extensive research, the mechanisms 
responsible for opioid tolerance have been only partially unmasked. The analgesic effects 
of opioids are mediated by µ-opioid receptors (MOR). Accumulating evidence suggests a 
close relation between the induction of opioid tolerance and the appearance of MOR 
desensitization. Classical mechanisms underlying MOR desensitization include receptor 
phosphorylation, β-arrestin binding, receptor/effector uncoupling and receptor 
internalization (Taylor and Fleming, 2001). Additionally, nitric oxide (NO) cascade 
seems to be involved in the adaptations occurring during tolerance to opioids (Pasternak 
et al., 1995; Taylor and Fleming, 2001). NO production in the brain is catalyzed from L-
arginine mainly by the neuronal NO synthase (nNOS) and is followed by different direct 
and indirect effects. Direct effects involve the interaction of NO with the soluble protein 
guanylate cyclase (sGC) to increase the production of 3´,5´-cyclic guanosine 
monophosphate (cGMP) (Hoffmann and Chen, 2014), which in turn regulates especific 
protein kinases (PKG) (Kots et al., 2009; Lohmann et al., 1997), phosphodiesterases 
(Degerman et al., 1997) and nucleotide-gated cationic channels (Zagotta and Siegelbaum, 
1996). On the contrary, the indirect effects of NO are triggered by interaction of this 
molecule with oxygen (O2) or superoxide radicals (O2
-), which form nitrogen and oxygen 
species (ROS) when high concentrations of NO are reached (Davis et al., 2001).  
The locus coeruleus (LC), which represents the major noradrenergic cluster in the 
brain, contains a high density of somatodendritic MOR and therefore it has been used to 
explore the molecular and cellular mechanisms of opioid effects (Nestler et al., 1994). 
MOR activation by opioid agonists inhibits LC neurons through Gi/o protein-coupled 
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inwardly rectifying K+ channels (Nestler and Aghajanian., 1997). Short-term exposure to 
high concentrations of opioid agonists desensitizes MOR in the LC in vitro (Harris and 
Williams, 1991; Torrecilla et al., 2001). Furthermore, chronic treatments with opiates 
induce various adaptive changes in the LC that lead to cellular tolerance (Santamarta et 
al., 2005), including up-regulation of cAMP pathway (Cao et al., 2010), desensitization 
by protein kinase-dependent phosphorylation (Dang and Christie, 2012) or changes in 
receptor trafficking and resensitization (Arttamangkul et al., 2012). Moreover, previous 
reports have described the involvement of NO cascade in the LC in the induction of 
cellular withdrawal (Pineda et al., 1998) and tolerance (Highfield and Grant, 1998; 
Santamarta et al., 2005) in morphine-dependent animals. Accordingly, prolonged 
treatment with morphine increases the expression of nNOS in the LC (Cuéllar et al., 
2000) and non-selective and neuronal NOS inhibitors reduce MOR desensitization in the 
LC in vitro (Santamarta et al., 2014; Torrecilla et al., 2001). Recent work has suggested 
that ROS may mediate part of NO effects during opioid desensitization in the LC 
(Llorente et al., 2012). Thus, the ROS-generating molecule H2O2 enhances ME-induced 
MOR desensitization without affecting α2-adrenoceptor desensitization. However, a 
further characterization of NO-dependent pathways causing MOR desensitization has not 
been previously undertaken in the LC. 
Therefore, the aim of this work was to investigate the contribution of NO-dependent 
sGC and ROS signaling to MOR desensitization induced by ME in the LC. We explored, 
by single-unit extracellular recordings of LC neurons, the effect of different activators or 
inhibitors of sGC/PKG and ROS pathways on opioid desensitization in the rat in vitro.  
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2. Materials and Methods 
2.1. Animals 
Adult male Sprague-Dawley rats weighing 200–300 g were housed under controlled 
laboratory conditions (22 °C and 12-h light/dark cycles) with free access to food and 
water. All experimental procedures reported in this manuscript were conducted in 
accordance with U.K. Animals (Scientiﬁc Procedures) Act, 1986, and associated 
guidelines, and with the European Community Council Directive on "Protection of 
Animals Used in Experimental and Other Scientific Purposes" of 24 November 1986 
(86/609/EEC). The procedures were approved by the Animal Care and Use Committee of 
the University of the Basque Country. All efforts were made to minimize animal suffering 
and to reduce the number of animals used. The animals for this study were obtained from 
the animal house of the University of the Basque Country (Leioa, Spain).  
 
2.2. In vitro electrophysiology  
2.2.1. Brain slice preparation 
In vitro experiments were performed as previously described (Mendiguren and 
Pineda, 2007). Briefly, animals were first anaesthetized with chloral hydrate (400 mg/kg, 
i.p.) and sacrificed by decapitation. The brain was removed and a block of tissue 
containing the brainstem was placed in ice-cold modified artificial cerebrospinal fluid 
(aCSF) where NaCl was equiosmotically substituted with sucrose to improve neuronal 
viability. Coronal slices of around 500 µm thickness containing the LC were cut by an 
oscillating vibratome (FHC Inc., Brunswick, USA) and then allowed to recover from the 
slicing for 90 min in oxygenated aCSF. Next, slices were placed on a nylon mesh and 
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maintained at 33 ± 0.5 ºC in a modified Haas-type interface chamber continuously 
perfused with oxygenated aCSF (95% O2/5% CO2, pH 7.34-7.38) at a flow rate of 1-1.5 
ml/min. The aCSF contained (in mM): NaCl 130, KCl 3, NaH2PO4 1.25, D-glucose 10, 
NaHCO3 21, CaCl2 2, and MgSO4 2. 
 
2.2.2. Recording procedures 
Extracellular recordings of single neurons were performed as previously described 
(Grandoso et al., 2004). The recording electrode consisted of an Omegadot glass 
micropipette (Sutter Instrument Co., Novato, CA, USA) that was pulled and ﬁlled with a 
solution of 50 mM NaCl (tip size of 2-5 μm, 3–5 MΩ). The microelectrode was placed in 
the LC, which was visually identified in the rostral pons as a dark oval area on the lateral 
borders of the central gray and the 4th ventricle, just anterior to the genu of the facial 
nerve (–9.48 to –9.96 mm from Bregma; Paxinos and Watson, 2005: figures 112–116). 
The extracellular signal recorded by the microelectrode was passed through a high-input 
impedance amplifier system (Axoclamp 2A, Axon Instruments, Foster City, CA) and 
monitored on an oscilloscope and by an audioanalyzer (Cibertec S.A., Madrid, Spain). 
Individual (single-unit) neuronal spikes were isolated from the background noise with a 
window discriminator and counted. The firing rate was represented and analyzed by a PC-
based custom-made program (HFCP®; Cibertec S.A. Madrid, Spain), which generated 
histogram bars representing the cumulative number of spikes in consecutive 10 s bins. 
Noradrenergic neurons in the LC were identified by the following electrophysiological 
criteria: a spontaneous and regular discharge, a slow firing rate and a positive-negative 
biphasic waveform of 3–4 ms duration (Andrade and Aghajanian, 1984). We only 
recorded cells that showed stable firing rates between 0.4 and 1.5 Hz for at least 3–5 min 
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and strong inhibitory effects induced by ME (0.8 µM, 1 min) (higher than 80%). Only 
one neuron was recorded per slice and only one slice was obtained from each animal. 
 
2.3 Pharmacological procedures 
Acute MOR desensitization in LC neurons was studied by testing the inhibitory 
effect of ME (0.8 µM; 1 min) before (basal effect) and 5 min after perfusion with a high, 
desensitizing concentration of ME (3 or 10 µM, 10 min) (Santamarta et al., 2014). ME 
was selected on the basis of its good efficacy in inhibiting the firing of LC neurons almost 
exclusively through MOR (Williams and North, 1984), and because it rapidly washes out 
from the tissue after its perfusion (Santamarta et al., 2014). ME concentrations were 
chosen on the basis of previous studies (Harris and Williams, 1991; Santamarta et al., 
2014; Torrecilla et al., 2001).  
To characterize the involvement of the NO-dependent sGC/PKG and ROS pathways 
in ME-induced desensitization, the following drugs were perfused for at least 20-30 min 
before inducing the desensitization with ME (3 or 10 µM) and, then, during the whole 
experiment: BAY 418543 (1 μM) and A 350619 (30 μM) (sGC activators), NS 2028 (10 
or 30 μM) and ODQ (10 or 30 μM) (sGC inhibitors), 8-Br-cGMP (100 or 300 μM) (PKG 
activator), Rp-8-Br-PET-cGMP (1 μM) and H8 (30 or 100 μM) (PKG inhibitors), or 
Trolox (200 µM), melatonin (100 µM) and U-74389G (10 µM) (antioxidants). In some 
assays, the NO donor DEA/NO (100 µM) or the nNOS inhibitor 7-NI (100 μM) were 
perfused to induce enhancement or blockade, respectively, of ME-induced desensitization 
and thereby to explore their interaction with drugs targeting sGC/PKG pathway. Finally, 
in one series of experiments, Trolox (200 µM) was administered together with NS 2028 
(10 μM) to further evaluate the involvement of both sGC/PKG and ROS pathways in 
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MOR desensitization. The desensitization induced by ME (3 µM) was used to investigate 
the effect of sGC/PKG activators, since we have previously demonstrated that this 
protocol of desensitization (by ME 3 µM) can be readily enhanced by NO donors 
(Llorente et al., 2012). Moreover, the desensitization induced by a higher concentration of 
ME (10 µM) was tested to explore the effect of sGC/PKG inhibitors or antioxidants, 
because this paradigm of desensitization (by ME 10 µM) has been shown to be sensitive 
to NOS inhibitors (Santamarta et al., 2014; Torrecilla et al., 2001). 
 
2.4 Drugs and Reagents 
8-Bromoguanosine 3′,5′-cyclic monophosphate (8-Br-cGMP), chloral hydrate, 
diethylamine NONOate (DEA/NO), N-(2-[methylamino]ethyl)-5-isoquinoline-
sulfonamide (H8), 7-nitroindazole (7-NI), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one 
(ODQ) and Rp-β-Phenyl-1,N2-etheno-8-bromoguanosine 3′,5′-cyclic 
monophosphorothioate (Rp-8-Br-PET-cGMP) were obtained from Sigma-Aldrich 
Química S.A. (Madrid, Spain). 8-Bromo-1H,4H-[1,2,4]oxadiazolo[3,4-
c][1,4]benzoxazin-1-one (NS 2028) and 3-[2-[(4-chlorophenyl)thiophenyl]-N-[4-
(dimethylamino)butyl]-2-propenamide hydrochloride (A 350619) were purchased from 
Tocris Bioscience (Bristol, UK). Met5-enkephalin (ME) was obtained from Bachem (Weil 
am Rhein, Germany) and 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-
5-(4-morpholinyl)-4,6 pyrimidinediamine (BAY 418543), from Biotrend Chemikalien 
GMBH (Köln, Germany). 21-[4-(2,6-Di-1-pyrrolidinyl-4-pyrrimidinyl)-1-piperazinyl]-
pregna-1,4,9(11)-triene-3,20-dione(Z)-2-butenedioate (U-74389G), melatonin and Trolox 
were purchased from Enzo Life Sciences Inc. (New York, USA). All other chemicals 
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were obtained from standard sources and were of the highest purity commercially 
available. 
Drugs were dissolved in the final volume of aCSF just before each assay, to ensure 
full potency, and applied by turning a three-way valve that switched from aCSF to the test 
solution. DEA/NO was first dissolved in NaOH (25 mM; pH = 12) to prevent the 
spontaneous release of NO and then it was neutralized with HCl 1M and diluted in aCSF 
to its final concentration just before the assay. 8-Br-cGMP, 7-NI and Trolox were directly 
dissolved in aCSF on the day of the experiment. 7-NI required prolonged sonication to 
facilitate homogeneity. The rest of the drugs were prepared as stock solutions in milliQ 
water (ME, A 350619, H8, Rp-8-Br-PET-cGMP), ethanol (melatonin) or DMSO (NS 
2028, U-74389G, BAY 418543, ODQ), stored at -25 ºC and, on the day of the 
experiment, diluted in aCSF to their final volume. The maximal final concentration of 
DMSO or ethanol was 0.1%, which fails to significantly affect the firing rate of LC 
neurons (Wang and Aghajanian, 1987). Drugs were administered for enough time (10–30 
min) to reach a steady-state response and maintained during the whole experiment.  
 
2.5. Data analysis and statistics 
Values are expressed as the mean ± standard error of the mean (S.E.M) of n (number) 
experiments. The firing rate of LC cells was recorded before (baseline), during and after 
drug applications and throughout the experiment. The inhibitory effect of ME (0.8 µM, 1 
min) was calculated as follows: E = [(FRbasal - FRpost) · 100] / FRbasal, where FRbasal is the 
mean firing rate for a 60 s period immediately before ME (0.8 µM, 1 min) application and 
FRpost is the average firing rate for a 90 s period after onset of ME (0.8 µM, 1 min) 
perfusion. The degree of ME (3 or 10 μM)-induced opioid desensitization was calculated 
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as follows: desensitization percentage = 100 · [ 1 - (Epost)/Ebasal)], where Ebasal and Epost 
are the inhibitory effects of the test agonist (ME 0.8 µM, 1 min) before (basal) and 5 min 
after (post) the perfusion with the desensitizing concentrations of ME (3 or 10 μM). This 
value indicates the reduction in the inhibitory effect of the opioid agonist after perfusion 
with a high agonist concentration as compared with its basal effect.  
To validate statistically the development of desensitization, the test effects of ME 
before and after the high concentration of ME were compared by a paired Student’s t test. 
In addition, to evaluate the differences in the degree of ME-induced desensitization 
between groups, we compared the desensitization percentage values in the absence 
(control) or the presence of the drug by a two-sample Student’s t test. Possible changes 
induced by drugs in the basal firing rates or the acute effects of ME (0.8 µM) were 
evaluated by a paired Student’s t test when compared within the same cell or by a two-
sample Student’s t test when compared between different cells. The level of significance 
was considered as p = 0.05. 
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3. Results 
3.1. Involvement of soluble guanylate cyclase in opioid-induced MOR desensitization in 
the locus coeruleus 
We have previously reported that NO donors enhance ME (3 µM)-induced MOR 
desensitization (Llorente et al., 2012). It is well known that NO targets the heme group of 
the sGC to elevate cGMP concentrations (Ignarro et al., 1991). To study the involvement 
of sGC in NO-induced regulation of MOR desensitization, we tested the effect of 
DEA/NO, a nucleophile complex that spontaneously releases NO in aqueous solution, in 
the absence and the presence of the sGC inhibitor NS 2028. Perfusion with ME (3 M, 10 
min) desensitized by 30 ± 6% the inhibitory effect of ME (0.8 M) (n = 5, P < 0.05), 
whereas DEA/NO (100 µM) enhanced by 65 ± 18% the degree of ME (3 µM)-induced 
desensitization (n = 5, p < 0.05 vs control) (Figs. 1A, 1B and 1D). The firing rate of LC 
cells was elevated by 101 ± 14% (n = 5, p < 0.05) during DEA/NO (100 µM) perfusion 
(see baselines in Fig 1A and 1B), which is in agreement with previous studies showing a 
neuronal activation by various NO donors (Llorente et al., 2012; Pineda et al., 1996; 
Torrecilla et al., 2007). More importantly, administration of NS 2028 (10 µM) fully 
prevented both DEA/NO (100 µM)-induced enhancement of MOR desensitization (ME 3 
M) (n = 5, p < 0.05 DEA/NO + NS 2028 vs DEA/NO) (Figs. 1C and 1D) and DEA/NO 
(100 µM)-evoked activation of LC neurons (firing rate change by DEA/NO, after NS 
2028: -9 ± 5%, n = 5, p < 0.005 vs control, see above). NS 2028 (10 µM) itself did not 
modify MOR desensitization (n = 3) (Fig. 1D). Finally, no changes were found in the 
acute effects of ME (0.8 µM) between the different groups (ME effect, control: 86 ± 3%, 
n = 5; NS 2028: 90 ± 2%, n = 3; DEA/NO: 87 ± 5%, n = 5; and DEA/NO + NS 2028: 92 
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± 2%, n = 5). These data suggest the contribution of sGC in the enhancement of MOR 
desensitization and hyperactivity of LC cells induced by NO.  
To further explore the involvement of sGC in MOR desensitization, we evaluated the 
direct effect of sGC activation on ME (3 and 10 µM)-induced desensitization. Perfusion 
with the sGC activators A 350619 (30 μM) and BAY 418543 (1 μM) enhanced by 93 ± 
15% and 90 ± 6%, respectively, the ME (3 µM)-induced MOR desensitization (n = 5, p < 
0.01 vs control; and n = 5, p < 0.005 vs control; respectively) (Figs. 2A, 2B and 2C). 
BAY 418543 (1 μM) elevated by 51 ± 16% the firing activity of LC neurons (n = 5, p < 
0.05). There was no change in the acute effects of ME (0.8 µM) between the different 
groups (ME effect, A 350619: 88 ± 3%, n = 5; BAY 418543: 94 ± 2%, n = 5). On the 
other hand, perfusion with a higher concentration of ME (10 M, 10 min) reduced by 61 
± 3% the inhibitory effect of ME (0.8 M) (n = 8, p < 0.005), which was a significantly 
stronger desensitization (p < 0.005) than that induced by ME (3 M) (see above; Figs. 3A 
and 3C). Unexpectedly, administration of two different concentrations of the sGC 
inhibitors NS 2028 (10 and 30 μM) and ODQ (10 and 30 μM) failed to modify the degree 
of ME (10 µM)-induced MOR desensitization, so that opioid effects were still 
desensitized in the presence of these inhibitors (NS 2028 10 and 30 μM: n = 6, p < 0.005 
and n = 3, p < 0.005, respectively; ODQ 10 and 30 μM: n = 5, p < 0.005 and n = 6, p < 
0.005, respectively) (Figs. 3B and 3C). 
 
3.2. Involvement of cyclic GMP-dependent protein kinase in opioid-induced MOR 
desensitization in the locus coeruleus 
We have previously postulated that endogenous NO may mediate MOR 
desensitization and tolerance in the LC (Santamarta et al., 2005; 2014). To investigate the 
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contribution of cGMP/PKG pathway to NO-mediated MOR desensitization, we explored 
the effect of a soluble cGMP analogous that activates the PKG (8-Br-cGMP). Herein, 
administration of the neuronal NOS inhibitor 7-NI (100 µM) reduced by 60 ± 8% the 
degree of ME (10 µM)-induced desensitization in LC neurons (n = 4, p < 0.005 vs control 
desensitization) (Fig. 4A and 4D, see above for control). Perfusion 8-Br-cGMP (100 and 
300 μM) fully prevented 7-NI from blocking MOR desensitization, so that ME (10 µM)-
induced desensitization in the presence of 8-Br-cGMP (100 or 300 μM) + 7-NI (100 µM) 
was significantly greater than in the presence of 7-NI (100 µM) alone (n = 3, p < 0.05; 
and n = 5, p < 0.01, respectively) (Figs. 4B and 4D). Therefore, cGMP-dependent events 
(i.e., PKG) may take part in NO-mediated MOR desensitization. Unexpectedly, 
administration of the PKG inhibitors H8 (30 and 100 μM) or Rp-8-Br-PET-cGMP (1 μM) 
failed to modify the degree of ME (10 µM)-induced desensitization (Fig. 4C and 4D) and, 
thereby, ME (10 µM) caused standard desensitization in the presence of H8 (30 and 100 
µM) or Rp-8-Br-PET-cGMP (1 μM) (n = 5, p < 0.005; n = 3, p < 0.05; and n = 4, p < 
0.005, respectively) (Fig. 4D).  
 
3.3. Involvement of reactive oxygen species in opioid-induced MOR desensitization in the 
locus coeruleus 
NO reacts with oxygen derivatives to produce reactive nitrogen and oxygen species 
(ROS) (Davis et al., 2001), which have been shown to contribute to NO-induced 
enhancement of MOR desensitization in the LC (Llorente et al., 2012). We further 
explored whether ROS would itself mediate ME (10 µM)-induced desensitization by 
administration of three structurally unrelated antioxidants. Thus, perfusion of the 
antioxidants U-74389G (10 µM), melatonin (100 µM) or Trolox (200 µM) failed to 
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modify the degree of ME (10 µM)-induced desensitization (n = 4 in each group) when 
compared with the corresponding control group (Figs. 5A and 5C). However, combined 
perfusion of the antioxidant Trolox (200 µM) and the sGC inhibitor NS 2028 (10 μM) 
reduced by 37 ± 6% the magnitude of ME (10 µM)-induced desensitization (n = 5, p < 
0.005 vs control) (Figs. 5B and 5C). This combination (Trolox 200 µM + NS 2028 10 
μM) slightly decreased the firing activity of LC neurons (firing rate reduction: 22 ± 4%, n 
= 5, p < 0.005), although the basal firing rate after perfusion with Trolox + NS 2028 was 
not significantly different from control (basal firing rate before desensitization, control: 
0.72 ± 0.09 Hz, n = 8; Trolox + NS 2028: 0.67 ± 0.13 Hz, n = 5). Finally, no changes in 
the acute ME (0.8 µM) effects were found between the groups (ME effect, control: 93 ± 
1%, n = 8; Trolox + NS 2028: 91 ± 3%, n = 5). This indicates that activation of either of 
the NO-dependent ROS and sGC/PKG signaling cascades may be enough for induction of 
MOR desensitization and, therefore, both pathways may be independently triggered by 
NO to mediate this process. 
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4. Discussion 
Previous electrophysiological experiments have shown that NO regulates MOR 
desensitization in the LC (Llorente et al., 2012; Santamarta et al., 2014; Torrecilla et al., 
2001). We have used single-unit extracellular recording techniques in brain slices to 
characterize the NO-dependent pathways (i.e., sGC and ROS) involved in MOR 
desensitization in the LC in vitro. Our results confirm that ME (3–10 μM) causes a 
concentration-related desensitization of MOR in the LC, so that the inhibitory effect of 
ME (0.8 μM) was markedly reduced. ME (3 μM)-induced MOR desensitization was 
enhanced by perfusion with the NO donor DEA/NO, whereas this enhancement was 
blocked by the sGC inhibitor NS 2028. Accordingly, ME (3 μM)-induced MOR 
desensitization was enhanced by two activators of sGC, A 350619 and BAY 418543. On 
the other hand, ME (10 μM)-induced MOR desensitization was blocked by the nNOS 
inhibitor 7-NI, a blockade that was prevented by the PKG activator 8-Br-cGMP. In 
contrast, ME (10 μM)-induced desensitization was not modified by inhibition of sGC 
(with NS 2028 and ODQ) or PKG (with H8 and Rp-8-Br-PET-cGMP). Perfusion with the 
antioxidants Trolox, melatonin or U-74389G failed to change ME (10 μM)-induced 
desensitization, but a combination of an antioxidant (Trolox) with a sGC inhibitor (NS 
2028) was able to attenuate ME (10 μM)-induced desensitization.  
To study MOR desensitization in the LC, we measured the inhibitory effect of a test 
concentration of the opioid agonist ME (0.8 μM). ME was used as an indicator of MOR 
function, because it exerts a full inhibition of the firing activity of LC neurons almost 
exclusively through MOR (McPherson et al., 2010; Williams and North, 1984). 
Moreover, ME effect can be tested several times in the same cell, since it rapidly washes 
out from the tissue after bath perfusion. Therefore, MOR desensitization can be readily 
measured by extracellular recordings after recovery of the firing from ME-induced 
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inhibition. Our results confirm that sustained application of ME (3 and 10 μM) causes 
MOR desensitization in the LC, expressed as a concentration-related decline in the test 
ME effect (30% and 61%, respectively). This protocol including variable desensitization 
degrees (i.e., by ME 3 and 10 μM) allowed us to investigate possible regulation of this 
phenomenon by activators or inhibitors of sGC pathway. Similar degrees of MOR 
desensitization by ME (3 and 10 µM) have been described by both intracellular electrodes 
measuring ion currents (Harris and Williams, 1991) and extracellular electrodes recording 
cell firing rates (Llorente et al., 2012; Santamarta et al., 2014). The firing activity 
recorded by extracellular techniques may be considered as a closer physiological end-
point of MOR desensitization at the synaptic level of the neuron.  
ME (3 μM)-induced MOR desensitization was enhanced by 65% in the presence of 
the NO donor DEA/NO. Likewise, previous electrophysiological experiments in vitro 
have shown that the NO donor sodium nitroprusside also enhances MOR desensitization 
in the LC (Llorente et al., 2012). The main direct target of NO is the sGC, which 
catalyzes the production of cGMP from GTP (Hoffmann and Chen, 2014; Kots et al., 
2009). The LC has been reported to express the α1 and ß1 subunits of the sGC (Furuyama 
et al., 1993; Matsuoka et al., 1992; Pifarré et al., 2007) and, accordingly, detectable 
concentrations of cGMP are measured in the LC (Vulliemoz et al., 1999; Xu et al., 
1998a). Herein, ME (3 µM)-induced MOR desensitization in LC neurons was enhanced 
by ~90% after perfusion with two structurally unrelated sGC activators, A 350619 or 
BAY 418543. Both activators enhance the catalytic function of sGC in an NO-
independent manner, although they can also act synergically with NO (Mayer and 
Koesling, 2001; Stasch et al. 2002). BAY 418543 lacks any effect on phosphodiesterase 
activity (Stasch et al., 2002). Accordingly, we found that DEA/NO-induced enhancement 
of MOR desensitization was prevented by NS 2028, an irreversible inhibitor of NO-
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dependent sGC activation in homogenates and slice preparations of the brain (Olesen et 
al., 1998). A high concentration of NO in the LC as that reached during DEA/NO 
administration could be obtained when nNOS expression is elevated in this nucleus, as 
described by chronic morphine treatments (Cuéllar et al., 2000). None of the drugs 
targeting the NO/sGC pathway in the present work (DEA/NO, NS 2028, A 350619 or 
BAY 418543) altered the acute effects of ME (0.8 μM) (before desensitization). 
Therefore, our data indicate that activation of sGC signaling can enhance MOR 
desensitization and also mediate the enhancement of MOR desensitization induced by 
raising the NO concentration in the LC. Other authors have reported in vivo that treatment 
with sGC activators enhances the development and expression of analgesic tolerance to 
morphine (Ozdemir et al., 2011) and administration of sGC inhibitors prevents the 
development of analgesic tolerance to morphine (Durmus et al., 2014; Xu et al., 1998b).  
As discussed above, perfusion with high concentrations of ME (10 μM) induce a 
near-maximal degree of MOR desensitization in the absence of NO enhancers (“high 
MOR desensitization”) (Harris and Williams, 1991; Santamarta et al., 2014). We herein 
found that the neuronal-selective NOS inhibitor 7-NI reduced by more than 50% the 
magnitude of high MOR desensitization. Previous in vitro reports have described that 
lowering the endogenous production of NO by different neuronal-selective NOS 
inhibitors also attenuates the development of high MOR desensitization in the LC 
(Santamarta et al., 2014; Torrecilla et al., 2001). Likewise, inhibition of nNOS in vivo has 
been described to reduce the induction of morphine tolerance (Highfield and Grant, 1998; 
Santamarta et al., 2005) and morphine withdrawal (Pineda et al., 1998) in the LC. A high 
amount of type II PKG mRNA, one of the main cGMP targets (Kots et al., 2009), has 
been detected in the LC (El-Husseini et al., 1995). In the present study, we observed that 
high MOR desensitization was restored from 7-NI-induced blockade by addition of 8-Br-
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cGMP, a cell permeable cGMP analog with high potency for type II PKG activation 
(Pöhler et al., 1995). This suggests that downstream regulation of cGMP/PKG pathway 
by NO may account for the effect of nNOS inhibitors on high MOR desensitization in the 
LC. Interestingly, sGC activity and type II PKG expression are up-regulated by morphine 
treatments in mice (Liang and Clarck, 2004; Muraki et al., 1982) and, therefore, the 
contribution of cGMP to MOR desensitization mediated by endogenous NO could be 
functionally relevant in vivo. Paradoxically, we did not detect any change in the extent of 
high MOR desensitization after independent administrations of high concentrations of 
sGC inhibitors (NS 2028 10–30 μM or ODQ 10–30 μM) or PKG inhibitors (H8 30-100 
μM or Rp-8-Br-PET-cGMP 1 μM). These drugs have been previously used as effective 
inhibitors of cGMP/PKG signaling. Thus, ODQ is a NS 2028 analog that inhibits brain 
sGC activity in vitro with lower potency than NS 2028 (Garthwaite et al., 1995; Olesen et 
al., 1998). H8 and Rp-8-Br-PET-cGMP are two cell-permeable, potent inhibitors of PKG 
that show 3- and 300-fold higher selectivities for PKG, respectively, than for PKA 
(Hidaka et al., 1984; Smolenski et al., 1998). H8 has been shown to antagonize the 
electrophysiological effects of cGMP but not cAMP on LC neurons (Pineda et al., 1996). 
Similarly, intracerebroventricular administration of the PKG inhibitor KT-5823 fails to 
alter morphine tolerance in vivo (Bernstein and Welch, 1997).  
On the other hand, ROS have been reported to regulate MOR desensitization in the 
LC (Llorente et al., 2012). We found no change in the degree of high MOR 
desensitization (ME 10 μM) after separate administrations of antioxidant agents (U-
74389G, melatonin or Trolox). U-74389G and melatonin are two lipid-soluble 
antioxidants that protect against the effects induced by ROS (Khalil et al., 1998; Noda et 
al., 1999; Taherzadeh et al., 2006), whereas Trolox is a cell-permeable vitamin E 
derivative that prevents oxidative stress in rat models (Balogh et al., 2005). In contrast, 
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combined administrations of a sGC inhibitor (NS 2028) and an antioxidant agent (Trolox) 
significantly attenuated the development of high MOR desensitization, whereas they did 
not affect the acute effect of ME. Therefore, these results (together with 8-Br-cGMP data, 
see above) indicate that endogenous production of NO from nNOS purportedly caused by 
high ME concentrations would induce MOR desensitization by independent activation of 
sGC/PKG and ROS signaling pathways. Either of these cascades would be enough by 
itself to trigger the induction of high MOR desensitization by endogenous NO, so that 
both pathways should be simultaneously blocked to observe a reduced desensitization. 
The mechanism by which NO is generated and the exact NO-dependent events regulated 
by sGC/PKG and ROS remain as yet to be elucidated. Thus, NO-dependent activation of 
PKG has been speculated to mediate MOR desensitization by phosphorylating a substrate 
that affects MOR/G protein interaction or by counteracting the opioid effect on 
nonselective cation channels (Santamarta et al., 2014). Furthermore, several oxidative 
mechanisms have been proposed to regulate MOR desensitization, including possible 
ROS-induced activation of PKC (Llorente et al., 2012).  
It has been reported that NO modulates the firing activity of LC neurons by 
activation of sGC, the subsequent increase of cGMP levels and stimulation of PKG 
(Pineda et al., 1996; Xu et al., 1998a). Our work demonstrates that DEA/NO elevates by 
about 100% the firing rate of LC neurons and this excitatory effect is prevented by 
administration of the sGC inhibitor NS 2028. Furthermore, a 51% elevation of the 
spontaneous firing rate of LC cells was obtained after sGC stimulation with BAY 418543 
and a slight reduction of the firing activity was observed after a combined perfusion with 
a sGC inhibitor (NS 2028) and an antioxidant (Trolox). Therefore, data obtained from the 
present work are compatible with an excitatory regulation of the firing activity of LC 
neurons by NO through the sGC/PKG pathway.  
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Morphine dependence and withdrawal are associated with neuroadaptive changes in 
the neuronal NOS activity (Vaupel et al., 1997). During conditions in which nNOS 
expression is raised (such as during morphine dependence), NO concentrations would be 
expected to be higher (Cuéllar et al., 2000). Our results demonstrate that submaximal 
MOR desensitization induced by an intermediate concentration of ME (3 μM) can be 
enhanced by raising the concentrations of NO and by activating the sGC in the LC. NO-
induced enhancement appears to be blocked by a sGC inhibitor. Our previous work has 
shown that antioxidant agents attenuate the enhancement of MOR desensitization induced 
by high concentrations of NO in the LC (Llorente et al., 2012). Removal of ROS also 
prevents the appearance of analgesic tolerance caused by opioids (Muscoli et al., 2007). 
Therefore, these data indicate that a combined activation of both signaling cascades, 
cGMP and ROS, may be needed to enhance MOR desensitization by high NO levels in 
this nucleus, so that inhibition of either of these pathways would disrupt the enhancement 
induced by NO. On the other hand, strong MOR desensitization obtained by high ME 
concentrations (10 μM) can be blocked by nNOS inhibition or by a combination of an 
antioxidant and a sGC inhibitor. MOR desensitization is restored from nNOS inhibition 
by activation of PKG. Therefore, we conclude that endogenous NO derived from nNOS 
activity may mediate the development of strong MOR desensitization through 
downstream regulation of independent sGC/PKG and ROS pathways in the LC. 
Hypothetically, a pharmacological protection against NO-derived cGMP and ROS 
generation would result in prevention of opiate tolerance and maintaining a better control 
of pain with chronic opiates.  
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Figure legends  
Figure 1. Effect of DEA/NO and DEA/NO + NS 2028 on ME (3 M, 10 min)-induced 
MOR desensitization. A, B, C. Representative examples of firing-rate recordings of LC 
cells showing the effect of ME (0.8 µM, 1 min) before and 5 min after application of ME 
(3 M, 10 min) in control slices (A), in slices perfused with DEA/NO (100 µM (B) or 
DEA/NO (100 µM) + NS 2028 (10 µM) (C). The horizontal bars indicate the period of 
drug applications and the vertical lines show the number of spikes recorded every 10 s. D. 
Bar histograms show the mean ± S.E.M of ME (3 M, 10 min)-induced desensitization in 
the absence (n = 5) or the presence of NS 2028 (10 μM, n = 3), DEA/NO (100 μM, n = 5) 
or NS 2028 (10 μM) + DEA/NO (100 μM) (n = 5). Desensitization degrees were 
calculated as percentage values (see Data analysis and statistics). Note that DEA/NO 
markedly enhanced MOR desensitization and NS 2028 fully prevented the enhancement 
of MOR desensitization induced by DEA/NO. *p < 0.05 when compared with the control 
group (two-sample Student’s t test), and † p < 0.05 when compared with the DEA/NO 
group (two-sample Student’s t test). 
 
Figure 2. Effect of A 350619 and BAY 418543 on ME (3 M, 10 min)-induced 
desensitization. A, B. Representative examples of firing-rate recordings of LC cells 
showing the effect of ME (0.8 µM, 1 min) before and 5 min after application of ME (3 
M, 10 min) in slices perfused with A 350619 (30 µM) (A) or BAY 418543 (1 µM) (B). 
The horizontal bars indicate the period of drug applications and the vertical lines show the 
number of spikes recorded every 10 s. C. Bar histograms show the mean ± S.E.M of ME 
(3 M, 10 min)-induced desensitization in the presence of A 350619 (30 μM, n = 5) or 
BAY 418543 (1 μM, n = 5). Desensitization degrees were calculated as percentage values 
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(see Data analysis and statistics). Note that A 350619 and BAY 418543 markedly 
enhanced MOR desensitization. *p < 0.01 and **p < 0.005 when compared with the 
control group (two-sample Student’s t test).  
 
Figure 3. Effect of NS 2028 and ODQ on ME (10 M, 10 min)-induced desensitization. 
A, B. Representative examples of firing-rate recordings of LC cell showing the inhibitory 
effect of ME (0.8 M, 1 min) before (basal) and 5 min after application of ME (10 M, 
10 min) in control slices (A) and in slices perfused with NS 2028 (10 M) (B). The 
horizontal bars indicate the period of drug applications and the vertical lines show the 
number of spikes recorded every 10 s. C. Bar histograms show the mean ± S.E.M of ME 
(10 M, 10 min)-induced desensitization in the absence (n = 8, control) or the presence of 
ODQ (10 M, n = 5 and 30 M, n = 6) or NS 2028 (10 M, n = 6 and 30 M, n = 3). 
Desensitization degrees were calculated as percentage values (see Data analysis and 
statistics).  Note that ME-induced desensitization was not changed in the presence of 
NS 2028 or ODQ.  
 
Figure 4. Effect of 7-NI, 8-Br-cGMP + 7-NI, H8 and Rp-8-Br-PET-cGMP on ME (10 
M, 10 min)-induced desensitization of LC neurons in vitro. A, B, C Representative 
examples of firing-rate recordings of LC cells showing the effect of ME (0.8 µM, 1 min) 
before and 5 min after application of ME (10 M, 10 min) in slices perfused with 7-NI 
(100 M) (A) 8-Br-cGMP (300 M) + 7-NI (100 M) (B) or H8 (100 M) (C). The 
horizontal bars indicate the period of drug applications and the vertical lines show the 
number of spikes recorded every 10 s. D. Bar histograms show the mean ± S.E.M of ME 
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(10 M)-induced desensitization in the absence (n = 8, control) or the presence of 7-NI 
(100 M, n = 4), 8-Br-cGMP (100 M and 300 M) + 7-NI (100 M) (n = 3 and n = 5, 
respectively), H8 (30 M, n = 5 and 100 M, n = 3) or Rp-8-Br-PET-cGMP (1 M, n = 
4). Desensitization degrees were calculated as percentage values (see Data analysis and 
statistics).  Note that 7-NI attenuated MOR desensitization and that both 
concentrations of 8-Br-cGMP (100 M or 300 M) restored the desensitization. *p < 
0.005 compared with the control group (two-sample Student’s t test), and †p < 0.05, ††p 
< 0.01 compared with the 7-NI group (two-sample Student’s t test). 
 
Figure 5. Effect of Trolox, Trolox + NS 2028, U-74389G and melatonin on ME (10 M, 
10 min)-induced desensitization. A, B. Representative examples of firing-rate recordings 
of LC cells showing the effect of ME (0.8 µM, 1 min) before and 5 min after application 
of ME (10 M, 10 min) in slices perfused with Trolox (200 M) (A) or Trolox (200 M) 
+ NS 2028 (10 M) (B). Drugs were bath applied for the time indicated by the horizontal 
bars. Vertical lines represent the number of spikes recorded every 10 s. C. Bar histograms 
show the mean ± S.E.M of ME (10 M)-induced desensitization in the absence (n = 8, 
control) or the presence of U-74389G (10 μM, n = 4), melatonin (100 μM, n = 4), Trolox 
(200 μM, n = 4) or Trolox (200 μM) + NS 2028 (10 μM) (n = 5). Desensitization degrees 
were calculated as percentage values (see Data analysis and statistics).  Note that in the 
presence of Trolox + NS 2028 MOR desensitization was markedly attenuated. *p < 0.005 
compared with the control group (two-sample Student’s t test).  
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Highlights 
 
- The involvement of sGC/PKG and ROS in MOR desensitization was explored by extracellular 
recordings in the rat LC. 
- MOR desensitization was enhanced by a NO donor and sGC activators. NO effect was blocked 
by a sGC inhibitor. 
- MOR desensitization was blocked by a nNOS inhibitor and also a combination of an 
antioxidant and a sGC inhibitor. A PKG activator restored MOR desensitization. 
- NO derived from nNOS would mediate MOR desensitization through independent regulation 
of PKG and ROS pathways in the LC. 
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FIGURE 5 
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Abstract  
BACKGROUND AND PURPOSE  
The ability of morphine to induce rapid MOR desensitization in native LC neurons has 
been questioned. The signaling messenger nitric oxide (NO) is a key mediator in the 
mechanisms underlying acute and chronic regulation of MOR. The aim of this study was 
to examine the involvement of neuronal nitric oxide synthase (nNOS) in morphine-
induced acute desensitization of MOR in LC neurons in vitro. 
EXPERIMENTAL APPROACH  
We studied by single-unit extracellular recordings the effect of nNOS inhibition on acute 
desensitization of MOR induced by morphine or ME in KCl-excited neurons from rat 
brain slices. To characterize desensitization, the reduction in the inhibition of a test 
concentration of [Met]5enkephalin (ME; 0.8 or 25.6 μM, 1 min) was measured before and 
after or during the application of a saturating concentration of the opioid agonist. 
KEY RESULTS  
Morphine (30 μM) induces significant desensitization of MOR in the LC, so that the 
inhibitory effect of a supramaximal test concentration of ME (25.6 μM, applied before 
and after or during the opioid perfusion) was markedly reduced. As expected, ME (10 
μM, 10 min) desensitized the inhibitory effect of a test application of ME (0.8 or 25.6 
μM, 1 min). Conversely, the inhibitory effect promoted by gamma-aminobutyric acid 
(GABA; 1 mM) was unaltered after either ME or morphine perfusion. A combination of 
the nNOS inhibitors 7-nitroindazole (7-NI, 100 μM) and S-methyl-L-thiocitrulline 
(SMTC, 10 μM) failed to affect the desensitization promoted by morphine, but attenuated 
ME (10 μM)-induced desensitization of MOR.  
CONCLUSIONS AND IMPLICATIONS  
These results demonstrate the ability of morphine to induce MOR desensitization in vitro 
and highlight the agonist-selective acute regulation of MOR desensitization by neuronal 
NOS.  
Abbreviations.  
aCSF, artificial CSF; CNQX, 6-cyano-7-notroquinoxaline-2, 3-dione; D-AP5, D-(–)-2-
amin-5-phosponopentanoic acid; GABA, gamma-aminobutyric acid; LC, locus coeruleus; 
ME, [Met]5enkephalin; MOR, µ-opioid receptor; 7-NI, 7-nitroindazole; nNOS, neuronal 
nitric oxide synthase; NMDA, N-methyl-D-aspartate; NO, nitric oxide; PKC, protein 
kinase C; ROS, reactive oxygen species; SMTC, S-methyl-L-thiocitrulline. 
   
3 
Introduction  
Opioids are potent analgesics used for acute and chronic pain. The major problem 
with the use of opioids in the clinic is the rapid development of tolerance, which requires 
escalating doses to maintain the same therapeutic effect. Despite extensive research, the 
cellular mechanisms underlying opioid tolerance are not fully understood (Dang and 
Christie, 2012). There is good evidence that desensitization of µ-opioid receptors (MOR) 
is intimately related to the development of tolerance (Allouche et al., 2014). Molecular 
mechanisms involved in opioid receptor desensitization include receptor phosphorylation, 
G protein uncoupling and receptor internalization (Williams et al., 2013). In addition, the 
nitric oxide (NO) cascade has been proposed to be involved in opioid tolerance 
(Pasternak, 2007). NO production in the brain is catalyzed from L-arginine principally by 
the neuronal NO synthase (nNOS). NO interacts with several effectors, including 
guanylate cyclase to elevate cGMP concentrations or with oxygen or superoxide anion, 
which enhances reactive oxygen species (ROS) and reactive nitrogen species production. 
The locus coeruleus (LC), which provides the most extensive noradrenergic 
projections in the central nervous system, contains a high density of MOR. For that 
reason, it has long been used to explore the cellular mechanisms underlying acute and 
chronic effects of opioids (Nestler, 2001). Acutely, MOR agonists hyperpolarize LC 
neurons through Gi/o protein-coupled inwardly rectifying K
+ channels (GIRK) 
(Torrecilla et al., 2002). Short-term application of high concentrations of opioid agonists 
desensitizes MOR-mediated responses in the LC in vitro (Harris and Williams, 1991). 
Opioids differ in their ability to desensitize the MOR. Thus, the highly efficacious 
endogenous peptide agonist [Met]5enkephalin (ME) causes profound desensitization in 
LC neurons (Alvarez et al., 2002; Santamarta et al., 2014). In contrast, morphine has been 
described as a partial agonist that induces desensitization and endocytosis to a lesser 
degree in the brain slice (Alvarez et al., 2002; Bailey et al., 2004), although it efficiently 
induces tolerance in the LC after chronic administration in vivo (Santamarta et al., 2005). 
On the other hand, the NO pathway has been shown to regulate the functional activity of 
LC neurons (Pineda et al., 1996; Torrecilla et al., 2007). ROS have been reported to 
mediate some of the NO-mediated effects on MOR desensitization in the LC (Llorente et 
al., 2012). Furthermore, nNOS inhibitors have been found to attenuate ME-induced MOR 
desensitization in the LC in vitro (Santamarta et al., 2014) and reduce cellular tolerance in 
morphine-treated animals (Santamarta et al., 2005). However, there is no information 
regarding the implication of the NO system in morphine-induced acute desensitization. 
Therefore, the aim of this study was to evaluate by single-unit extracellular recordings in 
vitro, the involvement of the neuronal isoform of NOS in MOR desensitization induced 
by morphine.  
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Methods 
 
Animals and treatments 
Adult male Sprague–Dawley rats (200–300 g) were housed under standard laboratory 
conditions (22°C, 12:12 h light/dark cycles) with free access to food and water. All 
experimental procedures reported in this manuscript were carried out in accordance with 
UK Animals (Scientific Procedures) Act, 1986, and associated guidelines (86/609/EEC) 
and approved by the Animal Care and Use Committee of the University of the Basque 
Country. All efforts were made to minimize the suffering of the animals and to reduce the 
number of animals used. The animals for this study were obtained from the animal house 
of the University of the Basque Country (Leioa, Spain). All studies involving animals are 
reported in accordance with the ARRIVE guidelines for reporting experiments involving 
animals (Kilkenny et al., 2010; McGrath et al., 2010). 
 
In vitro electrophysiology: brain slice preparation and extracellular recordings 
Animals were anaesthetized with chloral hydrate (400 mg/kgi.p.) and sacrificed by 
decapitation. The brain was rapidly removed, and a block of tissue containing the 
brainstem was obtained. Coronal slices of 500–600 μm thickness including the LC were 
cut using a vibratome. The tissue was then allowed to recover from the slicing for 90 min 
in a modified Haas-type interface chamber continuously perfused with artificial 
cerebrospinal fluid (aCSF) at 33°C, saturated with a mixture of 95% O2 and 5% CO2 , at a 
flow rate of 1.5 mL·min−1 (final pH = 7.34). The aSCF contained (in mM): NaCl 130, 
KCl 3, NaH2PO4 1.25, D-glucose 10, NaHCO3 21, CaCl2 2, and MgSO4 2. Single-unit 
extracellular recordings of LC cells were performed as described (Pineda et al., 1996). 
The recording electrode, an Omegadot glass micropipette, was pulled and filled with 
NaCl (0.05 M). The tip was broken back to a size of 2–5 µm (3–5 MΩ). 
The electrode was positioned on the LC, which was identified visually in the rostral 
pons as a dark oval area on the lateral borders of the central grey and the fourth ventricle, 
just anterior to the genu of the facial nerve. The extracellular signal from the electrode 
was passed through a high-input impedance amplifier and monitored on an oscilloscope 
and an audio unit. Individual neuronal spikes were isolated from the background noise 
with a window discriminator. The firing rate was analysed by means of a PC-based 
custom-made software, which generated histogram bars representing the cumulative 
number of spikes in consecutive 10 s bins (HFCP®, Cibertec S.A., Madrid, Spain). 
Noradrenergic cells were identified by their spontaneous and regular discharge activity, 
the slow firing rate and the long-lasting, positive-negative waveform (Andrade et al., 
1983). 
  
Pharmacological procedures 
The desensitization model that we have previously used in spontaneously firing 
neurons (Llorente et al., 2012; Santamarta et al., 2014) was particularly suitable to study 
the desensitization induced by ME because it rapidly washes out from the preparation, so 
that the effect of a test concentration of ME (0.8 µM, 1 min) can be evaluated several 
times in the same neuron within few minutes. However, that protocol is not suitable to 
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evaluate morphine effects repeatedly in the same neuron, since it does not quickly wash 
out from slices (Levitt and Williams, 2012). For those reasons, we quantified the extent of 
receptor desensitization induced by morphine by evoking a positive DC shift in the 
resting potential of LC neurons with a KCl (14 mM) containing aCSF, so that the 
maximal effect of morphine could be monitored. In these assays, the osmolarity of KCl 
was compensated with a lower concentration of NaCl (119 mM). All the experiments 
were performed in the presence of 6-cyano-7-notroquinoxaline-2 (CNQX, a non- N-
methyl-D-aspartate (NMDA) glutamate receptor antagonist, 30 μM) and D-(–)-2-amin-5-
phosponopentanoic acid (D-AP5, a NMDA receptor antagonist, 100 μM) to avoid the 
interference of KCl-induced glutamate release on MOR desensitization. In each of the 
experiments, GABA (1 mM) was tested as an internal control before and after the 
desensitization with ME (10 μM, 10 min) or morphine (30 μM, 10 min). 
ME and morphine effects on KCl-excited LC neurons were characterized by 
performing concentration-effect curves for the inhibitory effects of ME (0.1-25.6 µM, 2x, 
1 min) and morphine (0.1-30 µM, 3x, 5 min) on the firing rate of LC neurons from rat 
brain slices. To characterize the acute desensitization of MOR induced by ME or 
morphine under these experimental conditions, two possible designs were used. First, we 
compared the inhibitory effect of a supramaximal concentration of ME (25.6 μM, 1 min) 
before and 3-5 min after inducing desensitization with ME (10 μM, 10 min) or morphine 
(30 μM, 10 min). Once the last test concentration of ME (25.6 μM, 1 min) was applied, 
naloxone (1 µM) was perfused to reverse the morphine-induced hyperpolarization and to 
return the firing rate to control conditions. The decrease in the ME (25.6 μM, 1 min) 
effect after ME (10 μM) or morphine (30 μM) was taken as a measure of the degree of 
desensitization (see figure 1). With the purpose of comparisons, in some experiments, we 
used ME (0.8 μM, 1 min) as a test concentration before and after inducing desensitization 
with ME (10 μM, 10 min). Second, we measured the maximal response to ME (25.6 µM) 
at two times during a prolonged application of ME (10 µM, 10 min) or morphine (30 µM, 
10 min): (1) 40-60 s after initiating the 10 min ME (10 µM) or morphine (30 µM) 
perfusion and (2) just after finishing it (see figure 2). Finally, naloxone (1 µM) was 
applied to reverse morphine-induced effects. The decrease in the ME (25.6 μM, 1 min) 
effect after ME (10 μM) or morphine (30 μM) was taken as a measure of the degree of 
desensitization. In all cases, the application of the supramaximal test concentration of ME 
(25.6 μM) was limited to 1 min and a washout period of approximately 10 min was set 
between applications in order to reduce the induction of desensitization by test ME 
applications alone. 
To evaluate the effect of nNOS inhibitors on ME- and morphine-induced acute 
desensitization of MOR under KCl-induced activation, SMTC (10 µM) was perfused 
together with 7-NI (100 µM) for 20 min before starting the experiment and during the 
entire desensitization assay with ME (10 μM, 10 min) or morphine (30 µM, 10 min). 
MOR desensitization in the presence of nNOS inhibitors was explored using the two 
experimental designs of MOR desensitization. 
 
Data analysis and statistics 
Values are expressed as the mean ± standard error of the mean (S.E.M) of n (number) 
experiments. The firing rate of LC cells was recorded before (baseline), during and after 
drug applications and throughout the experiment. The inhibitory effect of ME (0.8 or 25.6 
µM, 1 min) or GABA (1 mM, 1 min) was calculated as follows: E = [(FRbasal - FRpost) · 
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100] / FRbasal, where FRbasal is the mean firing rate for a 60 s period immediately before 
ME or GABA application and FRpost is the average firing rate for a 30 s period after onset 
of ME (0.8 or 25.6 µM, 1 min) or GABA (1 mM, 1 min) perfusion. The degree of ME (10 
μM)- or morphine (30 μM)-induced opioid desensitization was calculated as follows: 
desensitization percentage = 100 · [ 1 - (Epost)/Ebasal)], where Ebasal and Epost are the 
inhibitory effects of the agonist test concentrations (ME 0.8 or 25.6 µM; GABA 1 mM) 
when applied before (basal) and after (post) inducing desensitization with ME (10 μM) or 
morphine (30 μM); or the initial (basal) or final (post) inhibitory effects of (ME 25.6 µM) 
when applied during a continuous desensitizing concentration of ME (10 μM) or 
morphine (30 μM). This value indicates the reduction in the inhibitory effect of the opioid 
agonist after perfusion with a high agonist concentration (as compared with the basal 
effect).  
To validate statistically the development of desensitization, the effects of ME before 
and after inducing desensitization were compared by a paired Student’s t test. In addition, 
to evaluate the differences in the degree of ME- or morphine-induced desensitization 
between groups, we compared the desensitization percentage values in the absence 
(control) or in the presence of the drug by a two-sample Student’s t test. Possible changes 
induced by drugs in the basal firing rates or the acute effect of ME (0.8 or 25.6 µM) or 
GABA (1 mM, 1 min) were evaluated by a paired Student’s t test when compared within 
the same cell or by a two-sample Student’s t test when compared between different cells. 
The level of significance was considered as p = 0.05. 
 
Drugs and reagents 
ME was purchased from Bachem (Bodendorf, Germany). Morphine hydrochloride 
was purchased from Alcaliber (Madrid, Spain). 7-NI and SMTC were obtained from 
Sigma-Aldrich Quimica S.A. (Madrid, Spain). Chloral hydrate and GABA were obtained 
from Sigma-Aldrich Quimica S.A. (Madrid, Spain). D-(-)-2-Amino-5-
phosphonopentanoic acid (D-AP5) and 6-Cyano-7-nitroquinoxaline-2,3-dione disodium 
salt (CNQX) were purchased from Tocris (Bristol, UK). ME, SMTC, GABA, D-AP5 and 
CNQX were prepared as stock solutions in water, stored at –25 ºC and, on the day of the 
experiment, diluted in the final volume. 7-NI was directly dissolved in KCl (14 mM) 
containing aCSF and required prolonged sonication to facilitate homogeneity. All drugs 
were administered for enough time to reach a steady-state response and during the whole 
experiment. 
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Results  
 
Characterization of acute inhibitory effects of ME and morphine on KCl-excited LC 
neurons in vitro 
A sustained perfusion with KCl (14 mM) increased by 6 fold the firing rate of LC 
neurons (firing rate before KCl: 0.80 ± 0.04 Hz; after KCl: 4.29 ± 0.16 Hz, n = 52, p < 
0.005). In order to characterize the acute inhibitory effects of ME and morphine, 
increasing concentrations of ME (0.1-25.6 µM, 2x, 1 min) or morphine (0.1-30 µM, 3x, 5 
min) were perfused in the slice (Figs. 3A and B). No differences were found in the KCl-
excited basal firing rate between groups (basal firing rate, before ME: 3.08 ± 0.44 Hz, n = 
5; before morphine: 3.27 ± 0.56 Hz, n = 5). The pEC50 value for ME effect obtained by 
nonlinear analysis was 6.12 ± 0.02 (EC50 = 0.75 µM, n = 5), whereas the pEC50 for 
morphine effect was 6.41 ± 0.09 (EC50 = 0.39 µM, n = 5). The maximum inhibitory 
effects (Emax) induced by ME and morphine were 81 ± 8% and 55 ± 5% from the KCl-
excited basal firing rate, respectively (Figs. 3C and D). GABA promoted a 100% 
inhibition from baseline in all cases. These results suggest that ME has a higher efficacy 
at the MOR than morphine. 
 
Characterization of acute MOR desensitization induced by ME and morphine in LC 
neurons  
First, we evaluated the effect of short applications of two test concentrations of ME 
(0.8 μM or 25.6 μM, 1 min) before and after perfusing with a high, desensitizing 
concentration of ME (10 μM, 10 min) or morphine (30 μM, 10 min). ME (0.8 μΜ) is a 
concentration that is close to the EC50 in this KCl model and ME (25.6 μΜ) allows us to 
see changes in the maximum response. Thus, after finishing the ME (10 μM, 10 min) 
administration, the inhibitory effect of ME (0.8 μM) was desensitized by 55 ± 3% (n = 5, 
p < 0.005), whereas the effect of ME (25.6 μM) was reduced by 26 ± 3% (n = 5, p < 
0.005) (Figs. 4A, C and G). On the other hand, after finishing the morphine (30 μM, 10 
min) perfusion, the inhibitory effect of (25.6 μM) was desensitized by 39 ± 4% (n = 5, p < 
0.005) (Figs. 4D and G). This degree of desensitization was higher than that induced by 
ME (10 μM) (p < 0.05, Fig. 4G). Since morphine (30 μM) produces 100% receptor 
occupancy and it does not quickly wash out from the slice, we only studied changes in the 
maximum response caused by desensitization and therefore, ME (0.8 μΜ) was not tested 
in morphine experiments. After inducing desensitization with morphine, naloxone was 
applied to return to control firing rate values in the absence of MOR activation. In fact, 
the firing rate after naloxone (1 μM) was not different when compared to the firing rate 
before desensitization (firing rate, before desensitization: 4.1 ± 0.5 Hz, n = 5; after 
naloxone (1 μM): 4.0 ± 0.5 Hz, n = 5).  
Second, we compared the maximal response to ME (25.6 µM) applied at two times 
during a continuous application of ME (10 µM, 10 min) or morphine (30 µM, 10 min). 
By this approach the inhibitory effect of ME (25.6 µM, 1 min) was desensitized by 36 ± 
4% (n = 5, p < 0.05) following ME (10 µM, 10 min) perfusion and by 32 ± 5% (n = 5, p < 
0.01) after morphine (30 µM, 10 min) (Figs. 4E, F and G). The firing rate after naloxone 
(1 μM) did not differ from the firing rate before desensitization (firing rate, before 
desensitization: 4.7 ± 0.4 Hz, n = 5; after naloxone (1 μM): 4.5 ± 0.4 Hz, n = 5).  
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In each desensitization experiment, GABA (1 mM) was tested as an internal control. The 
inhibitory effect of GABA (1 mM, 1 min) was close to 100% from baseline (>95%) both 
before and after perfusion with ME (10 µM, 10 min) (n = 15) (Figs. 4B and G) or 
morphine (30 µM, 10 min) (n = 9) (Figs. 4G). 
 
Effect of neuronal NOS inhibitors on acute MOR desensitization induced by ME and 
morphine  
It has been shown that nNOS contributes to ME-induced MOR desensitization in 
spontaneously active LC neurons (Santamarta et al., 2014). To further study the 
involvement of nNOS on morphine (30 µM)-induced desensitization, we perfused a 
combination of two nNOS inhibitors 7-NI (100 µM) and SMTC (10 µM). Perfusion with 
the nNOS inhibitors did not alter the firing rate of LC neurons (firing rate change: 2 ± 
1%, n = 17). Moreover, acute effects of both test concentrations of ME (0.8 and 25.6 µM) 
in the presence of nNOS inhibitors were not different from those in the control group 
(change in acute effect, ME (0.8 µM): 15 ± 7%, n = 5; ME (25.6 µM): 5 ± 7%, n = 15). 
 As in spontaneously firing neurons, administration of nNOS inhibitors in KCl-
excited LC neurons reduced by 27 ± 6% (n = 5, p < 0.05 vs control) the desensitization 
induced by ME (10 μM) when ME (0.8 µM) was applied before and after inducing 
desensitization. In addition, nNOS inhibitors blocked the desensitization by 58 ± 8% (n = 
5, p < 0.005 vs control) when ME (25.6 µM) was applied before and after ME (10 μM), 
(Figs. 5B and E). Finally, nNOS inhibitors reduced by 43 ± 8% (n = 5, p < 0.05 vs 
control) the desensitization when ME (25.6 µM) was applied during ME (10 μM), (Figs. 
5D and E). The basal firing rate in the presence of nNOS inhibitors was not significantly 
different when compared to the control group (basal firing rate, control: 4.35 ± 0.26 Hz, n 
= 15; in the presence of nNOS inhibitors: 4.92 ± 0.32 Hz, n = 15). GABA (1 mM, 1 min) 
caused a 100% reduction from baseline before and after inducing desensitization (n = 14) 
(Fig. 5C and E). These results reaffirm that nNOS contributes to ME-induced MOR 
desensitization in rat LC neurons. 
On the contrary, perfusion with 7-NI (100 μM) together with SMTC (10 μM) failed 
to alter morphine (30 μM)-induced desensitization. Thus, desensitization induced by 
morphine (30 μM) in the presence of nNOS inhibitors was significant (n = 5, p < 0.005) 
(Fig. 6A and B). No differences were found between the firing rate before morphine (30 
μM) and after naloxone (1 μM) (firing rate before morphine (30 μM): 5.0 ± 0.2 Hz, n = 5; 
firing rate after naloxone (1 μM): 4.8 ± 0.3 Hz, n = 5). GABA (1 mM) promoted a 100% 
inhibition from baseline before and after inducing desensitization (n = 5) (Fig. 6A and B). 
These results suggest that nNOS is not involved in acute MOR desensitization induced by 
morphine in LC neurons. 
 
   
9 
Discussion  
The ability of morphine to induce rapid MOR desensitization in native LC neurons 
has been a matter of debate (Alvarez et al., 2002; Bailey et al., 2003, 2009b). In addition, 
NO has been shown to regulate ME-induced MOR desensitization in the LC in vitro 
(Torrecilla et al., 2001; Llorente et al., 2012; Santamarta et al., 2014) and morphine-
induced tolerance in this nucleus in vivo (Santamarta et al., 2005). However, the 
contribution of NO to MOR desensitization induced by non-peptide opioid agonists in 
vitro is unknown. In the present study, we used single-unit extracellular recordings in 
KCl-excited LC neurons from rat brain slices to characterize the desensitization of MOR 
induced by morphine and ME. We further explored the involvement of the neuronal NOS 
isoform in acute MOR desensitization. Our results show that morphine (30 μM) causes 
significant desensitization of MOR in the LC, so that the inhibitory effect of a 
supramaximal test concentration of ME (25.6 μM, applied before and after, or during the 
opioid perfusion) was markedly reduced. As expected, ME (10 μM) also induced 
substantial desensitization of MOR, since the inhibitory effect of ME (0.8 or 25.6 μM) 
was diminished. The inhibitory effect of GABA (1 mM) was unaltered after application 
of either ME (10 µM) or morphine (30 µM). Perfusion with a combination of two 
selective nNOS inhibitors (7-NI and SMTC) attenuated the induction of MOR 
desensitization induced by ME but, in contrast, it failed to alter the desensitization 
induced by morphine. 
As previously mentioned, to study MOR desensitization, we evoked an excitation of 
LC neurons with KCl (14 mM). This procedure allows us to continously monitor 
morphine effects and, at the same time, to assess supramaximal test concentrations of ME 
by extracellular recording techniques. This would not have been feasible in spontaneously 
firing LC neurons from brain slices, since morphine would induce a complete inhibition 
of the firing activity that would not recover to baseline values. Apart from the 
postsynaptic action, it has been shown that KCl depolarizes nerve terminals, which 
triggers GABA and glutamate release in slice preparations (Liachenko et al., 1999). To 
avoid the interference of the KCl-induced glutamate release on MOR desensitization, all 
the experiments were performed in the presence of D-AP5 and CNQX (NMDA and non-
NMDA glutamate receptor antagonist, respectively), as described by Mendiguren and 
Pineda (2007). Under these experimental conditions, most of the excitation of LC cells by 
KCl is due to postsynaptic changes in membrane potassium equilibrium. Thus, we first 
characterized the acute inhibitory effects of ME and morphine on KCl-excited neurons. 
Concentration-effect curves showed that morphine has a smaller maximum inhibitory 
effect (Emax) than ME, which is consistent with previous studies that have shown that 
morphine behaves as partial agonist at the MOR in LC neurons (Osborne et al., 2000; 
Bailey et al., 2003). The EC50 value for the inhibitory effect of ME effect in the presence 
of high K+ was found to be slightly shifted to the right as compared to that from 
spontaneously firing LC neurons (Santamarta et al., 2005) or by intracellular electrodes 
under voltage-clamp mode in the LC (Osborne and Williams, 1995). Likewise, the EC50 
value for morphine in the presence of high K+ is shifted rightward when compared to that 
reported using intracellular recording techniques in LC neurons (Chiu et al., 1993). This 
is likely due to a positive DC shift in the potassium equilibrium potential promoted by 
high concentrations of extracellular K+ and the fact that we are able to follow the effect 
of ME or morphine at membrane potentials close to the reversal potential for K+ (where 
GIRK channels show rectification). 
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To study MOR desensitization in the present study, we measured changes in the 
inhibitory effect of two test concentrations of the opioid agonist ME (0.8 or 25.6 μM). 
ME inhibits LC cell activity with high efficacy and almost exclusively through MOR 
(Williams and North, 1984). Moreover, it rapidly washes out from the slice so that MOR 
desensitization can be easily measured by extracellular recordings once the firing 
recovers from ME-induced inhibition. The use of an intermediate concentration of ME 
(0.8 µM), close to the EC50 value, allowed us to detect any minimal change in the 
sensitivity of MOR associated with ME-induced desensitization. On the contrary, 
application of a supramaximal test concentration of ME (25.6 µM) made it possible to 
study reductions in the maximal activity of MOR associated with ME-induced 
desensitization (Osborne and Williams, 1995). In the case of morphine, as a concentration 
of 30 µM produces near maximal receptor occupancy, we had to use the supramaximal 
test concentration of ME (25.6 µM) to measure maximal activity of MOR, overcoming 
morphine’s slow rate of receptor dissociation in the slice preparation.  
As expected, ME (10 μM) strongly desensitized the inhibition induced by a test 
application of ME (0.8 μM). This degree of desensitization was found to be similar to that 
reported in spontaneously firing LC neurons (Llorente et al., 2012; Santamarta et al., 
2014). In addition, ME (10 μM) desensitized the inhibition induced by a supramaximal 
concentration of ME (25.6 μM), applied before and after the opioid perfusion. However, 
this degree of desensitization was less strong than that quantified by ME (0.8 µM), as a 
supramaximal test concentration is less sensitive to detect changes in MOR 
responsiveness associated with desensitization. Finally, the inhibitory effect of ME (25.6 
μM), applied at two times during ME (10 μM, 10 min) administration, was also 
desensitized to a similar extent to that observed when the ME test was applied before and 
after.  
On the other hand, morphine caused significant MOR desensitization, since the effect 
of ME (25.6 μM), applied before and after morphine (30 μM) perfusion, was significantly 
reduced. In fact, the degree of desensitization induced by morphine was stronger than that 
induced by ME under the same experimental design. This is likely because MOR 
signaling starts recovering once the sustained perfusion of ME finishes, whereas it does 
not recover for a long time after morphine perfusion. Likewise, morphine (30 μM) 
desensitized the inhibitory effect of ME (25.6 μM), when it was tested at two times during 
the opioid perfusion. Interestingly, the degree of desensitization induced by morphine 
using the latter protocol was not different from that induced by ME. This finding seems to 
contradict previous electrophysiological experiments that showed that morphine induces 
significantly weaker MOR desensitization than higher efficacy opioid agonists such as 
ME in LC neurons in vitro (Alvarez et al., 2002; Bailey et al., 2003). Interestingly, these 
authors have reported that morphine-induced desensitization is enhanced by concomitant 
activation of PKC (Bailey et al., 2004; Arttamangkul et al., 2015). In our assays, high K+ 
concentration may facilitate calcium entry through voltage-dependent calcium channels 
(Meier et al., 1988), which has been shown to elevate PKC activity in different systems 
(Sakai et al., 1997; Dupont et al., 2000; Ratz and Miner, 2009). Other kinases such as 
CaMKII have been also reported to negatively regulate MOR signaling and to contribute 
to morphine-induced desensitization, tolerance and dependence (Mestek et al., 1995; 
Sánchez-Blázquez et al., 2008; Tang et al., 2006; Navidhamidi et al., 2012), with their 
activity being increased in a calcium-dependent manner (Kim et al., 2000; Song et al., 
2010). However, it is unclear if they interact directly or indirectly with MOR in LC 
neurons (Wang and Wang, 2006; Feng et al., 2011; Arttamangkul et al., 2015). Given that 
the mean firing rate after KCl (14 mM) was ~4 Hz, we can speculate that these kinases 
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would be activated during KCl perfusion to a similar extent to that observed in waking 
animals, since tonic LC discharge rates up to 5 Hz are typically observed during normal 
waking in rats and monkeys (Foote et al., 1980; Berridge and Waterhouse, 2003).  
On the contrary, our results suggest that, even in conditions where increased PKC 
activity would be expected (high K+), ME-induced desensitization was not found to be 
stronger than in control tissues. In agreement, a recent study using intracellular recordings 
in LC neurons has reported that PKC activators do not affect the desensitization induced 
by a saturating concentration of ME (30 µM), when the test was applied before and after 
the ME perfusion (Arttamangkul et al., 2015). Finally, we observed that the inhibitory 
effect of GABA, which was tested as an internal control, was ~100% and was not affected 
by either morphine or ME perfusion. GABA has been shown to induce stronger inhibitory 
effects at depolarized than at hyperpolarized membrane potentials on LC neurons 
(Osmanovic and Shefner, 1990), but these actions are not changed by opioid agonists. 
The NO system has been shown to modulate MOR signaling in the LC. We have 
previously reported that NO enhances ME-induced MOR desensitization (Llorente et al., 
2012). Independent administration of 7-NI and SMTC, two structurally unrelated 
molecules that selectively inhibit the neuronal NOS isoform (Babbedge et al., 1993; 
Furfine et al., 1994), attenuated ME-induced MOR desensitization in spontaneously firing 
LC neurons in vitro (Santamarta et al., 2014). In the present study, nNOS inhibition by a 
combined perfusion with 7-NI and SMTC attenuated ME-induced MOR desensitization 
in KCl-excited LC neurons, which confirms the involvement of nNOS in this process. In 
addition, NO has been shown to play a critical role in the adaptations induced by chronic 
morphine administration. Thus, morphine treatment leads to an increased NOS expression 
in the central nervous system (Cuéllar et al., 2000; Wong et al., 2000). In vivo 
administration of 7-NI prevents the development of tolerance in morphine-treated rats 
(Santamarta et al., 2005) and reduced the hyperactivity of LC neurons typically found 
after chronic morphine exposure (Pineda et al., 1998). Morphine-induced analgesic 
tolerance has been also shown to be attenuated by NO-activated sGC/cGMP-dependent 
mechanisms (Ozdemir et al., 2011; Durmus et al., 2014) and ROS generation (Muscoli et 
al., 2007; Batinić-Haberle et al., 2009). Surprisingly, perfusion with the nNOS inhibitors 
7-NI and SMTC failed to alter morphine-induced desensitization of MOR in vitro in our 
work. These results suggest that acute inhibition of neuronal NO synthesis does not affect 
morphine-induced MOR desensitization in vitro, whereas it attuenuates the induction of 
tolerance in vivo. 
The mechanisms by which nNOS might be differentialy involved in ME-, but not 
morphine-induced MOR desensitization are unknown. Results obtained in our laboratory 
have indicated that NO mediates the development of ME-induced MOR desensitization 
through independent regulation of downstream sGC/PKG and ROS pathways in the LC 
(see Results, Study 1). One of the most remarkable differences between ME and 
morphine is that ME causes robust receptor internalization (Arttamangkul et al., 2008; 
2012), whereas morphine fails to induce efficient internalization in adult rat LC neurons 
or HEK293 cells (Finn and Whistler, 2001; Alvarez et al., 2002; Bailey et al., 2003; 
Arttamangkul et al., 2008). It can be hypothesized that NO might act disrupting 
reinsertion of internalized receptors back into the plasma membrane, which would agree 
with the fact that morphine-induced desensitization is unaffected by nNOS inhibitors, 
since morphine does not promote efficient receptor endocytosis and recycling of the 
MOR. 
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On the other hand, the mechanisms by which nNOS inhibitors would attenuate 
morphine-induced cellular tolerance in LC neurons and morphine-induced analgesic 
tolerance, without affecting acute desensitization are unclear. One of the possibilities may 
involve alterations in MOR turnover in LC neurons, which has been suggested to underlie 
opioid tolerance (Dang and Christie, 2012). Thus, previous results from our group have 
reported that chronic treatment with morphine leads to a disruption in MOR functional 
recovery from complete receptor inactivation with β-funaltrexamine in the LC. Our 
preliminary data indicate that this modification of MOR turnover may be mediated by NO 
(M.T. Santamarta, Doctoral Thesis, unpublished data). In adition, several events 
dependent on NO signaling pathways have been reported to mediate in vivo morphine-
induced antinociceptive tolerance, including glutamatergic activation (Sánchez-Blázquez 
et al., 2013), neuronal apoptosis (Bonfoco et al, 1995) or glial activation and induction of 
proinflammatory processes (Little et al., 2013). Thus, nNOS inhibitors could alleviate 
morphine tolerance in vivo by attenuating some of these processes, without altering 
morphine-induced desensitization.  
In conclusion, the present study shows that morphine and ME induce acute MOR 
desensitization in LC neurons. On the basis of previous studies, we can hypothesize that 
morphine-induced desensitization could be mediated by high firing rate-dependent 
activation of PKC and/or CaMKII, to a similar extent as in vivo, but the exact mechanism 
has yet to be determined. Selective nNOS inhibition attenuates the induction of MOR 
desensitization by the opioid agonist ME, but it failed to alter the desensitization 
promoted by morphine. These results highlight the agonist-selective acute regulation of 
MOR by nNOS. Further studies are needed to investigate the underlying mechanisms. 
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Figure legends 
Figure 1. Scheme of one of the experimental designs used to evaluate the degree of 
opioid desensitization induced by ME or morphine in LC neurons under KCl-evoked 
excitation. The acute effect of ME (0.8 or 25.6 µM) was tested before and after inducing 
desensitization with ME (10 µM, 10 min) or morphine (30 µM, 10 min). The inhibitory 
effect induced by morphine was reversed by naloxone (1 µM). The decrease in the effect 
of ME (25.6 μM, 1 min) was taken as a measure of the degree of desensitization. All the 
experiments were performed in the presence of CNQX (non-NMDA glutamate receptor 
antagonist, 30 μM) and D-AP5 (NMDA receptor antagonist, 100 μM) to avoid the 
interference of KCl-induced glutamate release on MOR desensitization. 
Figure 2. Scheme of one of the experimental designs used to evaluate the degree of 
opioid desensitization induced by ME or morphine in LC neurons under KCl-evoked 
excitation. The maximal effect induced by ME (25.6 µM) was tested during the 
continuous perfusion with ME (10 µM, 10 min) or morphine (30 µM, 10 min). The 
inhibitory effect induced by morphine was reversed by naloxone (1 µM). The decrease in 
the effect of ME (25.6 μM, 1 min) was taken as a measure of the degree of 
desensitization. All the experiments were performed in the presence of CNQX (non-
NMDA glutamate receptor antagonist, 30 μM) and D-AP5 (NMDA receptor antagonist, 
100 μM) to avoid the effects of KCl-induced glutamate release on MOR desensitization. 
Figure 3. Characterization of acute ME and morphine effects under KCl-evoked 
activation of LC neurons in vitro. A, B. Examples of firing-rate recordings of LC cells 
showing the inhibitory effect of ME (A) and morphine (B). Each horizontal bar represents 
the period of application of each ME (0.1 - 25.6 μM, 2x) or morphine concentration (0.1 - 
30 μM, 3x) and the vertical lines show the number of spikes recorded every 10 s. C, D. 
Concentration-effect curves for the inhibitory effect of ME (C) and morphine (D) in KCl-
excited LC neurons. The horizontal axis represents the logarithms of ME and morphine 
concentrations in linear scale. The vertical axis expresses the reduction in the firing rate 
of LC neurons as a percentage from the KCl-induced basal firing rate. Symbols are the 
mean ± SEM of ME or morphine effects at each concentration obtained from n animals. 
The lines through the data are the theoretical curves constructed from the mean of the 
individual concentration-effect curve parameters, as estimated by nonlinear regression 
(see Methods for details). 
Figure 4. Characterization of acute desensitization of MOR induced by ME and 
morphine in KCl-excited LC neurons in vitro. A, B, C. Examples of firing-rate recordings 
of LC cells showing the effect of ME (0.8 μM, 1 min) (A), GABA (1 mM, 1 min) (B) or 
ME (25.6 μM, 1 min) (C) before and after inducing desensitization with ME (10 μM, 10 
min). D, Example of firing-rate recording of a LC neuron showing the effect of ME (25.6 
μM, 1 min) before and after inducing desensitization with morphine (30 μM, 10 min). E, 
F. Examples of firing-rate recordings of LC cells showing the effect of ME (25.6 μM, 1 
min) applied at two times during a sustained perfusion with ME (10 μM, 10 min) (E) or 
morphine (30 μM, 10 min) (F). The horizontal bars indicate the period of drug 
applications and the vertical lines show the number of spikes recorded every 10 s. G. Bar 
histograms show the mean ± S.E.M of ME (10 μM)-, or morphine (30 μM)-induced 
desensitization. Different test concentrations and experimental designs were used (see 
Pharmacological procedures). GABA was used as an internal control. All the experiments 
were performed in the presence of the glutamate receptor antagonists CNQX (30 μM) and 
D-AP5 (100 μM). Desensitization degrees were calculated as percentage values (see Data 
analysis and statistics). Note that significant reductions in the effect of ME (0.8 μM, 1 
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min) or ME (25.6 μM, 1 min) were observed when applied before and after or during ME 
(10 μM, 10 min) (n = 5, in all cases), but the degree of desensitization was greater when it 
was quantified by ME (0.8 μM). Likewise, substantial reduction in ME (25.6 μM) effect 
was observed when applied before and after (n = 5) or during (n = 5) morphine (30 μM, 
10 min). The desensitization induced by morphine (30 μM) was greater than that induced 
by ME (10 μM) when the test concentration was applied before and after. The effect of 
GABA (1 mM) was unaltered after perfusion with either ME (10 μM) or morphine (30 
μM) (n = 15 and n = 9, respectively). *p < 0.01, *p < 0.01 and **p < 0.005 when the 
effect of the test concentration of ME after desensitization was compared to the basal 
effect by a paired Student’s t test. #p < 0.005 when compared to the ME (0.8 μM) group 
by a two-sample Student’s t test; †p < 0.05 when compared to the corresponding ME (10 
μM) group by a two-sample Student’s t test. 
 
Figure 5. Effect of nNOS inhibitors on acute MOR desensitization induced by ME in 
KCl-excited LC neurons in vitro. A, B, C. Representative examples of firing-rate 
recordings of LC cells showing the effect of ME (0.8 μM, 1 min) (A), ME (25.6 μM, 1 
min) (B) or GABA (1 mM, 1 min) (C) applied before and after inducing desensitization 
with ME (10 μM, 10 min) in the presence of 7-NI (100 μM) and SMTC (10 μM). D. 
Example of firing-rate recording of LC cell showing the effect of ME (25.6 μM, 1 min) 
applied at two times during a sustained perfusion with ME (10 μM, 10 min) in the 
presence of 7-NI (100 μM) and SMTC (10 μM). The horizontal bars indicate the period of 
drug applications and the vertical lines show the number of spikes recorded every 10 s. E. 
Bar histograms show the mean ± S.E.M of ME (10 μM)-induced desensitization in the 
absence and in the presence of nNOS inhibitors. Different test concentrations and 
experimental designs were used (see Pharmacological procedures). GABA was used as an 
internal control. All the experiments were performed in the presence of the glutamate 
receptor antagonists CNQX (30 μM) and D-AP5 (100 μM). Desensitization degrees were 
calculated as percentage values (see Data analysis and statistics). Note that nNOS 
inhibitors attenuated ME (10 μM)-induced desensitization when it was quantified by ME 
(0.8 μM, n = 5), or ME (25.6 μM) applied before and after (n = 5) or during ME 10 μM (n 
= 5). In contrast, GABA (1 mM) effect was not affected (n = 14). *p < 0.05 and **p < 
0.005 when compared to the corresponding control group by two-sample Student’s t test. 
 
Figure 6. Effect of nNOS inhibitors on acute MOR desensitization induced by morphine 
in KCl-excited LC neurons in vitro. A. Representative example of a firing-rate recording 
of LC cell showing the effect of ME (25.6 μM, 1 min) applied at two times during a 
sustained perfusion with morphine (30 μM, 10 min) in the presence of 7-NI (100 μM) and 
SMTC (10 μM). The horizontal bars indicate the period of drug applications and the 
vertical lines show the number of spikes recorded every 10 s. B. Bar histograms show the 
mean ± S.E.M of morphine (30 μM)-induced desensitization in the absence and in the 
presence of nNOS inhibitors. GABA was used as an internal control. All the experiments 
were performed in the presence of the glutamate receptor antagonists CNQX (30 μM) and 
D-AP5 (100 μM). Desensitization degrees were calculated as percentage values (see Data 
analysis and statistics). Note that nNOS inhibitors failed to block morphine (30 μM)-
induced desensitization (n = 5). The effect of GABA (1 mM) was not affected by 
morphine perfusion (n = 5). 
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Abstract  
Nitric oxide (NO) has been implicated in acute μ-opioid receptor (MOR) desensitization 
in the locus coeruleus (LC) and in the neuroadaptations following chronic morphine 
administration. Herein, we examined by extracellular recording techniques in LC neurons 
the effect of 7-nitroindazole (7-NI; 30 mg/kg/12 h, i.p.), a selective neuronal nitric oxide 
synthase (nNOS) inhibitor, and the antioxidants Trolox + ascorbic acid (TX+AA; 40 and 
100 mg/kg/day, respectively, i.p.) and U-74389G (10 mg/kg/day, i.p.), on the 
development of cellular tolerance induced by three different opioid agonists (morphine, 
methadone and fentanyl). For induction of morphine tolerance, rats were treated 
subcutaneously (s.c.) with a slow release emulsion containing free base morphine (200 
mg/kg) for 72 h. For methadone (60 mg/kg/day, 6 days) and fentanyl (0.2 mg/kg/day, 7 
days), tolerance was induced by s.c. implantation of osmotic pumps. Concentration-effect 
curves for the inhibitory effect of the opioid agonist Met5-enkephalin (ME) on the cell 
firing rate was evaluated by single-unit extracellular recordings of LC neurons from brain 
slices. Morphine, methadone and fentanyl treatments shifted concentration-effect curves 
for ME to the right and increased the EC50 by 2-4 folds, as compared to those in sham-
treated animals. This suggests that opioids induce different degrees of cellular tolerance 
in LC neurons. Tolerance to ME effect by morphine was attenuated by co-administration 
of TX+AA or U-74389G, when compared to the control (morphine/vehicle group). In 
contrast, Co-treatment with either U-74389G or 7-NI failed to alter the tolerance to the 
inhibitory effect of ME in methadone- or fentanyl-treated animals. Taken together, our 
results suggest that NO/ROS pathways differentially modulate the development of 
cellular tolerance in LC neurons. 
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acid; U-74389G: 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrrimidinyl)-1-piperazinyl]-pregna-
1,4,9(11)-triene-3,20-dione(Z)-2 butenedioate  
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1. Introduction  
Morphine, methadone or fentanyl are among the most common clinically used opioid 
agonists. However, their long-term utility is greatly compromised because of the 
development of tolerance and dependence (Inturrisi, 2002). Opioid tolerance requires 
dose escalation to maintain adequate analgesia, which is associated with side effects, such 
as severe constipation or nausea. Understanding the mechanisms underlying opioid 
tolerance is essential to design better therapeutic approaches to improve pain 
management. Numerous mechanisms have been reported to contribute to opioid tolerance 
and it is difficult to integrate them into a unified theory. Tolerance may result from 
adaptive changes such as enhanced MOR desensitization, receptor internalization or 
receptor down-regulation, among other mechanisms (Dang and Christie, 2012; Williams 
et al., 2013). In addition, the N-methyl-D-aspartate receptor (NMDAR)/nitric oxide (NO) 
system has been proposed to be involved in opioid tolerance (Heinzen and Pollack, 2004). 
In the brain, NO is produced by the neuronal NO synthase (nNOS) and targets the heme 
group of guanylate cyclase, which elevates cGMP concentrations. Moreover, high, 
sustained concentrations of NO promote the generation of reactive nitrogen species and 
reactive oxygen species (ROS), such as the extremely oxidant molecule peroxynitrite 
(ONOO−), originated from the reaction of NO with superoxide anion (Davis et al., 2001; 
Radi, 2013). Both peroxynitrite and superoxide have been implicated in the development 
of pain of several etiologies including pain associated with chronic use of opioids such as 
morphine (Salvemini et al., 2011). 
The locus coeruleus (LC), the major noradrenergic nucleus in the brain, has long 
been used as a model for examining the cellular mechanisms of opioid tolerance and 
dependence (Nestler et al., 1994). It contains a homogeneous population of neurons that 
almost exclusively express the MOR (Williams and North, 1984). In brain slices, opioid 
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agonists induce a marked inhibition of LC neurons through a Gi/o protein-dependent 
activation of inwardly rectifying K+ channel (GIRK) conductance (Williams et al. 1982; 
Torrecilla et al., 2002). The NO system participates in the adaptive mechanisms 
underlying opioid tolerance in the LC. Thus, inhibition of neuronal NO synthase 
attenuates acute MOR desensitization induced by the opiod agonist Met5-enkephalin 
(ME) (Santamarta et al., 2014) and attenuates cellular tolerance in morphine-treated 
animals (Santamarta et al., 2005). Futthermore, ROS seem to contribute to the 
enhancement on MOR desensitization induced by NO in LC neurons (Llorente et al., 
2012). However, there is lacking evidence regarding the implication of NO/ROS pathway 
in the adaptations triggered by chronic treatments with other different opioid agonists in 
the LC. Morphine, methadone and fentanyl are opioid agonists that exert their effects 
mainly through MOR, but they promote quantitatively different actions at the cellular 
level. Thus, methadone and fentanyl have been reported to promote efficient 
desensitization and internalization of MOR in the LC (Alvarez et al., 2002; Arttamangkul 
et al., 2008, Virk and Williams, 2008). In contrast, morphine seems to be relatively 
inefficient at producing acute desensitization and internalization in this nucleus (Alvarez 
et al., 2002; Arttamangkul et al., 2008). 
The aim of this work was to investigate whether NO and ROS regulate the tolerance 
induced by opioids with different pharmacologic profiles, such as morphine, methadone 
and fentanyl. For that purpose, we performed uni-extracellular recordings in vitro to 
evaluate the effect of chronic treatment with 7-nitroindazole (7-NI), a relatively selective 
inhibitor of neuronal NO synthase (Moore et al., 1993; Moore and Handy, 1997) on 
methadone- and fentanyl-induced tolerance. Moreover, the effect of treatment with the 
antioxidants 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) 
administered together with ascorbic acid (TX+AA) or 21-[4-(2,6-di-1-pyrrolidinyl-4-
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pyrrimidinyl)-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione(Z)-2-butenedioate (U-
74389G) was also evaluated on morphine-, methadone- and fentanyl-treated animals.  
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2. Materials and Methods  
2.1 Animals and treatments.  
Male adult Sprague-Dawley rats (200-300 g) were housed under standard laboratory 
conditions (22ºC, 12:12 h light/dark cycles) with free access to food and water. All 
experimental procedures reported in this manuscript were carried out in accordance with 
the European Community Council Directive on "Protection of Animals Used in 
Experimental and Other Scientific Purposes" (86/609/EEC) and approved by the Research 
Committee of the Faculty of Medicine and Odontology (University of the Basque 
Country, Spain). Every effort was made to minimize animal suffering and use the fewest 
possible number of animals. 
For induction of morphine tolerance, an oily emulsion of morphine base (200 mg/kg) 
was subcutaneously injected in the back of the rat, under chloral hydrate (200 mg/kg, 
intraperitoneal (i.p.)) anesthesia. Sham animals were administered the same vehicle 
emulsion without morphine. Then, morphine or sham animals were daily injected with the 
antioxidants Trolox (40 mg/kg) and ascorbic acid (100 mg/kg) (TX+AA), U-74389G (10 
mg/kg) or 0.9% NaCl (saline) intraperitoneally (i.p.). Electrophysiological experiments 
were performed 72 h after emulsion implantation. 
For chronic treatments with methadone or fentanyl, osmotic mini-pumps (Alzet 
2ML1) were implanted subcutaneously, as described by Quillinan et al. (2011) and 
Trujillo et al. (2004), respectively. The mini-pumps have a 2 ml reservoir that delivers the 
content continuously at the rate of 10 µl/h. Pumps were filled with the required 
concentration of methadone (60 mg/kg/day) or fentanyl (0.2 mg/kg/day), dissolved in 
saline. Animals were first anaesthetized with isoflurane and an incision was made in the 
midscapular region to insert the minipump. Sham animals were implanted with saline-
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filled osmotic pumps under the same experimental conditions. For induction of 
methadone tolerance, rats were given methadone i.p injections before the implantation of 
the pump, as follows: the day before, they received 5 mg/kg at 9:00 h and 7 mg/kg at 
18:00 h. Next day, they received 7 mg/kg at 9:00 h and the osmotic pump was implanted 
at 18:00 h. Once the minipump was inserted, sham, methadone-, or fentanyl-treated 
animals were treated every 12 h with the nNOS inhibitor 7-NI (30 mg/kg) or its vehicle 
(peanut oil), i.p. In another group of experiments, sham, methadone-, or fentanyl-
receiving rats were daily injected with the antioxidant U-74389G (10 mg/kg) or its 
vehicle (saline), i.p. Experiments were carried out on day 7 in methadone-treated rats (6 
days after minipump implantation) and on day 8 in fentanyl-treated rats (7 days after 
minipump implantation). 
2.2 In vitro electrophysiology 
2.2.1 Brain slice preparation.  
Animals were anaesthetized with chloral hydrate (400 mg/kg, i.p.) and decapitated. 
The brain was rapidly removed and a block of tissue containing the brainstem was placed 
in ice-cold artificial cerebrospinal fluid (aCSF) containing 130 mM NaCl, 3 mM KCl, 
1.25 mM NaH2PO4, 10 mM D-glucose, 21 mM NaHCO3, 2 mM CaCl2, and 2 mM 
MgSO4. Coronal slices of 600 µm thickness containing the LC were cut using a 
vibratome. The tissue was allowed to recover from the slicing for 90 min in oxygenated 
aCSF. Next, slices were placed on a nylon mesh in a modified Haas-type interface 
chamber maintained at 33 °C and continuously perfused with aCSF saturated with 95% 
O2/ 5% CO2 (pH = 7.34) at a flow rate of 1.5 ml/min.  
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2.2.2 Recording procedures 
Single-unit extracellular recordings of LC cells were performed as described 
previously (Mendiguren and Pineda, 2004). The recording electrode, an Omegadot glass 
micropipette, was pulled and filled with NaCl (50 mM). The tip was broken back to a 
diameter of 2 – 5 µm (3 – 5 MΩ). The electrode was placed in the LC, visually identified 
as a dark oval area on the lateral borders of the central gray and the fourth ventricle, just 
anterior to the genu of the facial nerve. The extracellular signal from the electrode was 
passed through a high-input impedance amplifier and displayed on an oscilloscope and 
monitored with an audio unit. Individual neuronal spikes were isolated from the 
background noise with a window discriminator. The firing rate was analyzed by a PC-
based custom-made software, which generated histogram bars representing the 
cumulative number of spikes in consecutive 10 s bins (HFCP®, Cibertec S.A., Madrid, 
Spain). Noradrenergic cells were identified by their spontaneous and regular discharge 
activity, the slow firing rate and the long-lasting, positive-negative waveform (Andrade et 
al., 1983). 
2.3 Pharmacological procedures 
To assess the effect of 7-NI and antioxidants on the development of opioid 
tolerance in LC neurons, we performed concentration-effect curves for the inhibitory 
effect of the MOR agonist ME in sham and opioid-treated animals. Thus, we perfused 
increasing concentrations of ME (2x, 0.05 – 12.8 μM, each concentration applied for 1 
min) at 5-min intervals. ME was chosen because its washout is fast even at high 
concentrations and its action is mediated almost exclusively by MOR in LC neurons 
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(Williams and North, 1984). The inhibitory effect of each ME concentration was 
calculated as follows:  
E = (FRbasal – FRpost) · 100/ FRinitial 
where FRbasal is the average firing rate for 60 s before each ME application, FRpost is the 
average firing rate for 60 s after each ME perfusion, and FRinitial is the firing rate of each 
cell at the beginning of the recording. Curve fitting analysis was performed by the 
computer program GraphPad Prism (version 5.0 for Windows, San Diego, CA, USA) to 
obtain the best simple nonlinear fit to the following three-parameter logistic equation:  
E = Emax / [1 + (EC50/A)
n] 
in which E and A are the observed effect and the concentration of the agonist (ME), 
respectively; Emax is the maximal effect, expressed in percentage values; EC50 is the 
concentration of ME needed to elicit a 50% of the maximal effect, and n represents the 
slope factor of the function. EC50 values were finally expressed as negative logarithm 
(pEC50). 
2.4 Drugs and reagents 
The following drugs were purchased from Sigma-Aldrich Química (Madrid, Spain): 
Fentanyl, methadone, L-ascorbic acid and 7-nitroindazole (7-NI). Met5-enkephalin 
acetate salt (ME) was obtained from Bachem (Weil am Rhein, Germany). Morphine base 
was purchased from Alcaliber (Madrid, Spain). Trolox and U-74389G were obtained 
from Enzo Life Sciences (Lausen, Switzerland). For electrophysiological recordings, ME 
stock solutions were firstly prepared in miliQ water and then then diluted in aCSF to their 
final concentration. The aCSF contained (in mM): NaCl 129, KCl 3, NaH2PO4 1.25, D-
glucose 10, NaHCO3 21, CaCl2 2 and MgSO4 2 For subchronic treatment with morphine, 
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an oily emulsion of morphine free base (200 mg ml-1) containing mannide monooleate, 
liquid parafine, and 0.9% NaCl (0.08: 0.42: 0.5, v/v/v) was made (Santamarta et al., 
2005). All the drugs were dissolved in saline except 7-NI, which was dissolved in peanut 
oil.  
2.5 Data analysis and statistics 
Data are expressed as mean ± standard error of the mean (SEM). For statistical 
analysis, the EC50 values were transformed to the corresponding logarithmic data to 
convert them to a Gaussian distribution. Data among groups were compared by one-way 
analysis of variance (ANOVA) followed by Tukey´s post hoc test using the computer 
program GraphPad Prism (version 5.0). A probability level of 0.05 was accepted as 
statistically significant. 
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3. Results  
 
Effect of chronic treatments with morphine, methadone and fentanyl on 
concentration-effect curves for ME in rat LC neurons 
To evaluate the development of tolerance, concentration-effect curves for the 
inhibitory effect of ME were performed. It has been reported that the firing rate of LC 
neurons is elevated in brain slices from opioid-treated rats (Kogan et al., 1992). In this 
study we attempted to minimize the differences in firing rates among groups by 
performing concentration-effect curves only in cells that displayed standard spontaneous 
firing rates in the range of 0.4-1.5 Hz (mean ± SEM: 0.80 ± 0.02 Hz, n = 95). This 
procedure attempted to avoid the possibility that a change in the spontaneous activity of 
LC cells could influence the quantification of opioid effects (Andrade et al., 1983). Thus, 
the firing rate of LC neurons from morphine-, methadone- and fentanyl-treated animals 
was not different when compared to the corresponding sham groups (Tables 1 and 2). 
Subchronic treatment with morphine (200 mg/kg, s.c., 72 h) induced a strong degree of 
tolerance in the LC, which was revealed by a substantial rightward shift in the 
concentration-effect curves for ME and an increase in the EC50 of about 4 fold, as 
compared to the corresponding sham group (p < 0.005) (Figs. 1A and 2A; Table 2). 
Similarly, chronic treatment with methadone (60 mg/kg/day, s.c., 6 days) induced a 
rightward shift in the concentration-effect curves for ME and increased by about 2 fold 
the EC50 value when compared to the corresponding sham group (p < 0.005) (Figs. 1B 
and 2B; Table 2). Finally, chronic treatment with fentanyl (0.2 mg/kg/day, s.c., 7 days) 
also caused a rightward shift in the concentration-effect curves for ME with an increase of 
the EC50 of about 3 fold, as compared to the corresponding sham group (p < 0.005) (Figs. 
1B and 2C; Table 2). These results indicate that morphine, methadone and fentanyl 
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induce different degrees of tolerance to the inhibitory effect of ME in LC neurons. In all 
groups, the maximal effect of ME was 100% of baseline, which corresponded with an 
absolute inhibition from the basal firing rate. 
 
 
Effect of the nNOS inhibitor 7-NI on opioid tolerance in rat LC neurons 
 
In vivo administration of the nNOS inhibitor 7-NI has been shown to attenueate the 
development of cellular tolerance in LC neurons from morphine-treated rats (Santamarta 
et al., 2005). Herein, we tested the effect of 7-NI on the tolerance induced by chronic 
treatments with other opioid agonists such as methadone and fentanyl. Co-administration 
of 7-NI in methadone- and fentanyl-treated rats (methadone/7-NI group and fentanyl/7-NI 
group) failed to prevent the development of tolerance. Thus, the pEC50 values of 
concentration-effect curves for ME in the methadone/7-NI or fentanyl/7-NI group were 
statistically lower than those in the corresponding sham group (p < 0.005 vs sham/7-NI; 
in both cases), but they were not different from the corresponding vehicle groups (i.e., vs 
methadone/vehicle and fentanyl/vehicle) (Fig. 3; Table 1). 7-NI administration in sham-
treated animals (sham-7-NI group) did not modify the concentration-effect curves for ME 
in the LC as compared to the sham-vehicle group (Fig. 3; Table 1). No differences were 
found in the basal firing rate among groups (Table 1). Therefore, unlike morphine 
(Santamarta et al., 2005), the neuronal NOS inhibitor 7-NI fails to affect the development 
of opioid tolerance after methadone or fentanyl treatments. 
 
 
Effect of antioxidants on opioid tolerance in rat LC neurons 
 
Previous results from our group have shown that the co-administration of the free 
radical scavenger Trolox together with ascorbic acid (TX+AA) blocked partially the 
development of analgesic tolerance in morphine-treated rats (J. Llorente, Doctoral Thesis, 
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unpublished data). To verify these results with other antioxidants and other opioid 
agonists, we evaluated the effect of co-administration of TX+AA or U-74389 on the 
development of tolerance in morphine-, methadone- and fentanyl-treated animals. In 
agreement with previous results, co-administration of the vitamin E analogue Trolox, 
together with ascorbic acid in morphine-treated rats (morphine/TX+AA group) attenuated 
the development of cellular tolerance, which was shown by a blockade of the rightward 
shift of the concentration-effect curve in this group. Thus, the pEC50 value for ME effect 
in the morphine/TX+AA group did not differ statistically from the value in the 
sham/TX+AA group, but it was significantly less than that in the morphine/vehicle group 
(p < 0.05), indicating that the blockade of morphine tolerance by TX+AA was complete 
(Figs. 4A and C; Table 2). In contrast, TX+AA administration in sham-treated animals 
(sham/TX+AA) did not modify the concentration-effect curves for ME in the LC, as 
compared to the sham/vehicle group (Figs. 4A and C; Table 2). Likewise, co-treatment 
with U-74389G, a structurally unrelated antioxidant in morphine-treated rats 
(morphine/U-74389G group), attenuated the development of morphine tolerance, revealed 
by a blockade of the rightward shift of the concentration-effect curves in this group and 
an overlap with sham curves. Hence, the pEC50 for ME effect in the morphine/U-74389G 
group was not different from that in the sham/U-74389G group, but was significantly less 
than that in the morphine/vehicle group (p < 0.01) (Figs. 4B and C; Table 2). 
Administration of U-74389G in sham animals (sham/U-74389G) failed to modify the 
concentration-effect curves for ME when compared to the sham/vehicle group (Figs. 4B 
and C; Table 2). No differences were found in the basal firing rate among groups (Table 
2). 
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On the contrary, co-treatment with U-74389G in rats treated chronically with 
methadone or fentanyl (methadone/U-74389G and fentanyl/U-74389G group) did not 
prevent the development of cellular tolerance induced by these opioids, so that the 
concentration-effect curves from either methadone/U-74389G or fentanyl/U-74389G 
group were overlapped with those from their respective vehicle groups 
(methadone/vehicle and fentanylvehicle, respectively). Thus, the pEC50 values for ME 
effect in the methadone/U-74389G or fentanyl/U-74389G groups were statistically 
different from the corresponding sham group (sham/ U-74389G; p < 0.05 and p < 0.01, 
respectively), but they were not different from the corresponding vehicle groups 
(methadone/vehicle and fentanyl/vehicle, respectively) (Fig. 5; Table 2). U-74389G 
administration in sham animals (sham/U-74389G) failed to modify the concentration-
effect curves for ME when compared to the sham/vehicle group (Fig. 5; Table 2). No 
differences were found in the basal firing rate among groups (Table 2). 
Taken together, these data indicate that antioxidants reduce the development of 
opioid tolerance after morphine, but not methadone or fentanyl, and therefore, ROS seem 
to be differentially involved in opioid-induced cellular tolerance in the LC. 
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4. Discussion 
The NO system has been involved in the underlying mechanisms of acute 
desensitization of MOR (Llorente et al., 2012; Santamarta et al., 2014; Torrecilla et al., 
2001) and in the development of morphine-induced tolerance (Santamarta et al., 2005). 
The aim of this work was to investigate the role of neuronal NOS and NO-derived ROS in 
the development of tolerance induced by three different opioid agonists: morphine, 
methadone and fentanyl. For that purpose, we performed uni-extracellular recordings of 
LC neurons to test the effect of the nNOS inhibitor 7-NI and the ROS scavengers TX+AA 
and U-74389G on the induction of tolerance by chronic treatments with these three opioid 
agonists. Chronic treatments with morphine, methadone and fentanyl resulted in cellular 
tolerance in LC neurons, which was revealed by a rightward shift of 2-4 fold in the 
concentration-effect curves for the inhibitory effect of ME. Co-treatment with TX+AA 
and U-74389G attenuated the tolerance to the electrophysiological effect of ME induced 
by morphine. On the contrary, co-treatment with 7-NI or with U-74389G failed to modify 
the cellular tolerance induced by methadone or fentanyl. 
It has been described that basal firing rates of LC neurons are significantly higher in 
slices from morphine-treated animals (Kogan et al., 1992), although they fire at control 
rates in morphine-treated rats that have been acutely pretreated with 7-NI (Pineda et al., 
1998). In the present study, concentration-effect curves for ME were performed only in 
LC cells that spontaneously fired at slow rates (between 0.4 and 1.5 Hz, as in control 
animals), to avoid a biased quantification of opioid effects influenced by differences in 
the spontaneous activity of LC neurons. We used ME as an indicator of MOR function in 
the LC because it is a potent agonist that acts almost exclusively through MOR (Williams 
and North, 1984). Furthermore, it rapidly washes out after perfusion, which allows us to 
characterize the effect easily by extracellular recordings. Morphine tolerance was induced 
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by s.c. implantation of an oily emulsion containing morphine base (200 mg/kg, a single 
administration, 72 h). These emulsions have been described to provide a slow drug 
release and prolonged exposure to the opioid (Salem and Hope, 1999). According to the 
time course described in mice, the emulsion promotes a rise in morphine concentration in 
serum 3–12 h after implantation and a gradual clearance of morphine over 4–5 days 
(Garzón and Sánchez-Blázquez, 2001). In the present study, morphine caused a 4-fold 
shift to the right in the concentration-effect curves for ME in the LC. This degree of 
cellular tolerance is comparable to that reported previously in LC neurons in vitro, using 
the same morphine protocol (Santamarta et al., 2005). Likewise, in a previous study in the 
LC in vivo, we reported a 4-fold rightward shift in the morphine dose-effect curves after 
intraperitoneal administration of morphine hydrochloride solutions (10–100 mg/kg per 
injection, 15 injections, 5 days) (Pineda et al., 1998). However, Highfield and Grant 
(1998) implanted several slow-release pellets (75 mg morphine base per pellet, 6 pellets, 
6 days) and found a 2-fold rightward shift in the concentration-effect curves for morphine 
in LC cells. 
Chronic treatment with methadone osmotic pumps (60 mg/kg/day, 6 days) caused a 
2-fold shift to the right in the concentration-effect curves for ME in the LC. Likewise, 
Quillinan et al. (2011) observed a 2-fold shift to the right in the concentration-effect 
curves for ME measured by intracellular recordings in LC cells using the same 
methadone administration protocol. Methadone has been reported to cause 
antinociception in the tail flick and hot plate tests with a potency similar to that of 
morphine when given s.c. to rats (Giusti et al., 1997; He et al., 2009). Furthermore, the 
peak hyperpolarization caused by methadone (30 µM) is approximately the same as the 
hyperpolarization induced by morphine (30 µM) measured by extracellular recordings in 
LC neurons (Alvarez et al., 2002). The dose of methadone that is delivered daily by the 
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pump is comparable to that estimated to be released daily by the morphine emulsion (~66 
mg/kg/day), but elicited a less profound degree of cellular tolerance. In behavioral 
experiments chronic methadone treatment has been also reported to cause a less strong 
degree of antinociceptive tolerance than morphine when given at equianalgesic doses 
(Enquist et al., 2012). In our results, morphine treatment exerted a stronger degree of 
cellular tolerance than methadone in LC neurons (see above). Studies comparing different 
MOR agonists have found that those that induce robust receptor endocytosis and 
recycling tend to produce reduced analgesic tolerance and dependence (Whistler et al., 
1999). Morphine has a poor ability to promote internalization and recycling of the MOR 
(Alvarez et al., 2002; Arttamangkul et al., 2008), whereas methadone efficiently 
internalizes the MOR in different systems (Alvarez et al., 2002; Arttamangkul et al., 
2008; Celver et al., 2004; Keith et al., 1998; Koch et al., 2005). In agreement with this 
hyphothesis, mice with genetically modified MORs that have the ability to spontanelusly 
internalize and recycle develop a reduced tolerance to morphine (Kim et al., 2008). 
Similarly, animals with mutant MORs that show enhanced receptor degradation after 
endocytosis, developed stronger antinociceptive tolerance after methadone treatment 
(Enquist et al., 2012). 
On the other hand, chronic treatment with fentanyl minipumps (0.2 mg/kg/day, 7 
days) resulted in a 3-fold shift to the right in the concentration-effect curves for ME in LC 
neurons. Fentanyl has been reported to be up to 100 times more potent than morphine at 
producing analgesia (Vardanyan and Hruby, 2014). Surprisingly, this fentanyl 
administration protocol did not cause antinociceptive tolerance (Pablos et al., unpublished 
results). Paronis and Holtzman (1992) also observed that fentanyl (0.24 mg/kg/day) 
infused for 7 days by osmotic pumps failed to induce significant analgesic tolerance in 
rats. However, fenatnyl has been found to induce analgesic tolerance when given at a 
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dose of 0.04 mg/kg (s.c., 4 times a day, 3 days) in mice (Popik et al., 2000) and also at 
much higher doses, such as 2.4 mg/kg/day (72 h) or 3.2 mg/kg/day (5 days) by 
subcutaneously implanted pumps in neonatal rats and mice (Raehal and Bohn, 2011; 
Thornton and Smith, 1997). Fentanyl induces endocytosis and recycling of the MOR 
(Celver et al., 2004), which was been associated with a less potential to induce tolerance. 
In our study, fentanyl elicited a slightly less stronger rightward shift in the concentration-
effect curves than morphine in LC neurons (see above). 
Thus, it can be hypothesized that differences between opioids in their ability to 
induce receptor internalization and recycling may contribute, at least in part, to the 
different degrees of cellular tolerance observed in this study. In contrast, other studies 
show that β-arrestin2 knockout mice, in which MOR endocytosis is presumably unpaired, 
fail to develop both cellular tolerance (Dang et al., 2011) and antinociceptive tolerance 
after morphine (Bohn et al., 2000), but not after methadone or fentanyl treatments (Raehal 
and Bohn, 2011). Interistingly, the impaired MOR recycling that was found in wild-type 
LC neurons from morphine-treated rats was attenuated in β-arrestin2 knockout animals 
(Quillinan et al., 2011). Thus, β-arrestin2 may disrupt the ability of receptors to recycle 
after endocytosis, and therefore, contribute to the development of tolerance. 
Interactions between the opioid system and the NO cascade have been described in 
the brain (Pasternak et al., 1995; Sánchez-Blázquez et al., 2013). Thus, NOS activity and 
expression in the central nervous system is up-regulated after chronic morphine 
administration (Cuéllar et al., 2000; Machelska et al., 1997). Previous data from our 
laboratory have shown that perfusion with non-selective and selective NOS inhibitors 
attenuates acute MOR desensitization induced by ME in LC cells in vitro (Santamarta et 
al., 2014; Torrecilla et al., 2001). Moreover, the nNOS inhibitor 7-NI attenuates the 
development of cellular and antinociceptive tolerance in morphine-treated rats 
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(Santamarta et al., 2005). Likewise, nNOS-, but not eNOS-deficient mice, exhibit weak 
analgesic tolerance to morphine when compared to wild type animals (Heinzen and 
Pollack, 2004). NOS inhibitors also attenuated the withdrawal-induced hyperactivity of 
LC cells (Pineda et al., 1998). 7-NI is a heterocyclic compound that hardly distinguishes 
between nNOS and eNOS in brain homogenate preparations, but it exhibits a marked 
selectivity for neuronal NOS in intact cell models or in vivo (Babbedge et al., 1993; 
Hobbs et al., 1999), which is likely due to specific targets of 7-NI that are only present in 
neurons (Alderton et al., 2001; Handy and Moore, 1998). NO reacts with oxygen 
derivatives to produce ROS, such as the powerful oxidant peroxynitrite (Davis, 2001). 
ROS have been reported to regulate MOR desensitization in the LC (Llorente et al., 
2012). In this study, we found that TX+AA (40 and 100 mg/kg/day, respectively, i.p.) and 
U-74389G (10 mg/kg/day, i.p.), attenuated morphine-induced cellular tolerance to the 
inhibitory effect of ME on LC neurons. Trolox is a cell-permeable vitamin E derivative 
with powerful antioxidant properties (Balogh et al., 2005). Ascorbic acid is a potent 
antioxidant and ROS chelator by itself, but we used it as a Trolox recycler from oxidation 
(Guo and Packer, 2000). Vitamin E (40 mg/kg) and ascorbic acid (100 mg/kg) are 
effective in preventing oxidative damage in the rat brain (Delwing et al., 2005). U-
74389G is a 21-aminosteroid that potently inhibits ROS-mediated peroxidation and it has 
been shown to reduce cerebral superoxide anion concentration following brain injury 
(Fabian et al., 1998; Villa and Gorini, 1997). Similarly, TX+AA and U-74389G have 
been shown to block partially the development of antinociceptive tolerance induced by 
morphine (Pablos et al.,unpublished results). In agreement, other ROS scavengers such as 
melatonin (Raghavendra and Kulkarni, 2000), alpha-lipoic acid (Abdel-Zaher et al., 2013) 
or metalloporphyrins (Muscoli et al., 2007; Batinić-Haberle et al., 2009) attenuate the 
development of morphine-induced antinociceptive tolerance.  
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The mechanisms by which NO modulates morphine-induced tolerance via ROS 
generation remain unclear. One possible mechanism might be ROS-mediated activation 
of PKC. Opioids can induce a sustained increase in ROS (Koch et al., 2009) and PKC can 
be activated by raising the concentrations of ROS (Palumbo et al., 1992; Knapp and 
Klann, 2002). In the LC, PKC-induced phosphorylation enhances MOR desensitization 
induced by morphine without changing α2-adrenoceptor desensitization (Bailey et al., 
2004). There is also good evidence that PKC-dependent mechanisms play a significant 
role in the development of morphine analgesic tolerance (Newton et al., 2007; Smith et 
al., 2003; Zeitz et al., 2001). Molecular data have reported that in brain areas such as the 
PAG, morphine-activated MOR increases NO concentrations via the Akt-nNOS pathway 
and activates PKC, which stimulates the activity of NMDARs (Sánchez-Blázquez et al., 
2010). This increased NMDAR activity would induce the phosphorylation and 
uncoupling of MORs via nNOS/CaMKII pathway, which results in the development of 
morphine analgesic tolerance (Sánchez-Blázquez et al., 2013). Indeed, NMDAR 
antagonists and nNOS and CaMKII inhibitors attenuate opioid tolerance and withdrawal 
(Elliott et al., 1994; Herman et al., 1995). Future studies should test this hypothesis and 
the possible involvement of other kinases such as c-Jun N-terminal kinase (Melief et al., 
2010). 
Conversely, our results show that 7-NI and antioxidants did not affect the 
development of tolerance in rats treated chronically with methadone or fentanyl. 
Similarly, behavioral experiments showed that 7-NI and U-74389G failed to alter the 
development of antinociceptive tolerance in methadone-treated rats (Pablos et al., 
unpublished results). It has been described that methadone is a weak noncompetitive 
NMDAR antagonist (Ebert et al., 1998) and might counteract maladaptive changes in 
glutamate transmission. This might explain, at least in part, the less strong degree of 
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cellular tolerance after methadone treatment and the lack of effects of NO/ROS 
modulators on methadone-induced tolerance. Methadone and fentanyl may induce 
cellular tolerance by different mechanisms and cellular pathways from those described for 
morphine, as they trigger internalization and recycling of the MOR. Further assays should 
unmask the mechanisms underlying methadone- and fentanyl-induced adaptations. In 
conclusion, our results show that chronic treatments with morphine, methadone and 
fentanyl induce different degrees of cellular tolerance in LC neurons. In addition, in vivo 
administration of antioxidant agents attenuates the development of morphine-, but not 
methadone- or fentanyl-induced cellular tolerance. Therefore, NO/ROS pathways seem to 
be differentially involved in opioid cellular tolerance. Taken together, our results 
highlight the interest of a pharmacological protection against NO-derived ROS generation 
to attenuate the development of morphine tolerance and maintain a better control of pain.  
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Figure legends  
Figure 1. Effect of chronic treatments with morphine, methadone or fentanyl on the acute 
ME effect in rat LC neurons. Rats were treated for 72 h with a morphine (n = 5) or sham 
emulsion (n = 5). Another group of animals were treated for 6 days with methadone (n = 
7), 7 days with fentanyl (n = 5) or sham (n = 5) minipumps. A, B. Representative 
examples of firing-rate recording of LC cells from rats receiving the following treatments: 
sham (emulsion) or morphine (A), sham (minipump), methadone or fentanyl (B). Each 
horizontal bar represents the period of application of each ME concentration (0.05 - 12.8 
μM, 2x) and the vertical lines show the number of spikes recorded every 10 s. The 
inhibitory effect induced by each application was calculated as a percentage from the 
basal firing rate. Note that greater concentrations of ME are needed to inhibit the neuron 
activity in rats treated with morphine, methadone and fentanyl, compared with sham 
animals, indicative of tolerance. 
Figure 2. Concentration-effect curves for the inhibitory effect of ME in LC neurons from 
rats treated chronically with morphine, methadone or fentanyl. Rats were treated for 72 h 
with a morphine (n = 5) or sham emulsion (n = 5). Another group of animals were treated 
for 6 days with methadone (n = 7), 7 days with fentanyl (n = 5) or sham (n = 5) 
minipumps. A, B, C. Concentration-effect curves for the inhibitory effect of ME in LC 
neurons from rats receiving morphine (A), methadone (B), fentanyl (C) or sham 
treatment. The horizontal axis represents the logarithms of ME concentrations (0.05 - 
12.8 μM, 2x) in linear scale. The vertical axis expresses the reduction in the firing rate of 
LC neurons as a percentage from the basal firing rate. Symbols are the mean ± SEM of 
ME effect at each concentration obtained from n animals. The lines through the data are 
the theoretical curves in each group constructed from the mean of the individual 
concentration-effect curve parameters, as estimated by nonlinear regressions (see 
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Materials and Methods for details and Table 2 for mean values). Note that administration 
of morphine, methadone or fentanyl induces a shift to the right of the ME curves, 
representative of tolerance. In all groups, the maximal effect of ME was 100% of 
baseline, which corresponded with an absolute inhibition from the basal firing rate. 
Figure 3. Effect of 7-nitroindazole (7-NI) on the concentration-effect curves for the 
inhibitory effect of ME and pEC50 values for ME in LC neurons from methadone- and 
fentanyl-treated rats. Animals were co-treated with methadone or fentanyl minipumps and 
7-NI injections for 6 and 7 days, respectively (methadone/7-NI group, n = 5; fentanyl/7-
NI group, n = 5) or with their vehicles (sham/vehicle group, n = 5; sham/7-NI group, n = 
5; methadone/vehicle group, n = 5 and fentanyl/vehicle group, n = 6). A, B. 
Concentration-effect curves for the inhibitory effect of ME in LC neurons from rats 
receiving 7-NI together with methadone (A), fentanyl (B) or sham treatment. The 
horizontal axis represents the logarithms of ME concentration (0.05 - 12.8 μM, 2x) in 
linear scale. The vertical axis expresses the reduction in the firing rate of LC neurons as a 
percentage from the basal firing rate. Symbols are the mean ± SEM at each ME 
concentration obtained from n rats. The lines through the data are the theoretical curves in 
each group constructed from the mean of the individual concentration-effect curve 
parameters, as estimated by nonlinear regressions (see Materials and Methods for details 
and Table 1 for mean values). C, D. Ordinate represents pEC50 values for ME effect in 
sham-, methadone- or fentanyl-treated rats. Bars are mean ± S.E.M. of n rats. Note that 
administration of methadone and fentanyl induces a rightward shift to the right of the ME 
curves, but co-administration of the nNOS inhibitor 7-NI does not prevent this change. In 
all groups, the maximal effect of ME was 100% of baseline, which corresponded with an 
absolute inhibition from the basal firing rate. *p < 0.005 when compared to the 
corresponding sham group (one-way ANOVA followed by a post-hoc Tukey’s test). 
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Figure 4. Effect of Trolox + ascorbic acid (TX+AA) and U-74389G on the concentration-
effect curves for the inhibitory effect of ME and pEC50 values for ME in LC neurons from 
morphine-treated rats. Animals were co-treated for 72 h with a morphine emulsion and 
TX+AA or U-74389G injections (morphine/TX+AA group, n = 5; morphine/U-74389G 
group, n = 5) or with their vehicles (sham/vehicle group, n = 5; morphine/vehicle group, n 
= 5; sham/TX+AA group, n = 5; sham/U-74389G group, n = 5). A, B. Concentration-
effect curves for the inhibitory effect of ME in LC neurons from morphine-treated rats 
receiving TX+AA (A) or U-74389G (B). The horizontal axis represents the logarithms of 
ME concentration (0.05 - 12.8 μM, 2x) in linear scale. The vertical axis expresses the 
reduction in the firing rate of LC neurons as a percentage from the basal firing rate. Data 
points are the mean ± SEM at each ME concentration obtained from n animals. The lines 
through the data are the theoretical curves in each group constructed from the mean of the 
individual concentration-effect curve parameters, as estimated by nonlinear regressions 
(see Materials and Methods for details and Table 2 for mean values). C. Ordinate 
represents pEC50 values for ME effect in sham- and morphine-treated animals. Bars are 
mean ± S.E.M. of n rats. Note that administration of morphine induces a strong shift to 
the right of the ME curves, and co-administration of antioxidants TX+AA and U-74389G 
blocks this rightward displacement. In all groups, the maximal effect of ME was 100% of 
baseline, which corresponded with an absolute inhibition from the basal firing rate. *p < 
0.005, when compared to the corresponding sham group, †p < 0.05 and ††p < 0.01, when 
compared to the vehicle group (one-way ANOVA followed by a post-hoc Tukey’s test). 
Figure 5. Effect of U-74389G on the concentration-effect curves for the inhibitory effect 
of ME and pEC50 values for ME in LC neurons from methadone- or fentanyl-treated rats. 
Animals were co-treated with methadone or fentanyl minipumps for 6 and 7 days, 
respectively, and U-74389G injections (methadone/U-74389G group, n = 7; fentanyl/U-
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74389G group, n = 5) or with their vehicles (sham/vehicle group, n = 5; sham/U-74389G 
group, n = 5; methadone/vehicle group, n = 7 and fentanyl/vehicle group, n = 5). A, B. 
Concentration-effect curves for the inhibitory effect of ME in LC neurons from rats 
receiving U-74389G together with methadone (A), fentanyl (B) or sham treatment The 
horizontal axis represents the logarithms of ME concentration (0.05 - 12.8 μM, 2x) in 
linear scale. The vertical axis expresses the reduction in the firing rate of LC neurons as a 
percentage from the basal firing rate. Symbols are the mean ± SEM at each ME 
concentration obtained from n rats. The lines through the data are the theoretical curves in 
each group constructed from the mean of the individual concentration-effect curve 
parameters, as estimated by nonlinear regressions (see Materials and Methods for details 
and Table 2 for mean values). C, D. Ordinate represents pEC50 values for ME effect in 
sham-, methadone- and fentanyl-treated rats. Bars are mean ± S.E.M. of n rats. Note that 
administration of methadone of fentanyl induces a rightward shift to the right of the ME 
curves, but co-administration of the antioxidant U-74389G does not block this change. In 
all groups, the maximal effect of ME was 100% of baseline, which corresponded with an 
absolute inhibition from the basal firing rate. *p < 0.05, **p < 0.01 and ***p < 0.005 
when compared to the corresponding sham group (one-way ANOVA followed by a post-
hoc Tukey’s test). 
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Table 1. Effect of 7-nitroindazole (7-NI) on the basal firing rate and the inhibition 
induced by ME in the LC of sham- and opioid-treated rats. 
 
 
 
1Animals were co-treated for 6 days with methadone or 7 days with fentanyl by an 
osmotic minipump and 7-NI injections (methadone/7-NI group, fentanyl/7-NI group), or 
with their vehicles (sham/vehicle group, sham/7-NI group, methadone/vehicle group, and 
fentanyl/vehicle group). 
2Parameters of concentration-effect curves for ME were estimated in each experiment by 
nonlinear regression. pEC50 values (negative logarithm of the concentration needed to 
elicit a 50% of maximal effect) and slope factors are shown as mean ± SEM of n 
experiments. Maximal effect values were 100% in all cases. *p < 0.005 when compared 
to the corresponding sham group (one-way ANOVA followed by a post-hoc Tukey’s 
test). 
  
Concentration-effect curves
2
Treatment groups
1 Basal firing rate (Hz) pEC50 (M) (EC50, µM) Slope factor n
Sham (minipump)
     Vehicle (peanut oil) 0.74 ± 0.03 6.66 ± 0.03 (0.22) 1.15 ± 0.07 5
     7-NI 0.69 ± 0.06 6.84 ± 0.04 (0.15) 0.93 ± 0.07 5
Methadone
     Vehicle (peanut oil) 0.75 ± 0.06 6.29 ± 0.09* (0.52) 0.96 ± 0.03 5
     7-NI 0.57 ± 0.02 6.43 ± 0.04* (0.37) 1.02 ± 0.13 5
Fentanyl
     Vehicle (peanut oil) 0.96 ± 0.08 6.23 ± 0.05* (0.58) 1.03 ± 0.09 6
     7-NI 0.82 ± 0.10 6.38 ± 0.05* (0.42) 0.97 ± 0.04 5
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Table 2. Effect of antioxidants (Trolox + ascorbic acid and U-74389G) on the basal 
firing rate and the inhibition induced by ME in the LC of sham- and opioid-treated 
rats. 
 
 
 
1Animals were co-treated for 72 h with a morphine emulsion, for 6 days with methadone 
and 7 days with fentanyl by an osmotic minipump and Trolox + ascorbic acid or U-
74389G injections (morphine/TX+AA group, morphine/U-74389G group, methadone/U-
74389G group, fentanyl/U-74389G group), or with their vehicles (sham/vehicle group, 
sham/TX+AA group, sham/U-74389G group, morphine/vehicle group, 
methadone/vehicle group and fentanyl/vehicle group). 
Concentration-effect curves
2
Treatment groups
1 Basal firing rate (Hz) pEC50 (M) (EC50, µM) Slope factor n
Sham (emulsion)
     Vehicle (saline) 0.87 ± 0.05   6.66 ± 0.05 (0.22) 1.01 ± 0.05 5
     TX+AA 0.71 ± 0.04   6.58 ± 0.10 (0.26) 1.06 ± 0.06 5
     U-74389G 0.72 ± 0.05   6.52 ± 0.01 (0.30) 1.14 ± 0.05 5
Morphine
     Vehicle (saline) 1.05 ± 0.14   6.02 ± 0.10*** (0.95) 0.91 ± 0.04 5
     TX+AA 0.89 ± 0.09   6.41 ± 0.11
† (0.39) 0.92 ± 0.06 5
     U-74389G 0.85 ± 0.06   6.42 ± 0.08
†† (0.38) 1.03 ± 0.09 5
 
 
Sham (minipump)
     Vehicle (saline) 0.78 ± 0.04   6.64 ± 0.03 (0.23) 1.05 ± 0.08 5
     U-74389G 0.78 ± 0.03   6.58 ± 0.06 (0.27) 1.06 ± 0.05 5
Methadone
     Vehicle (saline) 0.81 ± 0.06   6.31 ± 0.05*** (0.49) 1.05 ± 0.04 7
     U-74389G 0.68 ± 0.09   6.34 ± 0.04* (0.45) 1.16 ± 0.10 7
Fentanyl
     Vehicle (saline) 0.93 ± 0.09   6.19 ± 0.03*** (0.64) 1.02 ± 0.11 5
     U-74389G 0.81 ± 0.09   6.19 ± 0.09** (0.65) 1.04 ± 0.11 5
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2Parameters of concentration-effect curves for ME were estimated in each experiment by 
nonlinear regression. pEC50 values (negative logarithm of the concentration needed to 
elicit a 50% of maximal effect) and slope factors are shown as mean ± SEM of n 
experiments. Maximal effect values were 100% in all cases. *p < 0.05, **p < 0.01 and 
***p < 0.005 when compared to the corresponding sham group. †p < 0.05 and ††p < 0.01 
when compared to the corresponding vehicle group (one-way ANOVA followed by a 
post-hoc Tukey’s test). 
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Abstract  
Previous studies have shown that nitric oxide (NO) is involved in the adaptations 
induced by chronic morphine treatment. In the present study, we used the tail-flick 
technique in rats to examine the effect of 7-nitroindazole (7-NI; 30 mg/kg/12 h, i.p.), a 
selective neuronal nitric oxide synthase (nNOS) inhibitor, and the antioxidant agents 
Trolox and ascorbic acid (TX+AA; 40 and 100 mg/kg/day, respectively i.p.) and U-
74389G (10 mg/kg/day, i.p.), on the development of opioid antinociceptive tolerance 
induced by prolonged treatments with morphine, methadone and fentanyl. For induction 
of morphine tolerance, rats were treated subcutaneously (s.c.) with a slow release 
emulsion containing free base morphine (200 mg/kg) for 72 h. For methadone (60 
mg/kg/day, 6 days) and fentanyl (0.2 mg/kg/day, 7 days), tolerance was induced by s.c. 
implantation of osmotic pumps. Morphine treatments induced a strong degree of tolerance 
to the antinociceptive effect of a challenge dose of morphine. Methadone treatments 
induced a weaker degree of antinociceptive tolerance. On the contrary, no tolerance to 
morphine challenge effects was observed in fentanyl-treated animals. Co-treatment with 
the antioxidants TX+AA or U-74389G partially blocked morphine-induced analgesic 
tolerance. On the contrary, 7-NI or U-74389G administration failed to affect the 
development of antinociceptive tolerance induced by methadone. Our results suggest that 
NO/ROS pathways are differentially involved in the development of opioid 
antinociceptive tolerance. 
Keywords: morphine, methadone, fentanyl, tolerance, nitric oxide, ROS. 
Abbreviations: LC: locus coeruleus; i.p.: intraperitoneal; 7-NI: 7-nitroindazole; NMDA: 
N-methyl-D-aspartate; NO: nitric oxide; NOS: nitric oxide synthase; nNOS: neuronal 
nitric oxide synthase; NOX: NADPH-oxidase; ROS: reactive oxygen species; s.c.: 
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subcutaneous; Trolox: 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; 
TX+AA: Trolox and ascorbic acid; U-74389G: 21-[4-(2,6-di-1-pyrrolidinyl-4-
pyrrimidinyl)-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione(Z)-2 butenedioate  
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1. Introduction  
Opioids are efficacious analgesics clinically used for pain management. However, 
one of the major problems associated with chronic opioid use is the significant risk of 
developing drug tolerance and dependence. When opioid tolerance develops, a dose 
escalation is needed to obtain equivalent pain relief, with the resulting risk of undesired 
effects. For that reason, it is necessary to unmask the mechanisms underlying tolerance to 
increase the efficacy of analgesic therapy. Since its isolation, chemistry research efforts 
have yielded thousands of morphine related opioids, resulting in a rich pharmacology 
(Corbett et al., 2006). Methadone is a good alternative to morphine for pain relief in 
cancer patients (Shelton et al., 2008). Fentanyl is estimated to be up to 100 fold more 
potent than morphine as an analgesic (Vardanyan and Hruby, 2014). Transdermal 
formulation of fentanyl is effective and well tolerated for the treatment of chronic pain 
caused by malignancy and non-malignant conditions (Kornick et al., 2003). Different 
regulatory events occurring at the MOR, including receptor desensitization, 
internalization, recovery from desensitization or down-regulation are though to be cellular 
mechanisms underlying opioid tolerance (Williams et al., 2013). Opioid agonists have 
widely differing signaling efficacies in each of these processes (Kelly, 2013; Von 
Zastrow, 2010). Other mechanisms including spinal glia activation and neuronal apoptotis 
also seem to contribute to opioid analgesic tolerance (Mao et al., 2002; Song and Zhao, 
2001; Watkins et al., 2005; Zhou et al., 2010).  
The chemical messenger NO is produced from L-arginine by the enzyme NO 
synthase (NOS), which can be classified as constitutive (neuronal and endothelial 
isoforms) or inducible (Alderton et al., 2001). Considerable evidence implicates the nitric 
oxide (NO) system in nociceptive processes either in the periphery or within the central 
nervous system (Haley et al. 1992) and in opioid-induced tolerance. Thus, inhibition of 
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the neuronal nitric oxide synthase (nNOS) attenuates the tolerance to the cellular and 
analgesic effects of MOR agonists after morphine treatment (Heinzen and Pollack, 2004; 
Santamarta et al., 2005). NO has been shown to react with oxygen derivatives, resulting 
in the formation of reactive oxygen species (ROS) and reactive nitrogen species (Davis et 
al., 2001). One of the most remarkable proinflammatory and proapoptotic reactive 
molecule is peroxynitrite, (ONOO–), the product of the interaction between superoxide 
(O2
–) and NO. NO/ROS pathways seems to play a key role in the development of pain of 
several etiologies (Salvemini et al., 2011). However, there is lacking information 
regarding the implication of NO/ROS in the development of analgesic tolerance 
following chronic treatments with different opioid agonists.  
The aim of this work was to explore in vivo the involvement of nNOS and ROS in 
the development of opioid analgesic tolerance. For that purpose, we examined by the tail-
flick test the development of analgesic tolerance following chronic treatments with 
different opioids (morphine, methadone and fentanyl) and we evaluated its regulation by 
a selective nNOS inhibitor and antioxidant agents.   
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2. Materials and Methods  
2.1 Animals and treatments 
The animals for this study were obtained from the animal house of the University of 
the Basque Country (Leioa, Spain). Male adult Sprague-Dawley rats (200-300 g) were 
housed under controlled environmental conditions (22ºC and 12-h light/dark cycle) with 
food and water ad libitum. Principles of laboratory animal care were followed in all 
experimental procedures reported in this manuscript. Experiments were carried out in 
accordance with the European Community Council Directive on "Protection of Animals 
Used in Experimental and Other Scientific Purposes" of 24 November 1986 
(86/609/EEC). The use of animals for this study was also approved by the Animal Care 
and Use Committee of the University of the Basque Country. All the efforts were made to 
minimize animal suffering and to reduce the number of animals used. 
For induction of morphine tolerance, rats were treated subcutaneously (s.c.) with a 
slow release emulsion containing free base morphine (200 mg/kg) for 72 h, as described 
by Santamarta et al. (2005). The emulsion was injected subcutaneously on the back of the 
rat under light anesthesia with chloral hydrate (200 mg/kg, intraperitoneally (i.p.)). Sham 
animals were implanted with the same vehicle emulsion without morphine. Behavioral or 
electrophysiological experiments were conducted 72h after administration of morphine or 
sham emulsions. 
For chronic treatments with methadone or fentanyl, osmotic minipumps (Alzet 
2ML1) were implanted subcutaneously, as described by Quillinan et al. (2011) and 
Trujillo et al. (2004), respectively. The minipumps have a 2 ml reservoir, which delivers 
the content continuously at the rate of 10 µl/h. Pumps were filled with the required 
concentration of methadone (60 mg/kg/day) or fentanyl (0.2 mg/kg/day), dissolved in 
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saline. Animals were first anaesthetized with isoflurane and an incision was made in the 
midscapular region to insert the minipump. Sham animals were implanted with saline-
filled osmotic pumps under the same experimental conditions. For induction of 
methadone tolerance, rats were given methadone i.p injections before the implantation of 
the pump, as follows: the day before, they received 5 mg/kg at 9:00 h and 7 mg/kg at 
18:00 h. Next day, they received 7 mg/kg at 9:00 h and the osmotic pump was implanted 
at 18:00 h. Once the minipump was inserted, sham and morphine-treated animals were 
daily injected with the antioxidant U-74389G (10 mg/kg, i.p.), Trolox (40 mg/kg, i.p.) or 
their vehichles (saline). Every time Trolox was administered, rats also received ascorbic 
acid (100 mg/kg, i.p.) (TX+AA) to prevent the oxidation of Trolox. Sham-, methadone- 
and fentanyl-receiving rats were intraperitoneally injected every day with U-74389G (10 
mg/kg) or its vehicle (saline). In another set of experiments, sham- and opioid-treated 
animals were intraperitoneally injected every 12 h with the nNOS inhibitor 7-NI (30 
mg/kg) or its vehicle (peanut oil). Experiments were carried out on day 7 in methadone-
treated rats (6 days after minipump implantation) and on day 8 in fentanyl-treated rats (7 
days after minipump implantation). 
2.2 Measurement of the antinociceptive response 
The analgesic effect of morphine was measured by the tail-flick test (Le Bars et al., 
2001), which evaluates the response of the animal to a thermal nociceptive stimulus. 
Thus, the rat was placed in a Plexiglas trap and kept inside for 20 min to minimize the 
stress due to manipulation. Next, a beam of light was focused on the dorsal tail, 
approximately in the middle. When the animal removed the tail with an energetic 
movement the time (latency) was recorded. Three basal measures were taken from each 
animal at three different points of the tail, with a 15 s interval between measures. The 
mean of these three values was used as the result. The light intensity was initially adjusted 
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with naive animals so that the basal latency (tbasal) was close to 3 s. Next, the rat was 
injected with a challenge dose of morphine hydrocloride (10 mg/kg, i.p.) and the latency 
(treaction) was tested again 30 min later to measure the effect of the opioid. This dose of 
morphine was selected based on previous experiments that observed a near maximal 
effect. This strong effect of morphine was appropriate to achieve a measurable tolerance 
after chronic opioid treatments. To minimize tail skin damage, a cut-off latency time 
(tmax) was set at 10 s. Antinociception was expressed as a percentage of the maximal 
possible effect (M.P.E) according to the following formula: 
M. P. E (%) =  
𝑡𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 − 𝑡𝑏𝑎𝑠𝑎𝑙
𝑡𝑚𝑎𝑥 − 𝑡𝑏𝑎𝑠𝑎𝑙
· 100 
2.3 Drugs and reagents 
The following drugs were purchased from Sigma-Aldrich Química (Madrid, Spain): 
Fentanyl, L-ascorbic acid, methadone and 7-nitroindazole (7-NI). Morphine base was 
purchased from Alcaliber (Madrid, Spain). Trolox and U-74389G were obtained from 
Enzo Life Sciences (Lausen, Switzerland). For acute administrations during tail-flick 
tests, morphine hydrochloride (10 mg/kg) was dissolved in 0.9% NaCl. For morphine 
treatment, an oily emulsion of morphine free base (200 mg/ml) containing mannide 
monooleate, liquid parafine, and 0.9% NaCl (0.08: 0.42: 0.5, v/v/v) was made. All the 
drugs were dissolved in saline except 7-NI, which was dissolved in peanut oil.  
2.4 Data analysis and statistics 
Data are expressed as mean ± standard error of the mean (S.E.M). Latencies before 
and after the morphine challenge were compared by a paired Student’s t test. In addition, 
to evaluate the differences between two groups, we compared latency values in the 
absence (control) or the presence of the drug by a two-sample Student’s t test. When 
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values were compared between more than two groups, one-way analysis of variance 
(ANOVA) was performed followed by Tukey’s post-hoc test using the computer program 
GraphPad Prism (version 5.0 for Windows). In some cases, when ANOVA showed that 
the basal values were significantly different between groups, analysis of covariance 
(ANCOVA) was performed with the basal data as covariate, followed by a Tukey’s post-
hoc test, using the software SPSS statistics (version 22.0 for Windows). A probability 
level of 0.05 was accepted as significantly different. 
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3. Results 
Development of tolerance for morphine-induced antinociception in morphine-, 
methadone- and fentanyl-treated animals 
In nontreated animals, morphine challenge (10 mg/ kg, i.p.) increased by more than 
three times the tail-flick latency, which corresponded with an average antinociceptive 
effect of 97 ± 1% (M.P.E.; basal latency = 3.04 ± 0.05 s; n = 124). To explore the 
development of opioid analgesic tolerance, the tail-flick test was performed in animals 
treated with different opioids (morphine, methadone and fentanyl). As expected, before 
opioid treatments the basal latencies and the antinociceptive effects induced by a 
challenge dose of morphine were not significantly different between groups. 
After subchronic treatment, basal latencies were not different between sham 
(emulsion) and morphine-treated animals. Morphine challenge increased by four times 
the latency in sham animals when compared to the basal latency (p < 0.005). In contrast, 
it failed to change the latency in morphine-treated animals (Fig. 1A; Table 1). Thus, the 
analgesic effects induced by morphine challenge were statistically different between sham 
and morphine-treated animals, so that post-hoc analysis showed that morphine challenge 
induced a less pronounced analgesic effect in the morphine/vehicle group than it did in 
the sham/vehicle group (p < 0.005) (Fig. 1C; Table 1), which indicated the development 
of tolerance.  
On the other hand, basal latencies were found to be significantly different between 
sham (minipump) and methadone-treated rats (p < 0.005) (Table 2; compare 
methadone/vehicle vs sham/vehicle group). In sham animals, morphine challenge 
increased by four times the latency (p < 0.005 vs basal latency) and in methadone-treated 
rats it increased the latency by two times (p < 0.005 vs basal latency) (Fig. 1B; Table 2). 
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The analgesic effects induced by a challenge dose of morphine were significantly 
different between sham and methadone-treated rats even when the basal latency values 
were used as a covariate by ANCOVA. Thus, morphine challenge caused a less 
antinociceptive effect in the methadone/vehicle group than in the sham/vehicle group, 
representative of tolerance (p < 0.005) (Fig. 1C; Table 2).  
Finally, basal latencies were not significantly different between sham (minipump) 
and fentanyl-treated rats. The challenge dose of morphine in fentanyl-treated rats 
increased more than three times the latency when compared to the basal latency (p < 
0.005). This increase was not different when compared to that in the sham group (Fig. 1B; 
Table 2). Hence, the antinociceptive effect of morphine challenge in the fentanyl/vehicle 
group did not differ from that in the sham/vehicle group (Fig. 1C; Table 2). Therefore, 
unlike morphine and methadone, this protocol of fentanyl infusion did not induce 
significant tolerance. 
Effect of the antioxidants Trolox + ascorbic acid and U-74389G on morphine-
induced analgesic tolerance 
We have previously shown that the co-administration of the selective nNOS inhibitor 
7-NI prevents the antinociceptive tolerance induced by a subchronic morphine treatment 
(3 days) in rats (Santamarta et al., 2005). To further explore the involvement of ROS, the 
product of reaction between NO and oxygen derivatives (Davis et al., 2001), we tested the 
effect of two structurally unrelated antioxidants, Trolox administered with ascorbic acid 
(TX+AA) and U-74389G. Basal latencies were found to be statistically different between 
sham/TX+AA and sham/vehicle groups (Table 1). Furthermore, the analgesic effects 
induced by a challenge dose of morphine treatment were significantly different between 
groups even when the basal latency values were used as a covariate by ANCOVA. Thus, 
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co-treatment with TX+AA (40 mg/kg and 100 mg/kg, respectively) in morphine-treated 
animals partially prevented the development of tolerance, since the analgesic effect of 
morphine challenge in the morphine/TX+AA group was significantly greater than that in 
the morphine-vehicle group (p < 0.005), but smaller than that in the corresponding sham 
group (Figure 2A; Table 1). Likewise, co-treatment with U-74389G (10 mg/kg/day) 
partially prevented the development of tolerance in morphine-treated rats. Hence, the 
antinociceptive response of the challenge dose of morphine in the morphine/U-74389G 
group was significantly greater than that in the morphine/vehicle group (p < 0.005) but 
smaller than that in the corresponding sham group (Fig. 2B; Table 1). On the other hand, 
subchronic administration of either TX+AA or U-74389G in sham-treated animals 
(sham/TX+AA and sham/U-74389G group) failed to affect the morphine-induced 
analgesic effect, as compared to the sham/vehicle group (Fig. 2A, 2B; Table 1). 
Effect of the neuronal nitric oxide synthase inhibitor 7-NI and the antioxidant U-
74389G on methadone-induced analgesic tolerance 
To study the role of neuronal NOS in the antinociceptive tolerance induced by other 
opioid agonists, we tested the effect of 7-NI in the group of rats receiving methadone. As 
noted above, basal latencies were found to be significantly higher (p < 0.05) in 
methadone/vehicle than in sham/vehicle groups (Table 2). However, in animals co-treated 
with 7-NI, basal latencies were not different between methadone and sham groups. Co-
administration of the nNOS inhibitor 7-NI (30 mg/kg/12 h) in rats treated chronically 
with methadone failed to modify the development of analgesic tolerance, even when the 
basal latency values were used as a covariate by ANCOVA. Thus, the analgesic effect 
induced by morphine challenge in the methadone/7-NI group did not differ from that in 
the methadone/7-NI vehicle group, but it was lower than that in sham/7-NI group (Fig. 
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3A; Table 2). Chronic treatment with 7-NI failed to change the morphine-induced effect, 
as compared the sham/7-NI group with the sham/7-NI vehicle group (Fig. 3A; Table 2).  
To further explore the involvement of ROS, methadone-treated animals were co-
treated with the antioxidant U-74389G (10 mg/kg/day). As mentioned, basal latencies 
were significantly higher in methadone/vehicle than in sham/vehicle groups, but this 
difference was not significant between methadone and sham animals after co-treatment 
with U-74389G. Co-treatment with U-74389G in methadone-treated rats failed to modify 
the development of analgesic tolerance, even when the basal latency values were used as 
a covariate by ANCOVA. Thus, the analgesic response after a challenge dose of 
morphine in the methadone/U-74389G group was not different from that in the 
methadone/U-74389G vehicle group, but it was lower than that in sham/ U-74389G group 
(Fig. 3B; Table 2). Chronic treatment with U-74389G failed to affect the morphine 
challenge-induced analgesic effect, as compared the sham/ U-74389G group with the 
sham/ U-74389G vehicle group (Fig. 3B; Table 2). 
Taken together, these data indicate that NO/ROS pathways play a key role in the 
development of morphine-, but not methadone-induced analgesic tolerance and therefore, 
these pathways seem to be differentially involved in opioid-induced analgesic tolerance in 
vivo.  
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4. Discussion 
In this study, we evaluated by the tail-flick technique the development of analgesic 
tolerance after chronic treatments with three different MOR agonists. We present 
behavioral evidence for a role of NO/ROS pathway in morphine-, but no other opioids-
induced antinociceptive tolerance. Thus, morphine and methadone treatments induced 
tolerance to the antinociceptive effect of a challenge dose of morphine. In contrast, no 
tolerance to morphine effect was observed in fentanyl-treated animals. Co-administration 
of the antioxidants TX+AA or U-74389G partially prevented the development of 
antinociceptive tolerance in morphine-treated animals. On the contrary, co-treatment with 
neither the nNOS inhibitor 7-NI nor the antioxidant U-74389G affected the development 
of antinociceptive tolerance in methadone-treated rats.  
Morphine tolerance was induced by subcutaneous implantation of an oily emulsion 
containing morphine base (200 mg/kg, a single administration, 72 h). Morphine base 
containing emulsions provide a slow drug release and prolonged exposure to the opioid 
(Salem and Hope, 1999). According to the time course described in treated mice, the oily 
emulsion promotes a rise in morphine concentration in serum 3–12 h after implantation 
and a gradual clearance of morphine over 4–5 days (Garzón and Sánchez-Blázquez, 
2001). This morphine administration protocol has been reported to efficiently induce both 
analgesic and cellular tolerance in rats (Santamarta et al., 2005). The degree of tolerance 
was similar to that observed by Goodchild et al. (2009) who induced tolerance by a s.c. 
sustained release morphine emulsion (125 mg/kg/day, 2 days) in rats. Likewise, chronic 
administration of s.c. morphine (10 mg/kg, twice daily, 5 days) showed a similar degree 
of antinociceptive tolerance in thermal and mechanical test paradigms (Raghavendra et 
al., 2004). 
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Chronic treatment with methadone-filled osmotic pumps (60 mg/kg/day, 6 days) 
induced a less strong degree of tolerance. In agreement, chronic methadone treatment has 
been reported to cause substantially less antinociceptive tolerance than morphine when 
given at equianalgesic doses (Enquist et al., 2012). The dose was selected based on 
previous studies where cellular tolerance was observed in LC neurons (Quillinan et al., 
2011). Methadone has been reported to produce antinociception in the tail flick and hot 
plate tests with a potency similar to that of morphine when given s.c. to rats (Giusti et al., 
1997; He et al., 2009). The dose of methadone that is daily administered by the osmotic 
pump in the present study is similar to that estimated to be released by the morphine 
emulsion (~66 mg/kg/day), yet induces a less profound degree of tolerance. Methadone 
has been found to induce analgesic tolerance at higher doses, such as 96 mg/kg/day (s.c., 
5 days) (Raehal and Bohn, 2011) and also at much lower doses, such as 3 mg/kg/day (s.c., 
4 days) in mice (Enquist et al., 2012). However, no tolerance was observed with 4 mg/kg 
(s.c., twice daily, 5 days) (Kim et al., 2008). It has been proposed that the degree of 
tolerance that an agonist can induce is inversely related to its ability to induce receptor 
internalization (Whistler et al., 1999). It could be hypothesized that in the present study 
methadone causes a less strong degree of tolerance induces endocytosis and recycling of 
the MOR, whereas morphine is less effective (Alvarez et al., 2002; Celver et al., 2004; 
Keith et al., 1998; Koch et al., 2005). Indeed, in an animal model in which the MOR is 
genetically modified to enhance receptor degradation after endocytosis, mice show a 
stronger degree of antinociceptive tolerance after methadone treatment (Enquist et al., 
2012). In agreement, transgenic mice with genetically modified MORs that have the 
ability to internalize and recycle develop a reduced tolerance to morphine (Kim et al., 
2008).  
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 On the other hand, chronic treatment with fentanyl pumps (0.2 mg/kg/day, 7 days) 
did not cause antinociceptive tolerance. Fentanyl has been reported to be up to 100 times 
more potent than morphine as an analgesic (Vardanyan and Hruby, 2014). The dose of 
fentanyl used in the present study is sufficient to activate the MOR and promote 
behavioral changes and neuronal adaptations, as it was found to produce locomotor 
sensitization (Trujillo et al., 2004) and cellular tolerance in LC neurons (Pablos et al., 
unpublished results). In another study, fentanyl (0.24 mg/kg/day) infused for 7 days by 
osmotic pumps also failed to induce significant analgesic tolerance in rats (Paronis and 
Holtzman, 1992). However, it was found to cause tolerance when given at a dose of 0.04 
mg/kg (s.c., 4 times a day, 3 days) in mice (Popik et al., 2000) and also at much higher 
doses, such as 2.4 mg/kg/day (72 h) or 3.2 mg/kg/day (5 days) by subcutaneously 
implanted pumps in neonatal rats and mice (Raehal and Bohn, 2011; Thornton and Smith, 
1997). Our results suggest that fentanyl, at doses expected to activate MOR and promote 
neuronal adaptations, is resistant to tolerance induction. Fentanyl induces endocytosis and 
recycling of the MOR (Celver et al., 2004), which was been associated with a less 
potential to induce tolerance. Furthermore, it could be hypothesized that the absence of 
antinociceptive tolerance may be the result of other adaptations in the whole animal 
caused by fentanyl that may counteract the development of cellular tolerance observed in 
LC neurons (Pablos et al., unpublished results). 
Thus, we propose that the different magnitudes of tolerance among opioid agonists, 
may be explained, at least in part, by their different abilities to induce receptor 
internalization and recycling. However, β-arrestin2 knockout mice have been shown to 
develop attenuated analgesic tolerance to morphine but not to fentanyl or methadone 
(Bohn et al., 2000, 2002; Raehal and Bohn, 2011), which seems to contradict this 
hypothesis. Interistingly, Quillinan et al., (2011) showed that in morphine-treated rats 
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recovery from acute ME-induced desensitization and receptor recycling was diminished, 
an effect that was not present in mice lacking β-arrestin2. Thus, it can be hypothesized 
that β-arrestin2 may disrupt the ability of receptors to recycle after endocytosis, which 
would contribute to tolerance development. 
Previous studies have implicated the NO system in the adaptations triggered by 
chronic morphine treatment. Thus, chronic treatment with morphine has been found to 
increase NOS activity and expression in the brain and spinal cord (Bhargava et al., 1998; 
Machelska et al., 1997; Cuéllar et al., 2000). Our previous studies show that in vivo 
administration of the nNOS inhibitor 7-NI attenuates the development of cellular and 
analgesic tolerance in morphine-treated rats (Santamarta et al., 2005). Likewise, at the 
cellular level, non-selective and selective NOS inhibitors block opioid-induced MOR 
desensitization in vitro (Santamarta et al., 2014; Torrecilla et al., 2001). 7-NI hardly 
distinguishes between nNOS and eNOS in brain homogenate preparations, but it exhibits 
a marked selectivity for neuronal NOS in intact cell models (Babbedge et al., 1993), 
which seems to be due to specific targets of 7-NI that are only present in neurons 
(Alderton et al., 2001; Handy and Moore, 1998). In agreement, following sustained 
morphine administration, nNOS-, but not eNOS-deficient mice, exhibit weak analgesic 
tolerance development when compared to wild type animals (Heinzen and Pollack, 2004). 
It is well known that NO reacts with oxygen derivatives to produce ROS, such as the 
powerful oxidant peroxynitrite (Davis, 2001). In electrophysiological experiments 
performed in the LC, Trolox and U-74389G separately attenuated the enhancement of 
MOR desensitization induced by NO donors (Llorente et al., 2012). In our study, both 
TX+AA and U-74389G blocked partially the development of analgesic tolerance induced 
by a subchronic treatment with morphine, whereas they did not alter the animal pain 
threshold. Trolox is a cell permeable derivative of vitamin E that has a relatively high 
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selectivity for scavenging peroxynitrite and hydroxyl radical (Balogh et al., 2005). 
Ascorbic acid is a potent antioxidant and ROS chelator by itself but in this study we used 
it as a Trolox recycler from oxidation (Guo and Packer, 2000). Delwing et al. (2005) 
reported that vitamin E (40 mg/kg) and ascorbic acid (100 mg/kg) prevent oxidative 
damage in the rat brain. The 21-aminosteroid U-74389G, whose molecular structure is 
unrelated to that of Trolox, potently inhibits ROS-mediated lipid peroxidation and has a 
strong antioxidant activity (Fabian et al., 1998; Villa and Gorini, 1997). Thus, we can 
assume that reduction of morphine tolerance by TX+AA and U-74389G is the 
consequence of prevention of ROS-induced effects. In agreement, targeting peroxynitrite 
by metalloporphyrins blocks the development of morphine-induced antinociceptive 
tolerance in mice (Batinić-Haberle et al., 2009; Muscoli et al., 2007). Likewise, 
antioxidant agents such as melatonin or alpha-lipoic acid have been reported to attenuate 
the development of morphine tolerance (Raghavendra and Kulkarni, 2000; Abdel-Zaher 
et al., 2013). Mice lacking NOX1, a major source of ROS formation, exhibited weaker 
analgesic tolerance induced by repeated administration of morphine than wild type 
animals (Ibi et al., 2011). NOX2 knockout mice developed antinociceptive tolerance 
similar to wild type mice after 3 days of continuous morphine, but showed restored 
morphine analgesia on day six, whereas wild type mice mice continued to develop 
tolerance (Doyle et al., 2013). In electrophysiological experiments, TX+AA and U-
74389G separatedly blocked the development of cellular tolerance in morphine-treated 
rats (Pablos et al., unpublished results). 
The mechanisms by which ROS modulate opioid tolerance remain unclear. The 
potent ROS peroxynitrite has emerged as a pivotal component of opioid antinociceptive 
tolerance and pain. (Little et al., 2012; Salvemini and Neumann, 2009). Thus, there are 
some mechanisms by which ROS formation might contribute to opioid tolerance. 
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Peroxynitrite has been shown to alter glutamate homeostasis within the dorsal horn of the 
spinal cord by the post-translational nitration of key proteins involved in maintaining a 
normal glutamate balance, such as NMDARs, glutamate transporters or glutamine 
synthase (Trotti et al., 1996; Zanelli et al., 2000, 2002). Nitration of these proteins by 
peroxynitrite would lead to a constant potentiation of the glutamatergic system. There is 
general agreement that dysfunction of the NMDAR/NO pathway is a key component of 
nociception. It has been described that morphine activation of MOR increases NO 
production via the Akt-nNOS pathway and activates PKC, which stimulates the activity 
of NMDARs (Sánchez-Blázquez et al., 2010). This increased NMDAR activity would 
induce the phosphorylation and uncoupling of MORs via nNOS/CaMKII pathway, which 
results in the development of morphine analgesic tolerance (Sánchez-Blázquez et al., 
2013). In agreement, NMDAR antagonists and nNOS and CaMKII inhibitors attenuate 
opioid tolerance and dependence (Elliott et al., 1994; Herman et al., 1995). A second 
alternative would involve ROS-mediated activation of PKC (Knapp and Klann, 2000). 
Indeed, morphine tolerance is attenuated by administration of PKC inhibitors, or when 
PKC expression is reduced (Newton et al., 2007; Smith et al., 2003; Zeitz et al., 2001). A 
third potential ROS-dependent mechanism underlying tolerance might be glial activation 
and the consequent induction of proinflammatory processes. Chronic administration of 
morphine promotes neuroimmune activation as evidenced by activation of spinal cord 
glial cells and production of proinflammatory cytokines (Song and Zhao, 2001; Watkins 
et al., 2005, 2007; Zeng et al., 2014). The induction of those proinflammatory molecules 
would be relevant in the development of morphine tolerance, since the glial modulators 
propentofylline (Raghavendra et al., 2004), minocycline (Cui et al., 2008) or paeoniflorin 
(Jiang et al., 2014) attenuate morphine-induced antinociceptive tolerance. The possible 
mechanisms by which chronic morphine induces glial cell activation and cytokine 
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production are not known, but a role for peroxynitrite as a signaling molecule involved in 
this process has been reported (Little et al., 2013). Resveratrol, a potent anti-inflammatory 
and antioxidant molecule, has been reported to attenuate morphine analgesic tolerance by 
inhibiting microglial activation and down-regulating NMDAR expression in the spinal 
cord (Han et al., 2014; Tsai et al., 2012). A fourth ROS-related mechanism might involve 
neuronal cell death, which is present in morphine-induced antinociceptive tolerance (Mao 
et al., 2002; Sharifipour et al., 2014). Chronic morphine exposure causes apoptosis within 
the spinal cord dorsal horn (Mao et al., 2002) and increases supraspinal apoptosis in the 
cortex and amygdala in neonatal rats (Bajic et al., 2013). The mechanisms involved in 
morphine-induced apoptosis remain unclear, but ROS seem to take part in this process. 
Thus, low concentrations of peroxynitrite trigger apoptotic death, whereas higher 
concentrations induce necrosis (Bonfoco et al., 1995; Virág et al., 2003). The nuclear 
enzyme poly(ADP-ribose) polymerase (PARP) has been shown to contribute to 
peroxynitrite-induced neuronal cell death in the spinal cord in vitro (Scott et al., 2004). 
Inhibitors of PARP, which is involved in different paradigms of cell death (Aredia and 
Scovassi, 2014), prevent the development of morphine antinociceptive tolerance (Mayer 
et al., 1999). 
On the other hand, we show that 7-NI and U-74389G did not affect the development 
of antinociceptive tolerance in methadone-treated rats. These findings are in agreement 
with electrophysiological experiments (Pablos et al., unpublished results), where 7-NI and 
U-74389G failed to alter the development of cellular tolerance in LC neurons from 
methadone-treated rats. These results suggest that the NO system is not involved in 
methadone-induced adaptations. Methadone has been described to behave as a weak 
noncompetitive NMDAR antagonist (Ebert et al., 1998). This ability of methadone to 
antagonize NMDA receptors and counteract maladaptive changes in glutamate 
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transmission might explain, at least in part, the reduced tolerance after methadone 
treatment and lack of effects of NO/ROS modulators on methadone-induced tolerance. 
Further studies are needed to unmask the mechanisms underlying methadone-induced 
adaptations. 
In conclusion, our results show that morphine treatment induces a stronger degree of 
antinociceptive tolerance than methadone in rats, whereas fentanyl was resistant to 
tolerance induction. In addition, in vivo administration of antioxidant agents partially 
prevents the development of morphine-, but not methadone-induced analgesic tolerance, 
suggesting that the NO/ROS pathway is differentially involved in opioid antinociceptive 
tolerance. We provide pharmacological basis for the potential use of antioxidants as 
useful co-adjuvants in the management of chronic pain to prevent or, at least, attenuate 
the development of morphine analgesic tolerance. 
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Figure legends  
Figure 1. Development of tolerance for morphine-induced antinociception in morphine-, 
methadone- and fentanyl-treated animals. A, B. Bar histograms show the mean ± S.E.M 
of the latency before (basal) and after a challenge dose of morphine in sham (emulsion) (n 
= 10), sham (minipump) (n = 10), morphine- (n = 9), methadone- (n = 9) and fentanyl-
treated animals (n = 6). Basal latencies were statistically different between methadone 
and sham groups &p < 0.005 when compared to the corresponding sham/vehicle group. 
Note that morphine challenge significantly increased the latency in sham-, methadone- 
and fentanyl-treated rats, but not in morphine-treated animals. *p < 0.005 when compared 
to the corresponding basal latency by a paired Student’s t test, and #p < 0.005, when 
compared to the corresponding sham group by two-sample Student’s t test. C. Bar 
histograms represent the mean ± S.E.M of the maximum possible effect (M.P.E.) in sham 
(emulsion) (n = 10), sham (minipump) (n = 10) morphine- (n = 9), methadone- (n = 9) 
and fentanyl-treated animals (n = 6). Note that morphine and methadone treatments 
reduce the analgesic effect of morphine challenge, indicative of tolerance. $p < 0.005 
when compared to the corresponding sham group by two-sample Student’s t test. †p < 
0.005 when compared to the morphine group by two-sample Student’s t test. 
Figure 2. Effect of Trolox + ascorbic acid (TX+AA) and U-74389G on the on the 
antinociception induced by a challenge dose of morphine in sham-, and morphine-treated 
rats. A. Bar histograms show the mean ± S.E.M of the maximum possible effect (M.P.E.) 
in rats co-treated with the morphine emulsion and TX+AA (morphine/TX+AA group, n = 
10) or with their vehicles (sham-vehicle group, n = 10; morphine-vehicle group, n = 9; 
sham/TX+AA group, n = 10). B. Bar histograms show the mean ± S.E.M of the 
maximum possible effect (M.P.E.) in rats co-treated with the morphine emulsion and U-
74389G (morphine/U-74389G group, n = 8) or with their vehicles (sham-vehicle group, n 
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= 10; morphine-vehicle group, n = 9; sham/U-74389G group, n = 7). Note that morphine 
treatment reduces the analgesic effect of morphine challenge and co-administration of 
TX+AA or U-74389G partially blocks this change. $p < 0.05 and $$p < 0.005, as 
compared to the corresponding sham group (ANCOVA followed by a post-hoc Tukey’s 
test); †p < 0.005, as compared to the corresponding vehicle group (ANCOVA followed by 
a post-hoc Tukey’s test). 
Figure 3. Effect of 7-NI and U-74389G on the on the antinociception induced by a 
challenge dose of morphine in sham-, and methadone-treated rats. A. Bar histograms 
show the mean ± S.E.M of the maximum possible effect (M.P.E.) in rats co-treated with 
methadone and 7-NI (methadone/7-NI group, n = 8) or with their vehicles (sham/vehicle 
group, n = 7; methadone/vehicle group, n = 9; sham/7-NI group, n = 7). B. Bar 
histograms show the mean ± S.E.M of the maximum possible effect (M.P.E.) in rats co-
treated with methadone minipumps and U-74389G (methadone/U-74389G group, n = 7) 
or with their vehicles (sham/vehicle group, n = 10; methadone/vehicle group, n = 9; 
sham/U-74389G group, n = 7). Note that chronic methadone treatment reduces the 
analgesic effect of morphine challenge, but co-administration of either 7-NI or U-74389G 
fails to block this change. $p < 0.005, as compared to the corresponding sham group 
(ANCOVA followed by a post-hoc Tukey’s test). 
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Table 1. Effect of Trolox and ascorbic acid (TX+AA) and U-74389G on the tail-flick 
latencies and the analgesic response of sham- and morphine-treated rats.  
 
1Animals were co-treated for 72 h with a morphine emulsion and TX+AA or U-74389G 
injections (morphine/TX+AA group and morphine/U-74389G group), or with their 
vehicles (sham/vehicle group, sham/TX+AA group, sham/U-74389G group and 
morphine/vehicle group). 
2Basal latency values refer to the time until tail removal before administration of the 
morphine challenge. Data are shown as mean ± SEM of n experiments. After chronic 
treatments, basal latencies were statistically different between groups. #p < 0.05 when 
compared to the sham/vehicle group (one-way ANOVA followed by a post-hoc Tukey’s 
test). 
3Latency values refer to the time until tail removal after administration of the morphine 
challenge. Data are shown as mean ± SEM of n experiments. Latencies were statistically 
different when compared to basal latencies in all groups except in morphine/vehicle 
group. *p < 0.005 (paired Student’s t test). 
Treatment groups
1
Basal latency (s)
2
Latency (s)
3
M.P.E (%)
4 n
Sham (emulsion)
     Vehicle (saline) 2.66 ± 0.14   9.41 ± 0.33*  92.41 ± 4.23 10
     TX+AA 3.43 ± 0.23
#   9.10 ± 0.35*  85.64 ± 5.69 10
     U-74389G 2.57 ± 0.14   9.93 ± 0.06*  99.08 ± 0.73 7
Morphine
     Vehicle (saline) 3.19 ± 0.26 3.94 ± 0.30  13.77 ± 4.38
$$ 9
     TX+AA 2.92 ± 0.17   7.42 ± 0.51*  62.04 ± 8.37
$†
10
     U-74389G 2.80 ± 0.14   7.20 ± 0.65*  61.74 ± 8.85
$$† 8
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4M.P.E is the percentage of the maximal possible effect (see Materials and Methods). 
Data are shown as mean ± SEM of n experiments. Note that morphine treatment 
attenuates the analgesic effect of morphine challenge and co-administration of TX+AA or 
U-74389G partially blocks this change. $p < 0.05 and $$p < 0.005, when compared to the 
corresponding sham group (ANCOVA followed by a post-hoc Tukey’s test), †p < 0.005 
when compared to the corresponding vehicle group (ANCOVA followed by a post-hoc 
Tukey’s test).  
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Table 2. Effect of 7-nitroindazole (7-NI) and U-74389G on the tail-flick latencies and 
the analgesic response of sham and methadone-treated rats. 
1Animals were co-treated for 6 days with methadone by an osmotic minipump and 7-NI 
or U-74389G injections (methadone/7-NI group, methadone/U-74389G group) or with 
their vehicles (sham/7-NI vehicle group, sham/U-74389G vehicle group, sham/7-NI 
group, sham/U-74389G group, methadone/7-NI vehicle group and methadone/U-74389G 
group). Another group of animals were co-treated for 7 days with fentanyl by an osmotic 
minipump. 
2Basal latency values refer to the time until tail removal before administration of the 
morphine challenge. Data are shown as mean ± SEM of n experiments. After chronic 
treatments, basal latencies were statistically different between groups. &p < 0.05 and &&p 
< 0.005 when compared to the corresponding sham/vehicle group (one-way ANOVA 
followed by a post-hoc Tukey’s test). 
Treatment groups
1
Basal latency (s)
2
Latency (s)
3
M.P.E (%)
4 n
Sham (minipump)
     7-NI vehicle (peanut oil) 2.64 ± 0.14 9.87 ± 0.10* 98.29 ± 1.29 7
     7-NI 2.93 ± 0.14 9.74 ± 0.14* 96.43 ± 2.00 7
     U-74389G vehicle (saline) 2.59 ± 0.14 9.79 ± 0.11* 97.31 ± 1.43 10
     U-74389G 2.66 ± 0.17 9.90 ± 0.06* 98.75 ± 0.73 7
Methadone
     7-NI vehicle (peanut oil)   3.24 ± 0.07
&
6.61 ± 0.41* 49.48 ± 6.40
$
9
     7-NI 2.86 ± 0.16 5.51 ± 0.61* 37.77 ± 8.12
$
8
     U-74389G vehicle (saline)      3.32 ± 0.09
&&
6.51 ± 0.45* 47.98 ± 6.40
$
9
     U-74389G 3.01 ± 0.07 5.99 ± 0.52* 42.45 ± 7.41
$
7
Fentanyl
     Vehicle (saline) 2.90 ± 0.11 9.58 ± 0.18* 94.14 ± 2.66 6
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3Latency values refer to the time until tail removal after administration of the morphine 
challenge. Data are shown as mean ± SEM of n experiments. Latencies were statistically 
different when compared to basal latencies in all groups. *p < 0.005 (paired Student’s t 
test). 
4M.P.E is the percentage of the maximal possible effect (see Materials and Methods). 
Data are shown as mean ± SEM of n experiments. Note that chronic methadone treatment 
attenuates the analgesic effect of morphine challenge, but co-administration of either 7-NI 
or U-74389G failed to block this effect, even when the basal latency values were used as 
a covariate. $p < 0.005 when compared to the corresponding sham group (ANCOVA 
followed by a post-hoc Tukey’s test). Chronic treatment with fentanyl does not alter the 
analgesic effect of morphine challenge.  
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FIGURE 1 
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FIGURE 2 
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FIGURE 3 
